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ABSTRACT OF THE DISSERTATION 
NOVEL NUCLEOSIDE ANALOGUES WITH BASES MODIFIED WITH (β-
HALO)VINYL SULFONE OR β-KETO SULFONE AS PROBES TO STUDY 
RNA/DNA-PROTEINS INTERACTIONS 
by 
Sk Md Sazzad Hossain Suzol 
Florida International University, 2017 
Miami, Florida 
Professor Stanislaw F. Wnuk, Major Professor 
The C-5 modified pyrimidine analogues are well-known anticancer and antiviral 
drugs which underscore further development of novel probes to study their physical, 
chemical, and biological properties. In my dissertation the syntheses and properties of 
(β-halo)vinyl sulfone and/or (β-keto)sulfone analogues of C-5 modified pyrimidine 
have been discussed. In the first part of the dissertion, the synthesis of 5-(β-halo)vinyl 
sulfones either by transition metal-catalyzed or iodine-mediated halosulfonylation 
reaction of 5-acetylene pyrimidine nucleosides have been explored. The novel (β-
chloro/bromo/iodo)vinyl sulfones efficiently undergo addition-elimination reaction 
with different nucleophiles such as thiols, amines, amino acid, peptides to provide (β-
substituted)vinyl sulfone analogues. The rate of these substitution reactions depends on 
the nature of halogen atom presents at the β-position and increases with the order of  
I ≥ Br > Cl. (β-chloro/bromo/iodo)vinyl sulfones possess exclusively E stereochemistry 
while their β-substitued analogues possess either E (for β–thio analogues) or Z (for β–
amino analogue) stereochemistry. It has been observed that the vinylic proton of (β-
vi 
 
chloro) or (β-amino)sulfone analogue undergoes exchanges with deuterium in polar 
protic deutorated solvents. The antiproliferative activities of those analogues have been 
explored and was found that protected 5-(E)-(1-chloro-2-tosylvinyl)-2'-deoxyuridine 
inhibited the growth of L1210, CEM and HeLa cells in lower micromolar range.  
In the second part of the dissertation the syntheses and reactivities of 5-(β-keto) 
sulfone of pyrimidine nucleosides were investigated. Thus, 5-(β-halovinyl)sulfone of 
uracil and cytosine nucleosides have been efficiently converted into corresponding 5-
(β-keto) sulfone analogues by displacement of halogen with ammonia followed by acid-
catalyzed hydrolysis of the resulting (β-amino)sulfone analogues. A number of 
electrophiles were trapped at the acidic α-carbon of the 5-(β-keto)sulfones by treatment 
with electrophiles such as methyl, benzyl, or allyl halide in the presence of base. The 5-
(α-iodo-β-keto)sulfone analogues of uracil nucleosides have been tested as an 
alternative substrates to probe the incorporation of nucleophiles at α-carbon. 
In the third part of the dissertation, the synthesis of 5'-phosphates of 5-(β-chloro) 
and 5-(β-keto) sulfones of 2'-deoxyuridine and their polymerase-catalyzed 
incorporation into DNA were evaluated. Thus, 5'-O-phosphorylated analogues have 
been efficiently incorporated into the DNA by human DNA repair polymerase (pol β) 
or bacterial polymerase (pol I). 
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1. INTRODUCTION 
1.1. Importance of nucleosides and nucleotides 
Nucleosides are the glycosyamines which possess a β-glycosidic bond between the base 
and the sugar moiety while nucleotides additionally have one or more phosphate groups at the 
sugar moiety. Nucleosides can be converted into nucleotides inside the cell by nucleoside 
kinases which are the basic building blocks of deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA). Both DNA and RNA are the source of life in living cells where DNA carries the 
message. The discovery of the double helix structure of DNA by Watson and Crick is the 
milestone for the development of modern nucleoside and nucleotide chemistry. Both 
nucleosides and nucleotides play key roles in DNA and RNA replication which is critical for 
cell proliferation. Specific nucleoside transporters transport nucleoside analogues inside the 
cells where they are phosphorylated by nucleoside kinases.1,2 The phosphorylated nucleoside 
analogues are incorporated into DNA by DNA polymerase catalyzed reaction and thus induce 
the termination of chain elongation,3 the accumulation of mutation4-6 as well as apoptosis.7,8 
So, through the modification of either the base or sugar moiety, nucleosides can inhibit the 
carcinogenic cell proliferation and viral DNA and RNA replication thus captivate attention to 
study as a precursor molecule in chemistry and biology. 
1.1.1. Nucleoside analogues as anticancer drugs 
Both pyrimidine and purine nucleoside analogues serve as potent anticancer drugs. For 
example cytarbine contributes to cure amyeloid leukeamia9, while 6-mercaptapurine is 
efficacious against acute lymphoblastic leukaemia.10 Gemcitabine, a bifluorinated pyrimidine 
nucleoside derivative is very active against haematological malignancy and different solid 
tumors.11 So far 14 nucleoside analogues have been approved by the US Food and Drug 
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Administration (FDA) for the treatment of cancer which is 10% of the total cancer drugs 
available in the market. In addition a couple of nucleoside analogues such as Sapacetabine,12 
8-chloro-adenosine,13,14 8-amino adenosine15 are waiting for the approval of FDA. 
Table 1. FDA approved anticancer purine and pyrimidine nucleoside analogues16 
Drug Category   Year 
6-mercaptopurine (Purinethol)                                                        Purine 1953 
5-fluorouracil (Adrucil)                                                                   Uracil    1962 
6-thioguanine (Lanvis) Guanine   1966 
arabinofuranosylcytosine (Cytarabine) Cytidine 1969 
5-fluoro-2'-deoxyuridine (Floxuridine) 2′-Deoxyuridine         1970 
arabinofuranosyl-2-fluoroadenine (Fludarabine) Purine analogue        1991 
2'-deoxycoformycin (Pentostatin) Adenosine             1991 
2-chloro-2'-deoxyadenosine (Cladribine) 2′Deoxyadenosine     1992 
2,2-difluoro-2'-deoxycytidine (Gemcitabine) 2′-Deoxycytidine        1996 
N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine 
(Capecitabine)      
Cytidine 1998 
2'-fluoro-2'-deoxyarabinofuranosyl-2-chloroadenine 
(Clofarabine)       
Cytidine   2004 
5-aza-cytidine (Azacitidine) 2′-Deoxyadenosine 2004 
O6-methylarabinofuranosyl guanine (Nelarabine) Guanosine   2005 
5-aza-2'-deoxycytidine (Decitabine) 2′-Deoxycytidine         2006 
 
1.1.2. Nucleoside analogues as antiviral drugs 
Nucleoside analogues are well-known drugs because of their capability to treat a variety of 
viral infected patients including Hepatitis C virus (HCV), Hepatitis B virus (HBC), Human 
immunodeficiency virus (HIV), Herpes simplex virus (HSV), Varicella zoster virus (VZV), 
and Influenza virus.  Several 2'-deoxy-2'-fluorocytidine (FdC) derivatives are well-known 
anti-HCV compounds such as methylated form of FdC (PSI-6130) can effectively inhibit the 
3 
 
genotype 1b HCB subgenomic replicon system.17  Mericitabine in combination with pegylated 
interferon and ribavirin and or a first –generation protease inhibitor is very active to inhibit 
hepatitis C viral replication.18,19 Elvucitabine and Apricitabine are potent inhibitor of human 
immunodeficiency viral (HIV) replication.20,21 Festinavir which is also known as BMS-
986001 is a chemically modified first generation anti-HIV nucleoside analogue stavudine 
increased potency and reduced mitochondrial toxicity.22,23 Cyclopropavir which as a 
guanosine derivative and structurally related to actyclovir and ganciclovir is active against 
many herpesveuses including human cytomegalovirusm human herpesvirus 6A, human 
herpesvirus 6B and human herpesvirus 8.24,25 Because of the potency against a wide range of 
herpes simplex virus, many protides of cyclopropavir have been synthesized and their 
antiviral activities are under investigation.26 
                                                                                                                                                    
Table 2. Antiviral properties of purine and pyrimidine nucleoside analogues27 
Drug Category Year 
5-iodo-2'-deoxyuridine (Idoxuridine Uridine    1962 
5-ethyl-2'-deoxyuridine (Edoxudine) Thymidine 1969 
9-β-D-arabinofuranosyladenine (Vidarabine) Adenosine 1976 
(E)-5-(2-bromovinyl)-2'-deoxyuridine (Brivudine) Uridine 1980 
2-amino-1,9-dihydro-9-[(2-
hydroxyethoxy)methyl]-6H-purin-6-one          
Guanosine 1982 
3'-azido-3'-deoxythymidine (Zidovudine) Thymidine 1987 
2',3'-didehydro-2',3'-dideoxythymidine (Stavudine) Thymidine 1994 
2',3'-dideoxy-3'-thiacytidine (Lamivudine) Cytidine 1998 
2',3'-didehydro-2',3'-dideoxythymidine (Stavudine) Thymidine 2001 
4-Hydroxy-3-(hydroxymethyl)-2-
methylidenecyclopentylguanosine  
       
Thymidine 2005 
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5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-
oxathiolan-5-yl]cytosine 
Cytidine 2006 
Tenofovir disoproxil fumarate, mixture of purine 
analogues (Tenofovir) 
Purine 2008 
2'-deoxy-2'-fluoro-2'-methyluridine-5'-phosphate 
(Sofosbuvir)                 
Thymidine 2013 
 
 1.2. 5-Modified pyrimidine nucleosides as reactive probes for bioconjugation 
Considering the importance of bioconjugation in medicinal chemistry, chemical biology, 
nanotechnology, and material sciences, a considerable amount of effort has been given to 
connect new probes of nucleotides with peptides, proteins, and other biomolecule.28 The 
bioconjugation strategy enables us to link important modified biomolecules to study chemical 
reactions on living cells, which can be crucial to verify the credibility of the anticancer or 
antiviral properties of the corresponding compound.29 Bioconjugation is a useful chemical 
strategy to study DNA-protein interactions.30 Attachment of reactive functionalities such as 
alkyne, alkene, azide, diene, or aldehyde at the base moiety of nucleosides/nucleotides and 
their incorporation into DNA offer good programmability to connect the modified DNA with 
important biomolecules. These functionalities allowed the modified DNA to tether with other 
biomolecules via click chemistry,31 Straudinger ligation,32 Diels-Alder reactions33 etc.  
Some of the notable works in bioconjugation have been done by Hocek’s lab who 
introduced aldehyde functionality at 5 position of cytidine nucleotide and incorporated them 
into DNA and subsequently stained with 2,4-dintrophenyl hydrazine (2,4-DNPH) or 
nitrobenzofurazanehydrazine via hydrazone formation.34  He also tethered reactive aldehyde 
functional group containing formaryl moieties at 5 position of 2'-deoxycytidine nucleotides 
which incorporated via polymerase incorporation. The reactive aldehyde functional group 
containing modified DNA was connected with amino acid lysine and peptides.35 Recently Dr. 
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Hocek attached acrylamide and vinylsulfonamide to the 5 position of cytidine triphosphate 
and incorporated them into DNA via DNA polymerase. Later he did bioconjugation of these 
vinylsulfonamide and acrylamide modified DNA with the tumor-suppressor protein p53.36 
These bioconjugations have been taken place via Michael addition reactions where the 
modified DNA acts as a Michael acceptor while the protein p53 acts as a Michael donor. 
 
Figure 1. Synthesis of vinylsulfonamide modified DNA by PEX and its cross-linking with 
p53 protein36 
 From all of the examples of bioconjugation, we have been inspired to link the (β-
halo)vinyl sulfone modified DNA with amino acid cysteine or proteins having thiol or amine 
residues. The 5-modified 2'-deoxypyrimidine nucleoside analogues modified with (β-
halo)vinyl sulfone will be an excellent probe in bioconjugate chemistry as they are very 
susceptible to different nucleophiles (amine, cysteine etc.) and readily give product via 
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addition-elimination reaction. So, our first goal is to synthesize triphosphorylated pyrimidine 
nucleoside analogues having (β-halo)vinyl sulfone tethered at 5 postion of the nucloebase to 
polymerase catalyzed incorporation into DNA. Next, we want to link this modified DNA with 
amino acid cysteine or protein having amino or thiol residue which will efficiently react with 
(β-halo)vinyl sulfone through addition-elimination reactions. Note that Michal Hocek did 
similar types of bionconjugation via Michael addition reaction but our conjugation is totally 
different and occurs via an addition-elimination process. The 5' position of pyrimidine 
nucleoside analogues modified with (β-halo)vinyl sulfone, polymerage mediated 
incorporation in DNA and subsequent treatment of this modified DNA with suitable protein 
(having amino or thiol residues) will efficiently give bio-conjugated product via addition-
elimination mechanism. In summary, phosphorylation at 5' position of pyrimidine nucleoside 
analogues modified with (β-halo)vinyl sulfone, polymerase mediated incorporation in DNA 
and subsequent treatment of this modified DNA with suitable protein will give our desired 
bio-conjugated product. 
1.3. Overview of (β-halo)vinyl sulfone  
The (β-halo)vinyl sulfones having halogen atom at the β-positions of the vinyl functional 
group are important precursurs due to their capabilities of serving as synthetic intermediate in 
organic chemistry.37,38 Moreover, owing to the presence of reactive functional groups, and 
biologically important C-S bond, it has drawn considerable amount of attention to explore 
their biological activities.39 
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Figure 2. General structure of (β-halo)vinyl sulfones 
1.3.1. Synthesis 
Terminal alkyne functional group offers unique opportunity to synthesize regio and 
stereoselective (β-halo)vinyl sulfone.40 The Eiichi Nakamura group developed Iron-catalyzed 
and phosphine ligand-mediated regio and stereoselective chlorosulfonylation reaction. Thus, 
treatment of terminal alkyne substrate A with aryl sulfonyl chloride in the presence of iron (II) 
acetate and tri(p-tolyl)phosphine and affords (E)-(β-chloro)vinyl sulfone B with excellent 
yield (Scheme 1).41 
 
Scheme 1. Synthesis of (E)-(β-chloro)vinyl sulfone analogue from aryl acetylene  using 
aryl sulfonyl chloride by Eiichi Nakamura’s group 
Sulfonyl hydrazide is a well-known source of sulfonyl moiety and widely used reagent 
during the halovinylsulfonylation reaction.42 Xiangsheng Xu’s group developed transition 
metal catalyzd regio and stereoselective halosulfonylation reaction to synthesize (E)-(β-
chloro/bromo)vinyl sulfone B by the treatment of phenyl acetylene A with p-tolyl sulfonyl 
hydrazide in the presence of iron(III) halides and TBHP afford the halovinyl sulfone B 
(Scheme 2).43 
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Scheme 2. Synthesis of (E)-(β-chloro/bromo)vinyl sulfone by transition metal catalyzed 
halosulfonylation reaction by Xiangseng Xu’s group 
The plausible mechanism of the reaction can be explained by the interaction of tertiary 
butyl hydroperoxide with iron(III) halide generates tertiary butyl peroxide radical I (Scheme 
3). The resulting peroxide radical generates tosyl radical III from tosyl hydrazide through the 
removal of nitrogen gas. Attack on the alkyne group by the reactive tosyl radical and 
subsequent interaction with iron (III) halide generates regio and stereoselective products (E)-
β-chloro/bromovinyl sulfone IV (Scheme 3). 
 
Scheme 3. Plausible mechanism of iron(III) halide-mediated halosulfonylation reactions 
to afford (E)-β-(chloro/bromo)vinyl sulfones 43 
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Xiaoqing Li’s group successfully synthesized (E)-(β-iodo)vinyl sulfone using I2 instead of 
iron halides44 as depicted below in Scheme 4. In this reaction interaction of tertiary butyl 
hydroxyl radical with tosyl hydrazide generates tosyl radical. Subsequent interaction of tosyl 
radical and iodine with alkyne moiety gives (E)-(β-iodo)vinyl sulfone (Scheme 4). 
 
 
Scheme 4. Synthesis of (E)-(β-iodo)vinyl sulfone via iodine mediated halosulfonylated 
reaction by Xiaoqing Li’s  group 
Treatment of terminal alkyne probes with sodium salt of p-toluene sulfinic acid and iodine 
in the presence of sodium acetate afford (E)-(β-iodo)vinyl sulfone as shown in Scheme 5.45  
 
Scheme 5. Synthesis of (E)-(β-iodo)vinyl sulfone using sodium salt of p-toluenesulfinic 
acid 
N-halosuccinimide (NXS) promoted halosulfonylation of terminal alkyne give (E)-(β-
bromo/iodo)vinyl sulfones. Treatment of aryl acetyle A with sodium tosylate and N-halo 
succinamides (NXS) affords E)-(β-bromo/iodo)vinyl sulfones B as depicted in Scheme 6.46 
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Scheme 6. Synthesis of (E)-(β-bromo/iodo)vinyl sulfones via N-bromo/iodo succinamide 
mediated halosulfonylation reaction 
The plausible mechanism of the reaction can be explained by the formation of the iodide 
radical I and succinamide radical by the hemolytic cleavage of N-I bond of NIS in the 
initiating step (Scheme 6). Later, tosyl radical II is formed by single electron transfer with the 
help of succinamide radical and subsequent regio and stereoselective interaction of these tosyl 
radical II and iodide radical I with the terminal alkyne moiety gives (E)-β-iodovinylsulfone 
compound III (Scheme 7). 
  
Scheme 7. Plausible mechanism of NIS promoted iodosulfonylation of aryl alkynes44 
Iodine and di-tert-butyl peroxide (DTBP) promototed difunctionalization of terminal 
alkyne A with  sodium benzene sulfinates  afforded (E)-β-iodovinylsulfone B with excellent 
yield (Scheme 8).47  
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Scheme 8. Synthesis of (E)-β-iodovinylsulfone via iodine and DTBP promoted reaction 
by Zhao et al. 
1.3.2. Biological activity 
As vinyl sulfones are organosulfur compounds, the investigation of their biological 
activities is always fascinating to the medicinal chemists and biologists. Research shows that 
certain type of vinyl sulfone inhibits the replication of human immunodeficiency syndrome 
virus type 1 (HIV-1).48 Vinyl sulfones also inhibit the protein degrading enzyme cathepsins L 
and B.49 It has been also reported that vinyl sulfones inhibits the activities of cysteine protease 
by binding the thiol residue of the enzymes via Michael addition reaction.50 
1.4. Overview of β-keto sulfone 
The β-keto sulfones also known as 2-oxo-sulfones is a class of organosulfur compound 
having active methylene group at the α-position and carbonyl group at the β-position serves as 
a versatile synthetic site that can be used to synthesize different classes of organic 
compounds.51 Important natural products have been synthesized where β-keto sulfones acts a 
structural feature of the target substrate. In addition, certain types of β-keto sulfones exhibit 
important biological activities. Considering these diverse applicability, β-keto sulfones have 
drawn significant attention in chemistry in last few decades and occupied major parts in 
organosulfur chemistry.52  
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Figure 3. General structure of (β-keto)sulfone 
1.4.1. Synthesis  
β-Keto sulfones have been synthesized from various precursor molecules by using a wide 
varieties of reagents.53 Treatment of arylmethyl sulfone A with Grignard reagents generates 
arylsulfonyl methylene anion which attack at the carbonyl carbon of  prop-2-ynals to give β-
hydroxy sulfones B. Oxidation of these β-hydroxy sulfones by PCC give β-keto sulfones C 
with alkyne moiety at the carbonyl group (Scheme 9).54  
 
Scheme 9. Synthesis of β-keto sulfones with alkyne moiety at the carbonyl carbon 
Treatment of 4-hydroxy-5-acyl[2.2]paracyclophane A with NaH and triflic anhydride or 
nonafluorobutanesulfonyl fluoride gives chiral[2.2]paracyclophane derivatives of β-keto 
sulfone B (Scheme 10) which is a potential ligand for asymmetric catalysis.55 
 
Scheme 10. Synthesis of β-keto sulfone with paracyclophane moiety 
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 The β-keto sulfone moiety attached at 3' position of thymidine analogue has been 
reported.56 Treatment of the allene sulfone A with piperidine at rt gives enamine sulfone 
intermediate B which convert to the β-keto sulfone C by hydrolysis (Scheme 11).  
 
Scheme 11. Synthesis of β-keto sulfone from sulfonyl allene attached at 3' postion of  2'-
deoxythymidine nucleoside 
 
The β-keto sulfone has been synthesized from aliphatic or aromatic alkenes by IBX/I2 
mediated reactions with sodium arene sulfinates.57 Treatment of the alkene substrates A with 
sodium salt of p-toluenesulfinic acid efficiently affords the β-keto sulfone B (Scheme 12). 
 
Scheme 12. Synthesis of β-keto sulfone from alkene via IBX/I2 mediated reaction 
Terminal alkyne is a convenient functional group for the synthesis of β-keto sulfone. 
Different research groups have synthesized β-keto sulfones reacting terminal alkyne probes 
with sulfonyl moiety containing precursors. 
Hua’s group successfully synthesized β-keto sulfones B by reacting aryl/heteroaryl 
acetylene substrates A with sulfonyl chloride and water in the presence of catalytic amount of 
p-toluenesulfonic acid  as depicted in scheme 13.58 
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Scheme 13. Synthesis of β-keto sulfones by p-toluenesulfonic acid catalyzed reaction 
The β-keto sulfones anologues B from acid sensitive acetylene precursors A have been 
synthesized using sodium salt of p-toluenesulfinic acid as shown in scheme 14. In this 
sulfonylation reaction nitroethane is used as solvent.59 
 
Scheme 14. Synthesis of β-keto sulfones from acid sensitive acetylene precursors 
  Lei’s group developed dioxygen triggered oxidative difunctionalization of terminal 
alkyne A gives β-keto sulfones B from good to excellent yield (Scheme 15).53 In this reaction 
pyridine acts a base and prevents atom transfer radical addition (ATRA) process to afford β-
keto sulfone instead of vinyl sulfone. 
 
Scheme 15. Synthesis of β-keto sulfones via pyridine catalyzed dioxygen triggered 
oxidative radical process 
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Scheme 16. Mechanism of synthesis of aryl (β-keto)sulfone via pyridine catalyzed 
dioxygen triggered oxidative radical reaction 
 
The mechanism of this reaction can be explained as depicted in Scheme 16 which involves 
generation of the more stable tosyl radical III from the interaction of p-toluene sulfinic acid 
with pyridine followed by oxygen molecule. Interaction of the aryl acetylene with p-toluene 
sulfonyl radical followed by molecular oxygen gives peroxy type radical V. Single electron 
transfer and protonation gives β-peroxyvinyl sulfone intermediate VII. Subsequent oxygen 
abstraction and tautomerization afford β-keto sulfone IX. 
1.4.2. Selected reactions of β-keto sulfones 
The β-keto sulfones have two reactive centers which are active methylene group and 
carbonyl group. So, the reactivity β-keto sulfones can be described by the reactions of each of 
these two groups separately or the interplay of these reactive groups. As the position of the 
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methylene group is in between two electron withdrawing groups which are carbonyl group 
and sulfonyl moiety, the proton of the methylene group is significantly acidic (pKa = 9-10).
60  
β-Keto sulfones undergoes a base promoted Knoevenagel type of reaction to afford 
sulfonyl substituted vinyl ketone derivatives as shown in Scheme 17. Thus treatment of 
benzyl sulfonyl ethan-2-one A with aryl aldehydes gives (E)-α-benzylsulfonyl chalcone 
derivatives B which possess antiproliferative activity.61 
 
Scheme 17. Knoevengal condensation of β-keto sulfones to afford (E)-α-benzylsulfonyl 
chalcone derivatives 
 
Palladium catalyzed allylic alkylation of phenylsulfonyl acetophenone A with  either 
methyl phenyl acetylene B,62 or phenyl allene C,63 or cinnamic alcohol D,64,65 gives 
corresponding highly E-stereoselective α-monoallylated product E as depicted in Scheme 18 
with excellent yield. 
 
Scheme 18.  Pd-catalyzed allylic alkylation of phenylsulfonyl acetophenone for the 
synthesis of E-stereoselective α-monoallylated β-keto sulfone 
The α-arylated analogue of β-keto sulfone have been synthesized via direct arylation 
reaction as demonstrated in Scheme 19. Thus, palladium catalyzed reaction of phenylsulfonyl 
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acetophenone A with aryl bromide in the presence of NaH affords α-arylated product B with 
moderate yield.66 
 
Scheme 19. Pd-catalyzed arylation at α-position of phenylsulfonyl acetophenone 
Treatment of 1-(4-methylsulfonyl)propane-2-ones A with 1-alkylpyrrolidine-2-thione 
methyl iodide salts in the presence of triethylamine; condensation product β-sulfonyl 
substituted enamines B are obtained as single E isomer as depicted in Scheme 20.67 
 
Scheme 20. Alkylation of β-keto sulfones with 1-alkylpyrrolidine-2-thione methyl iodide 
salts for the synthesis of β-sulfonyl substituted enamines 
When of β-keto sulfones A are treated with N-[1-acetoxy-2,22-trichloro)ethyl] urea in the 
sodium hydride, trichlorosubstituted oxoalkyl ureas B are obtained. Subsequent treatment of 
these oxoalkyl urea products B with para-toluenesulfonic acid give arylsulfonyl-substituted 
tetrahydropyrimidin-2(1H)-ones C as shown in Scheme 21.68 
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Scheme 21. Alkylation of β-keto sulfones with N-[1-acetoxy-2,22-trichloro)ethyl] urea to 
afford arylsulfonyl-substituted tetrahydropyrimidin-2(1H)-ones 
 
Treatment of nonaflyl acetone A with β-chloroethyl isocyanate in the presence of triethyl 
amine as base affords corresponding 1,3-oxazolidine B as shown in Scheme 22. In this 
reaction triethyl amine deprotonates at the α-carbon of A and subsequent electrophilic attacks 
at the isocyanate carbon followed by cyclization and tautomerization gives 1,3-oxazolidine 
product B.69                                
 
Scheme 22. Synthesis of 1,3-oxazolidine by the reaction of nonaflyl acetone with β- 
chloroethyl isocyanate 
 
α-Diazo β-keto sulfones B are synthesized by treating correspoding β-keto sulfones A with 
different sources of diazo group such asTsN3,
70 TfN3,
71 NfN3,
72 I(CF2)2O(CF2)2SO2N3,
73 and 
ionic-liquid supported sulfonyl azide as depicted in Scheme 23.74 
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Scheme 23. Synthesis of α-diazo β-keto sulfones 
Treatment of p-toluene sulfonyl acetophenone A with potassium halide and hydrogen 
peroxide in acetic acid gives α-monohalogenated product B with high yield where potassium 
halides are the source of halogen atoms. Subsequent treatment of these monohalogenated 
products B with SO2Cl2 or Br2 in the presence of triethylamine give α,α-dihalogenated 
products C as demonstrated in Scheme 24.75 
 
Scheme 24. Chemoselective α-mono and di-halogenation at the α-carbon of β-keto 
sulfones 
 
The α-iodo β-keto sulfone B can be prepared efficiently by treating corresponding β-keto 
sulfones A either with iodine monochloride in acetic acid,76  or molecular iodine in aqueous 
acidic hydrogen peroxide as shown in Scehme 25.77 
 
Scheme 25. Synthesis of α-Iodo β-keto sulfone using iodine monochloride or iodine 
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Treatment of β-keto sulfones A with [hydroxyl(tosyloxy)iodo] benzene affords to α-
tosyloxy substituted β-keto sulfones  B from very good to excellent yields as depicted in 
Scheme 26.78 No solvent is required in this reaction. 
 
Scheme 26. Synthesis of α-tosyloxy β-keto sulfone via solvent free reaction 
Treatment of β-keto sulfone A with formalin, and thiol or thiophenol in water gives 
Mannich type thiesters B in good to excellent yield (Scheme 27).79 In this reaction first β-keto 
sulfones interact with formaldehyde to give α-methylene β-keto sulfones through a 
Knoevangal type reaction. Later the intermediate is attacked by thiol and affords the product 
via a Michael addition reaction. 
 
Scheme 27. Incorporation of methylthiol moieties at α- position of β-keto sulfones by 
Mannich type reaction 
Treatment of methyl sulfonyl A acetone with triflic acid or methanesulfonic acid affords (E) 
β-ferrocenyl-α,β unsaturated sulfone B via Friedel-Crafts type reaction as depicted in Scheme 
28.80 
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Scheme 28. Synthesis of (E) β-ferrocenyl-α,β-unsaturated sulfone via Friedel-Crafts type 
reaction 
 
Treatment β-keto sulfone A with hydroxyl amine under reflux in ethanol afford β-hydroxy 
sulfone B as demonstrated in Scheme 29.81 
 
 
Corey-Bakshi-Shibata (CBS) catalyzed asymmetric reduction of β-keto sulfones A with 
N-ethyl-N-isopropylaniline-borane complex give optically active β-hydroxy sulfones with 
excellent enatiometric excess (ee) as shown in Scheme 30.82 
 
 
Scheme 29. Asymmetric borane reduction of β-keto sulfones for convertion into β-
hydroxy sulfones 
When β-keto sulfone A is treated with aryl azide in the presence of sodium methoxide, N-
aryl substituted 1H-1,2,3-trizoles B are afforded from good to excellent yield via base 
catalyzed Dimroth reaction (Scheme 31).83 
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Scheme 30. Synthesis of N-substituted triazoles from β-keto sulfones via base catalyzed 
Dimroth reaction 
 
The reaction of β-keto sulfones A with arylazide in the presence of  pyrrolidine as ograno 
catalyst affords 4-sulfonyl 1,2,3-triazoles B from good to excellent yields as depicted in 
Scheme  32.84 In this reaction pyrrolidine forms enamine with the β-keto moiety which played 
the key role for the success of this reaction. 
 
Scheme 31. Synthesis of N-substituted triazoles from β-keto sulfones using pyrolidine as  
organo catalyst 
1.4.3. Biological activity 
The β-keto sulfone contains biologically important sulfonyl moiety which captivates 
attention of the pharmaceutical chemist to investigates their pharmacological properties. 
Research shows that certain types of (β-keto) sulfones are potent and selective inhibitors of 
11β-hydroxysteroiddehydrogenase type 1 (11β-HSD1).85 In addition the (β-keto) sulfones are 
active against pernicious microorganism86 and cyclic (β-keto) sulfones also exhibit fungicidal 
activities.87 
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1.5. Short overview of prodrugs 
Prodrugs are the compounds which are metabolized after entering into the cell of the body 
to act as drugs.88 The chemical modification of a pharmacologically active agent that must 
undergo transformation to release the active drug after entering into the cell is a well known 
and convenient strategy to enhance the physiochemical, biopharmaceutical or 
pharmacokinetic properties of pharmacologically potent compounds.89-92 By designing and 
synthesizing prodrugs different parameters such as poor cell permeability, low aqueous 
solubility, chemical instability, insuffient oral absorption, rapid pre-systemic metabolism etc. 
can be overcome.92,93  In short, prodrugs enhance the absorbtion, distribution, metabolization, 
and excretion (ADME) properties of drugs.94 Currently 5-7% of approved drugs can be sorted 
out as prodrugs and in 2001-02 about 15% of new drugs were approved as prodrugs.95 
 
Scheme 32. General representation of prodrug concept96 
Some common functional groups which are convenient to design prodrugs are carboxylic, 
hydroxyl, amine, phosphate/phosphonate, and carbonyl group. These groups can be converted 
into esters, carbonates, carbamates, amides, phosphates, and oximes to obtain the 
corresponding prodrugs.96 In addition thiols can be converted into thioethers,97 or thioesters98 
whereas  amine can be converted into imines,99,100 and N-Mannich bases101 as the prodrug 
synthetic approach. 
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1.5.1. Prodrug of nucleoside analogues 
One of the convenient and effective methods used to synthesize nucleoside prodrugs is the 
incorporation of different liphophilic groups either at the base moieties or at the sugar 
moieties via acylation or an alkylation reaction to improve cell permeability to the drug. 
Gemcitabine is a well-known anticancer drug which is widely used to treat breast cancer, 
pancreatic cancer, bladder cancer, lung cancer, and others.102 However, research shows that 
significant amount of gemcitabine converts into corresponding uridine analogues in the cell as 
a result of the deamination by the cytidine deaminase enzyme.103 4-N-Alkonylation of 
gemcitabine can significantly reduce the extent of deamination process and exhibit better 
efficiency.104 On the basis of the finding 4-N acylated produg of gemcitabine LY2334737 has 
been developed (Figure 4).105,106 
 
Figure 4. 5'-Acylated CP-4126 (A), 4-N-acylated prodrug LY2334737 (B) of Gemcitabine 
and Capecitabine (C) prodrug of 5-fluorouracil 
 
The 5'-acylated gemcitabine analogues which is also known as CP-4126 is a well-known 
prodrug (Figure 4).107 The lipophilic alkyl long chain enhances the cell permeability of the 
original drug gemcitabine. After entering into the cell the prodrug converts into original drug 
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gemcitabine by the esterase enzyme.108 Capecitabine is a prodrug of 5-fluorouracil which is 
widely used for the treatment of breast cancer, gastric cancer, and colorectal cancer.109,110 
Mericitabine which is also known as RG7128 is an antiviral prodrug of PSI-6130 and used 
for the treatment of hepatitis C virus infected patients as a combination therapy with other 
antiviral drugs (Figure 5).111 The drug acts by inhibiting NS5B RNA polymerase, a primary 
transcript RNA.17  
 
Figure 5. PSI 6130 and its prodrug mericitabine (RG7128) 
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2. RESEARCH OBJECTIVES 
My first research objective was the synthesis of 5-(1-halo-2-tosylvinyl)pyrimidine 
nucleosides (A). Recently, (β-halo)vinyl sulfone analogues gained considerable amount of 
attention because of their reactivity and important biological activities. As (β-halo)vinyl 
sulfones possess reactive halovinyl sulfonyl moiety along with electronegative halogen atom 
at the β-position, I thought it would be interesting to synthesize nucleoside analogues 
modified with (β-halo)vinyl sulfone and exploring their reactivities and biological properties. 
To get access to 5-(β-chloro/bromo)vinyl sulfones (A) I explored transition-metal catalyzed 
halovinylsulfonylation of 5-alkynyl uracil and cytosine nucleosides with p-toluenesulfonyl 
hydrazine in the presence of tert-butyl hydrogen peroxide. The synthesis of 5-(β-iodo)vinyl 
sulfones (A) would be attempted via N-iodosuccinamide mediated halosulfonylation reactions 
of the 5-alkynyl uracil and cytosine nucleosides with sodium salt of sulfinic acid. 
The typical reaction of the unsubstituted vinyl sulfone with nucleophiles occurs via the 
Michael addition reactions. As (β-halo)vinyl sulfone possesses halogen atom at the β-position, 
it would be fascinating to explore these type of reactions with the (β-halo)vinyl sulfone. So, I 
was planning to explore reactivity of the novel (β-halo)vinyl sulfones with different 
nucleophiles i.e., thiolates, amines, amino acid to observe whether it underwent a Michael 
addition or conjugated addition-elimination reaction to give 5-(1-substituted-2-
tosylvinyl)pyrimidine nucleosides (B). I was also eager to investigate the feasibility of 
bioconjugation of these novel halovinyl sulfone analogues by reacting them with 
biomolecules such as tripeptide L-glutathione. The (β-chloro/bromo/iodo)vinyl sulfones 
would be prepared to study the mechanism of the conjugated addition-elimination reactions 
employing kinetic and synthetic approaches. Since (β-halo)vinyl sulfones as well as their 
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products of the addition-elimination reactions with nucleophiles are trisubstituted alkenes, the 
stereochemistry at the double bond of these novel pyrimidine-based 5-(β-halo)vinyl sulfones 
will be established using advanced 2D-NMR techniques and single X-ray crystallographic 
method. Moreover, since 5-modified pyrimidine nucleosides have been demonstrated to 
possess antiviral and antiproliferative properties, I would explore the biological properties of 
these novel (β-halo)vinyl sulfone in various viral (e.g. herplex simplex virus, human 
cytomegalovirus, parafluenza virus) and cancer (e.g. murine leukemia, human T-lymphocyte, 
human cervix carcinoma) cells. I was also planning to investigate if changing the polarity of 
the (β-halo)vinyl sulfone analogues by incorporating different liphophilic alkyl groups (as an 
carboxylic esters) at the sugar moiety would increase their antproliferative properties. 
 
Figure 6. General structure of 5-modified pyrimidine nucleoside analogues 
       My second research objective was the synthesis of novel 5-(β-keto)sulfone analogues of 
pyrimidine nucleoside (C) and exploring their reactivity at the α-carbon of these sulfones. 
Synthesis of these novel (β-keto)sulfone analogues would be attempted  by di-oxygen 
triggered oxidative radical reaction of the 5-ethynyl pyrimidine nucleosides with p-
toluenesulfinic acid in the presence of pyridine and oxygen. Alternatively the (β-halo)vinyl 
sulfone analogues would be converted into corresponding β-keto sulfone analogues by 
applying one-pot synthetic protocol which would involve conversion of the (β-halo)vinyl 
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sulfone into the corresponding (β-amino)vinyl sulfone followed by acid hydrolysis of the 
latter intermediate into (β-keto)sulfone will be also developed. Since the α-carbon of 5-(β-
keto)sulfones C possess acidic protons, I would explore further modification of these  novel 
probes. My ultimate goal was to verify the feasibility of the reactivity at the α-carbon of β-
keto sulfone analogues with different electrophiles and possibly nucleophiles and finally 
demonstrate the feasibility of the bioconjugation of the 5-(β-keto)sulfone modified DNA with 
proteins. 
My third and final research objective was to incorporate the novel 5-(β-chloro)vinyl and 5-
(β-keto)sulfone-2'-deoxyuridine triphosphatesinto DNA so that study of DNA-proteins 
interactions under the physiological conditions could be explored. Thus, Yoshikawa 
phosphorylation  of 5-(β-chloro)vinyl or 5-(β-keto) sulfones followed by coupling of the 
resulting 5'-O-monophosphate with ammonium pyrophosphate should afford the 
corresponding 5'-O-triphosphates. These novel 5-modified 2'-deoxyuridine nucleotides will be 
attempted to be incorporated   into DNA fragments by polymerase-catalyzed reaction. If 
successful, I was planning to investigate bioconjugation of these active probes with tripeptide 
L-glutathione. My final goal was to explore bioconjugation of such modified DNA with 
transcription factors such as c-Myc protein which is rich in nucleophilic thiol (cysteine) 
residues. If successful, further study might uncover critical information of the role of this 
protein in gene expression and DNA replication. 
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3. RESULTS AND DISCUSSIONS 
3.1. Chemistry of (E)-5-(1-halo-2-tosylvinyl)pyrimidine nucleosides  
3.1.1. Synthesis of (E)-5-(1-chloro/bromo/iodo-2-tosylvinyl)uracil nucleosides 
General approaches for the synthesis of targeted 5-modified pyrimidine nucleosides 
involve investigation of halosulfonylation reactions with the nucleoside-derived terminal 
alkynes. Thus, in the first step a reactive acetylene group was incorporated at C5-position of 
the uracil nucleosides which involved  highly efficient Sonogashira coupling of 5-iodo uracil 
nucleoside analogues following Robin’s procedure112 followed by sequential deprotection of 
the protecting groups (Scheme 34). 
 
Scheme 33. Incorporation of reactive acetylene group at 5 position of uracil nucleosides 
Iron (III) chloride mediated and TBHP promoted regio and stereoselective 
chlorosulfonylation reaction of  protected 5-ethynyluridine 5 gave a single E isomer of 2',3',5'-
tri-O-acetyl-5-(1-chloro-2-tosylvinyl)uridine (8) with 68% yield. Analogous treatment of 
protected 2'-deoxyuridine 4 afforded 3',5'-di-O-acetyl-5-(1-chloro-2-tosylvinyl)-2'-
deoxyuridine (9) with 76% yield. Treatment of 5-ethynyluridine 7 with p-toluenesulfonyl 
hydrazide and iron(III) chloride in the presence of tertiary butyl hydrogenperoxide gave (E)-5-
(1-chloro-2-tosylvinyl)uridine 10 with 59% yield. Analogous treatment of 6 in the same 
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condition gave (E)-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (9) with 90% yield (Scheme 
35).90  
 
Scheme 34. Synthesis of (E)-5-(1-chloro/bromo-2-tosylvinyl)uracil nucleosides via iron 
catalyzed halosulfonylation reaction 
Treatment of 5-ethynyluridine 7 with p-toluenesulfonyl hydrazide and iron(III) bromide in 
the presence of tertiary butyl hydrogenperoxide gave (E)-5-(1-bromo-2-tosylvinyl)uridine 11 
with 41% yield. The structure of 8-11 was determined by using NMR techniques and the E 
stereochemistry was established based on literature report and analysis from X-ray 
crystallography as described in Section 3.1.3.2. 
The 5-(1-iodo-2-tosylvinyl)uracil nucleoside analogues were synthesized by NIS 
promoted halosulfonylation reaction  with 5-ethynyl uracil nucleosides and sodium salt of p-
toluenesulfinic acid as depicted in Scheme 36. 
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Scheme 35. Synthesis of (E)-5-(1-iodo-2-tosylvinyl)uracil nucleosides via NIS promoted 
halosulfonylation reaction 
Thus treatment of 5-ethynyluridine 7 with sodium salt of p-toluenesulfinic acid gave (E)-
5-(1-iodo-2-tosylvinyl)uridine 12 with 42% yield. The structure of the compound was 
established by the applying different NMR techniques and mass was determined by using high 
resolution mass spectrometry. In 1H NMR 12 has vinylic proton peak at 7.72 ppm while the 
vinylic carbon peaks appeared at 105.5 ppm.s 
3.1.2. Synthesis of (E)-5-(1-chloro/bromo/iodo-2-tosylvinyl)cytosine nucleosides 
The β-halo sulfonylation reaction was also extended to cytosine nucleoside. An acetylene 
functional group at the C5-position offers a convenient way to synthesize 5-(β-chlorovinyl) 
sulfone of cytidine or 2'-deoxycytidine nucleosides. The acetylene moiety was efficiently 
incorporated at C5- position of these nucleosides  via an acetyl protection at the sugar moiety, 
iodination at 5 position, Sonogashira coupling, silyl deprotection (Scheme 37).113 
 
Scheme 36. Synthesis of acetyl protected 5-ethynylcytidine and 2'-deoxycytidine 
analogues 
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Thus, treatment of 5 ethynyl analogue 17 with tosyl hydrazide in the presence of iron (III) 
chloride and tertiary butyl hydrogen peroxide gave (β-chloro)vinyl sulfone analogue 19 with 
68% yield. Analogous treatment of 18 with tosyl hydrazide in the similar reaction condition 
gave 20 with 60% yield (Scheme 38).  
 
Scheme 37. Synthesis of (E)-β-chlorovinyl sulfone of protected cytidine and 2'-
deoxycytidine nucleosides 
The structure of the compounds 19 and 20 were established by applying different NMR 
techniques such as 1H, COSY, HMQC, DEPT-135, and 13C. The exact mass was determined 
by applying MALDI-TOF mass spectrometry. In proton NMR vinyl peak of 19 and 20 were 
obtained at 7.67 and 7.61 ppm respectively. For both 19 and 20 methyl peak of tosyl group 
was observed at 2.40 ppm while the aromatic peaks were observed in between 7.00 to 8.00 
ppm. In 13C NMR the vinyl peak of 19 and 20 was observed at 137.0, and 138.0 ppm 
respectively while the methyl carbon peak of tosyl group were appeared at 21.0, and 21.8 
ppm. Other aromatic peaks of the tosyl group were observed from 125 to 145 ppm. In addition 
a characteristics β-carbon peak was observed at 143.0, and 139.5 ppm respectively. In mass 
spectrum the characteristics isotopic pattern of one chlorine atom (peak intensity 3:1) was 
observed. Finally, the experimental mass value [M + H]+ 526.1048 and 583.1025 confirmed 
the successful synthesis of 19 and 20. 
33 
 
3.1.3. Addition-elimination reactions of (E)-5-(1-halo-2-tosylvinyl)pyrimidine nucleosides 
with nucleophiles 
The reactivity of the (β-halo)vinyl sulfones of uracil and cytosine nucleosides was studied 
in details, and it was observed that they react efficiently with different nucleophiles such as 
amines, thiols, amino acid etc. through addition-elimination process to give the substituted 
products from moderate to good yield. 
 
Scheme 38. Displacement of halogen atoms of uracil nucleosides by thiolates and amino 
acid to afford analogues with retention of configuration 
Treatment of 9 with propane thiol in the presence of triethyl amine afforded propanethio 
substituted analogue 26 with 73% yield. Analogous treatment of 10 with propane thiol in the 
presence of triethyl amine gave 27 with 75% yield (Scheme 39). Treatment of 9 with 
important amino acid derivative L-cysteine ethyl ester hydrogen chloride in the presence of 
triethyl amine afforded 28 as a 85/15 E/Z mixture and the yield was 60%. Analogous 
treatment of 10 with amino acid derivative L-cysteine ethyl ester hydrogen chloride afforded 
29 as a 85/15 E/Z mixture and the yield was 56% (Scheme 39). 
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The addition-elimination reaction of chlorovinyl sulfone analogue 9 was extended with 
well-known biomolecule and antioxidant L-glutathione. It is noteworithy to mention that 
glutathione is a tripeptide and thus can serve as a model compound to study bioconjugation 
with protein.  
Thus, treatment of chlorovinyl sulfone analogue 9 with L-glutathione in the presence of 
triethylamine in mixed solvent (water and methanol) afforded glutathione incorporated 
product 30 with 56% yield (Scheme 40). 
 
Scheme 39. Conjugation of 5- (β-chloro)vinyl sulfone of 2'-deoxyuridine with L-
glutathione via displacement reaction 
The structure of the compound 30 was determined by applying different NMR techniques 
such as 1H, COSY, HMQC, DEPT-135, and 13C. The exact mass was confirmed by taking 
MALDI-TOF mass spectrometry. In proton NMR distinguished peaks of glutathione moiety 
were observer at the region from 2.0- 5.0 ppm. Each peaks was figured out from their 
correlation in COSY.  
In carbon NMR four peaks of carbonyl carbon of the glutathione moiety were detected at 
170.5, 174.0, 175.2, and 176.2 ppm. The remaining six carbon peaks of glutathione were 
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observed at the region from 25.0 to 55.0 ppm. Finally, the experimental mass value of 30 
verified the success of this reaction. 
The success of the reaction is very encouraging because addition-elimination reaction of 
nucleophile with chlorovinyl sulfone probe can be performed in physiological condition and 
therefore can be explored for the bioconjugation of nucleic acid with protein. One of the 
potential candidate of such protein is c-Myc protein. Note that c-Myc is a DNA transcription 
regulatory protein which controls about 15% of gene expression114 and modified DNA- c-Myc 
protein interaction can significantly modulate the gene expression process and thus might play 
a crucial role in biological system. 
 
 
Scheme 40. Substitution of halogen atoms of 5-(β-halovinyl) sulfone of uridine and 2'-
deoxyuridine with amino group  
Interestingly, treatment of E vinyl sulfone 10 with methanolic ammonia for 3 h gave (Z)-
5-(1-amino-2-tosylvinyl) uridine 32 in 84% yields with a complete inversion of configuration 
(Scheme 41). The plausible mechanism of the reaction can be explained as depicted in the 
Scheme 42. 
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Scheme 41. Plausible mechanism for the substitution of chlorine atom by amino group in 
(β-halo)vinyl sulfones  
  If the nucleophiles after the addition-elimination type reactions are able to form 
hydrogen bonding with the oxygen atom of the sulfonyl moiety, then the products possess Z 
stereochemistry,89 means inversion of configuration takes place as the halo vinyl substrates 
have E stereochemistry. When β-halo vinyl sulfones were treated with methanolic ammonia, it 
gave the Z isomer exclusively (Figure 7). 
 
Figure 7. Intramolecular hydrogen bonding of amino group with oxygen atom of uracil 
ring and sulfone moiety 
The Z stereochemistry of the vinylic position of (β-aminovinyl) sulfone analogue 32 was 
confirmed by Tsui from X-ray crystallography.89 However, crystal was not obtained from the 
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5 modified amino vinyl sulfone analogue 32 as it readily converted into corresponding β-keto 
sulfone analogue during the approach to get crystal in MeOH or CH3CN solvent. 
 
Figure 8. Structure of β-aminovinyl sulfone analogue 33 (left) and its X-ray structure 
(right).89 
 
The Z-5-(β-amino)vinyl sulfone of uracil derivative 35 was synthesized from the 
corresponding E-5-(β-chloro)vinyl sulfone analogue 34.90 In the NOESY experiment 
correlation was observed between the vinylic and H6 proton in 35. This correlation is only 
possible when vinyl position possesses Z stereochemistry. It is important to mention that in 
similar NOESY experiment with E-5-(β-chloro)vinyl sulfone 34 no correlation observed 
between those two protons (Figure 9). 
 
Figure 9. NOESY correlation between the vinylic proton and the H6 proton 
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 Interesting findings from the NOESY experiments and the recent literature report by Tsui 
leads me to draw the conclusion that the vinylic position of the novel (β-amino)vinyl sulfone 
analogue 32 possesses Z stereochemistry. 
     However, when β-halo vinyl sulfones were treated with butyl amine, the product 33 was a 
mixture of E/Z isomers. The rationale for this can be explained that amino group has two 
hydrogen atoms which can form two intramolecular hydrogen bondings as shown in figure 10. 
The butyl amino group has only one hydrogen atom attached to the nitrogen atom which can 
form hydrogen bonding either with oxygen atom of the uracil base or oxygen atom of the 
sulfonyl group. This competition might results the mixtures of E/Z isomers. 
 
Figure 10. Intramolecular hydrogen bonding in (β-aminobutyl)sulfone 33 
To study the kinetics of the addition-elimination reactions of these halo vinyl sulfone and 
to compare reactivity of these halovinylsulfones with the unhalogenated vinyl sulfones, the 
(E)-5-(2-tosylvinyl)uridine (36) was synthesized.115 Thus treatment of 5 with p-toluenesulfinic 
acid in the presence of copper(II) acetate catalyst followed by acetyl deprotection gave 36 
with 35% yield (Scheme 43). 
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Scheme 42. Synthesis of (E)-5-(2-tosylvinyl)uridine 
The structure of 36 was established by applying different NMR techniques and molecular 
weight was determined by high resolution mass spectrometry. In 1H NMR, two vinylic proton 
showed two doublet at 7.19 and 7.62 ppm respectively. The coupling constant value was 15.0 
Hz which indicated that the vinylic position possessed E stereochemistry. In addition the tosyl 
peak was observed at 7.39 and 7.73 ppm respectively. The experimental mass of 36 was 
447.0802 [M+Na]+ which is very much similar to the theoretical value 447.0833. 
3.1.3.1. Kinetics of addition-elimination reaction of (E)-5-(1-halo-2-tosylvinyl)uridine 
The kinetics of the addition-elimination reactions was studied by examining reaction 
profile of β-halovinylsulfones 10, 11, 12, or 36 with n-propenthiol.  Kinetic data for the 
reactions between β-halovinylsulfone 10, 11, 12, and 36 and n-propanethiol in the presence of 
TEA were acquired by 1H NMR at room temperature using a Bruker 400 MHz spectrometer. 
For each of the experiment propanethiol (200 μL of the 29.8 mM in DMSO-d6) was added to 
NMR tube containing 200 μL of the 29.8 mM of β-halovinylsulfone (10, 11, 12, and 36) in 
DMSO-d6 and the proper ratio of PrSH to substrates (10, 11, 12, and 36) was confirmed by 
proton integration. Then TEA (200 μL of the 29.8 mM in DMSO-d6) was added for the total 
9.93 mM concentration of substrates and the reaction mixture was scanned once every 5 
minutes over first 30 minutes and later every 10 min. The procedure was repeated in 
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duplicate. For each of the halovinyl sulfones 10, 11, 12 tested, proton spectra showed 
formation of the substitution product 27. However, unsubstituted vinyl sulfone 36 was 
unreactive in that nucleophilic environment. The profile for the reaction was measured by 
integrating disappearance of the signal of H6 of substrate 10, 11 , and 12 at 8.25, 8.21, and 
8.07 ppm and appearance of H6 signal at 7.96 ppm for the product 27 on 1H NMR spectra. 
The y-intercept for each plot was set up to 1/[starting β-halovinylsulfone concentration]. Plots 
show data collected within ~40% (10), ~55% (11) and ~60% (12) conversion to the β-
(propylthio)vinylsulfone (27) product. 
 
Figure 11. The rate plots for the reactions between 10 (chloro), 11 (bromo), and 12 (iodo) 
with n-propanethiol in the presence of TEA. The second order rate constant was calculating 
by plotting 1/[β-halo vinyl sulfone] as a function of time 
The calculated second order rate constants for the substitution reaction were 0.0096 M-1s-1, 
0.0192 M-1s-1 and 0.0228 M-1s-1 for 10 (chloro), 11 (bromo), and 12 (iodo), respectively. Plots 
depicted in Figure 11 showed that iodo and bromo vinylsufones are more reactive compare to 
chloro counterpart (I ≥ Br > Cl). 
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3.1.3.2. Mechanism and stereochemistry 
When β-substituted vinylsulfones were dissolved in protic polar deuterated solvent the 
alpha vinylic proton exhibited interesting behavior. Thus, when β-amino vinyl sulfone 32 was 
dissolved in D2O or MeOH-d4 the alpha-vinylic proton underwent quick exchange with 
deuteriumto give deuterium labeled compound 37 (Scheme 44).  
 
Scheme 43. Deuterium exchange at vinylic proton of 5- (β-aminovinyl) sulfone of uridine 
to afford α-deuterated analogue 
When 10 was dissolved in MeOH-d4, no deuteration at the vinyl proton was observed. 
However in the presence of triethyl amine deuteration of the vinylic proton was observed and 
gave deuterated compound 38 (Scheme 45). However, the rate of deuteration of chlorovinyl 
analogue 10 was slow compare to the amino analogue 32. 
 
Scheme 44. Deuterium exchange at the vinylic proton of β-chloro analogue 
In the presence of propanethiol and triethyl amine fast deutaration was observed and 
afforded the α-deuterated compound 39 as shown in Scheme 46. 
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Scheme 45. Deuterium exchange at vinylic proton of β-chloro sulfone to give α-deuterated  
β-propanethio-analogue 
From these observations the plausible mechanism of the addition-elimination reaction 
could be proposed (Scheme 47). The β-carbon of the vinyl sulfone is vulnerable to the 
nucleophilic attack as it is partially positive due to the inductive effect of the halogen atom 
and neighboring electron withdrawing sulfonyl moiety. So, subsequent attack of the 
nucleophile and elimination of halogen atom give compound 43. It is also observed that under 
nucleophilic condition (PrSH/MeOH-d4/TEA) the vinylic proton is exchanged by deuterium 
to give compound 44. It is entirely possible that enolate like basicity of intermediate 41 is 
quenched by deuterium and subsequent deprotonation of more acidic proton of intermediate 
42 gave deuterium incorporated compound 44.  
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Scheme 46. Plausible mechanism for substitution of halogen in β-halovinyl sulfones with 
nucleophiles 
 Deuterium exchange was observed when β-amino vinyl sulfone 31 is treated with DMSO-
d6/D2O or MeOH-d4. However, vinyl thiether analogue 27 did not undergo such exchange in 
MeOH-d4 in the presence of TEA. Although deuterium exchange of the vinyl proton was 
observed in the chlorovinyl sulfone analogue 10 in MeOH-d4 in the presence of TEA, this 
exchange was slower compare to the aminovinyl analogue 31. In addition, in the presence of 
nucleophilic condition (PrSH/ TEA/ MeOH-d4) deuterium exchange occured faster compare 
to the absence of propane thiol. From this behavior of chlorovinyl compound 10, it is believed 
that faster deuterium acquision occurs through intermediate 42 instead of intermediate 45. 
 It is reported in the literature3-4 that the expected β-halo vinyl sulfone should have 
possessed E configuration at the double bond. In order to establish unequivocally the 
stereaochemistry in the novel nucleoside analogues, crystal of 5-(1-chloro-2-
tosylvinyl)uridine (10) was obtained by slow evaporation of ACN in H2O. X-ray analysis of 
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the single crystal of 10 was accuired in Dr. Raptis’s Lab at FIU from the X-ray analysis E 
stereochemistry around double bond was concretely established (Figure 12).90 
 
Figure 12. Ball-and-stick representation of 5-(1-chloro-2-tosylvinyl)uridine 10 showing 
the atom labeling scheme. H-atoms and interstitial H2O molecules are omitted for clarity.  
 In 5-(1-chloro-2-tosylvinyl)uridine 5 the glycosyl torsion angle C6−N1−C1′−O4′ is 43.9°, 
and the furanose pseudorotation angle is 164.9° (2T3 conformation). The C3′−C4′−C5′−O5′ 
torsion angle is 53.6° and is in the g+/gg range. Nearly parallel uracil and benzene ring 
orientation allowed favorable π-π interactions. 
  After addition-elimination reaction, the stereochemistry of the vinyl position of the 
products was studied. The crystal of the model compound 1-N-Benzyl-5-(1-(propylthio)-2-
tosylvinyl)uracil 45 was developed by the slow evaporation of acetonitrile and 
stereochemistry was confirmed after running X-ray of the crystal. 
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Figure 13. Ball-and-stick representation of 1-N-benzyl-5-(1-propanethiovinyl)uracil 45 
showing the atom labeling scheme. Disordered parts and H-atoms are not shown for clarity 
The 1-N-benzyl-5-(1-propanethiovinyl)uracil 45 crystallizes in the monoclinic P21/n space 
group with the whole molecule in the asymmetric unit. The molecule contains four 
intermolecular H-bonds including two from the uracil base: (N1-C13: 2.867(9) Å and N3-O5: 
2.920(4) Å). Compare to corresponding β-ketosulfone analogue as discussed in (Section  
3.2.1), the pi-pi interactions are weaker. 
 From the X-ray data it is clear that the propanethio analogue 45 possesses E 
stereochemistry. That means after the addition-elimination reaction the E configuration of the 
double bond remained unchanged for that substituted product. As an amino group can form 
hydrogen bonding with oxygen atom of the tosyl group and the uracil moiety, it was 
interesting to explore the stereochemistry of the double bond of the nucleoside analogue 5-(1-
amino-2-tosylvinyl) uridine 32. As crystal of amino compound was not obtained, the 
stereochemistry of the double bond having amino group was determined by analyzing the 1-
N-benzyl-5-(1-amino-2-tosylvinyl)uracil (35) by NOESY techiques. In a NOESY experiment, 
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the vinyl proton of chloro compound did not show any correlation with H6 proton while in the 
amino compound the vinyl proton showed strong correlation with the corresponding H6 
proton (Figure 9). This correlation could be only possible if the double bond of the vinilic 
position possesses Z stereochemistry. So, the amino analogue 31 has Z stereochemistry at the 
double bond due to the formation of hydrogen bonding of the amino group with the sulfonyl 
moiety of the tosyl group. The Z stereochemistry at the double bond of analogue 31 is totally 
consistent with the literature report published by Tsui et al.89 
3.2. Chemistry of 5-(2-tosylacetyl)uracil and cytosine nucleosides 
The C-5 position of the pyrimidine nucleoside is an active site where different reactive 
functional groups such as alkene, alkyne, azide etc can be incorporated to synthesize novel 
pyrimidine nucleosides.116 So, acetylene functional group was incorporated at the C-5 position 
of the pyrimidine nucleosides. The 5-(1-chloro-2-tosylvinyl)pyrimidine nucleosides were 
synthesized via halovinyl sulfonylation reactions as discussed above in section 3.1.1. These 
(β-chloro)vinyl sulfones 46 were converted into the corresponding β-keto sulfones 47 by the 
treatment of 46 with methanolic ammonia followed by acid hydrolysis of the intermediary (β-
amino)vinyl sulfone (Scheme 48).  
 
Scheme 47. Synthesis of β-keto sulfone from β-chloro vinyl sulfone analogue via 
substitution by ammonia and acid hydrolysis 
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The plausible mechanism for the conversion of 46 to 47 can be explained in the following 
way. Firstly, conversion of (β-chloro)vinyl sulfone (e.g. 46) into (β-amino)vinyl sulfone 
occurs via addition-elimination reactions as depicted in Scheme 42. The basic amino group in 
(β-amino)vinyl sulfone I accepts proton in acidic media and developed positive charge at the 
nitrogen atom to give intermediates II (Scheme 49). Water attacks at the β-carbon of II follow 
by elimination of ammonia pathway afford intermediate IV. Subsequent deprotonation and 
tautomerization generates β-keto sulfone VI. 
 
Scheme 48. Plausible mechanism of the conversion of β-amino sulfone into β-keto sulfone 
 
Since the α-proton of β-keto sulfone is acidic (pKa = ~9-10) and under sufficient basic 
conditions the α-carbon can trap electrophile. From this assumption, different electrophiles 
can be inserted at the α-carbon of the β-keto sulfone analogues as illustrates in Scheme 50. 
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Scheme 49. General scheme for the trapping of eletrophiles at the α-carbon of β-keto 
sulfone  
The plausible mechanism of this reaction is very straightforward and is depicted in 
Scheme 51. First the base picks up an acidic proton from the α-carbon and thus generates 
carbanion II which can be stabilized by forming enolate ion III. The π electron of the enolate 
ion attacks the electrophile and gives product IV as mixture of isomers. The rationale of 
forming products IV can be explained from the sp2 hybridization of α-carbon of III which can 
attack electrophile either from the top face or bottom face. 
 
Scheme 50. Plausible mechanism of electrophile trapping at the α- carbon 
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3.2.1. Synthesis of 5-(2-tosylacetyl)uracil nucleosides 
Initially the synthesis of uracil 5-(β-keto)sulfone were attempeted by pyridine-catalyzed 
oxidative radical reaction of 5-ethynyluracil analogues. Thus, treatment of 1-N-benzyl-5-
ethynyluracil 48 with p-toluenesulfinic acid and pyridine in the presence of oxygen afforded 
5-(β-keto)sulfone derivative 49 with the yield of 44% (Scheme 52).  
 
Scheme 51. Synthesis of 5-(β-keto)sufone of 1-N-benzyl-5-ethynyluracil 
The 5-(β-keto)sulfone 49 was characterized by NMR techniques and mass was confirmed 
from HRMS-TOF analysis. In 1H NMR the α-methylene peak was observed at 4.98 ppm and 
three peaks from tosyl group appeared at 2.42, 7.29 and 7.79 ppm. In 13C NMR the methylene 
carbon peak appeared at 52.9 ppm while β-carbonyl carbon peak was detected at 183.8 ppm.  
Treatment of acetyl protected 5-ethynyl-2'-deoxyuridine 4 with p-toluenesulfinic acid by 
pyridine-catalyzed aerobic oxidative reaction afforded protected 5-(β-keto)sulfone analogue 
50a with 16% yield (Scheme 53). Analogous treatment of protected 5-ethynyluridine 5 with 
sulfinic acid afforded 50b with 20% yield. The low yield of these reactions could be explained 
by the acid sensitive β-glycosidic bond which cleaved during the reaction. Both of the 
products were characterized using NMR techniques.  
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Scheme 52. Synthesis of 5-(β-keto)sufone of protected uridine from the corresponding 5-
ethynyl substrates 
In 50a the two peaks of α-methylene proton were observed at 4.95 and 5.05 ppm and the 
three tosyl peaks appeared at 2.45, 7.35, and 7.85 ppm. In 50b the two peaks from α-
methylene protons appeared at 4.90 and 5.10 ppm. The chemical shift value of H6 for both 
50a and 50b were appeared in the relatively downfield region compared to the 5-
ethynylsubstrates 4 and 5 (8.50 ppm vs 7.83 ppm) probably the result of the incorporation of 
electron withdrawing β-keto sulfonyl moiety at the C5 position. 
As a result of the low yield of the oxidative radical process, the 5-(β-keto)sulone of uracil 
nucleosides were synthesized from their 5-(β-halo)vinylsulofne precursors by applying one 
pot synthetic protocol as depicted in Scheme 48. Thus, acetyl protected (8) or unprotected (9-
10) β-chlorovinyl sulfone analogues of uracil nucleosides were efficiently converted into 
corresponding β-keto sulfones (51-52) by a one pot synthetic protocol. Thus, treatment of the 
vinyl sulfones (8-10) with methanolic ammonia gave β-amino vinyl sulfones in quantitative 
yield. Subsequent acid hydrolysis of these β-amino vinyl sulfones in acetonitrile gave β-keto 
sulfones in high yield. Analogoulsy, acetyl protected β-chlorovinyl sulfones 8 was converted 
into corresponding β-keto sulfone with 60% (52) yields and unprotected chlorovinyl sulfone 
51 
 
analogues 9 and 10 into corresponding β-keto sulfones afforded 74% and 70% yields 
respectively (Scheme 54). 
 
Scheme 53. Synthesis of 5-(β-keto)sulfone of uridine and 2'-deoxyuridine from their (β-
chlorovinyl) sulfone analogue 
The structure of (β-keto) sulfone analogues 51 and 52 were established using different 
NMR (1H, COSY, HMQC, DEPT-135 and 13C) techniques. In 51 and 52, a higher chemical 
shift value of H6 proton was observed at 8.68 and 8.80 ppm respectively as compared to the 
chemical shift value of H6 proton in the corresponding β-chlorovinyl sulfone substrates 8-10. 
The reason of higher chemical shift value of the keto analogues can be explained by the 
incorporation of electron withdrawing keto group at C5 position. In compounds 51 and 52, the 
peaks of methylene group appeared at 5.15 and 5.14 ppm respectively. In β-keto sulfone 
analogues 51 and 52, characteristics peaks of carbonyl carbon were observed at 184.0 and 
185.0 ppm respectively. In addition, distinct peak of methylene carbon peaks were observed at 
64.0 and 64.3 ppm respectively. In agreement with the proton NMR there was also higher 
chemical shifts value of C6 carbon peaks those were 149.0 and 149.3 ppm respectively. The 
mass obtained from the high resolution mass spectroscopy (HRMS) was in accord with the 
calculated value. 
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The single crystal of 1-N-benzyl-5-(2-tosylacetyl)uracil (49) for X-crystallography was 
obtained by diffusion crystallization (ethyl ether into a MeOH solution) of the corresponding 
aminovinylsulfone 35. Compound 49 was crystallized in the triclinic P-1 space group with the 
whole molecule in the asymmetric unit. Several intermolecular H-bonds stabilize the crystal 
structure, including a uracil N-O H-bond (N3-O4: 2.900(3) Å) (Figure 14). The (β-keto) 
sulfone analogue 49 is also stabilized by an intermolecular C-H-π-interaction between the 
tosyl methyl group and the phenyl ring from the benzyl group (C(H)-centroid distance: 3.893 
Å). The π-π interaction usually present between the uracil and the tosyl groups is weak or 
negligible in this analogue possibly due to other H-bonding and C-H-π interactions mentioned 
above. 
 
Figure 14. Ball-and-stick representation of 1-N-benzyl-5-(2-tosylacetyl)uracil (49); H-
atoms have been hidden for clarity 
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3.2.1.1. Electrophile trapping at the α- carbon of the corresponding β-keto sulfone 
 
Since the α-CH2 proton in β-keto sulfones is acidic (pKa = 10-11) the β-keto sulfone 
analogues (51-52) when treated with different electrophile sources such as benzyl bromide, 
methyl iodide, allyl bromide in the presence of dilute NaOH can serve as a convenient 
substrates for the synthesis of α-alkylated products 53-56 (Scheme 55).  
 
Scheme 54. Incorporation of electrophiles at the α-carbon of (β-keto) sulfone of uridine 
and 2'-deoxyuridine 
It is interesting to see that during the electrophile trapping, diastereomeric products were 
obtained and the ratio of the diastereomers varied upon treatment with different electrophiles. 
When benzyl bromide was used as electrophile source 51 gave (50/50) mixtures of 
diasteremeric product 53 with 28% yield. The reason of getting low yield was the formation 
of byproducts. Apart from the expected diastereomeric products, there were two additional 
compounds were characterized. First byproduct was benzylated product at N3 position and the 
second one was a consequence of benzylation both at N3 and α-carbon of the β-keto sulfone. 
Surprisingly, dibenzylation at α-carbon was not observed. In 53 two peaks of H6 proton at 8.6 
and 8.7 ppm with the integration ratio of 1:1 were observed which can be considered as the 
evidence for a 50/50 diastereomeric product. In 1H NMR triplet at 6.5 ppm was observed 
54 
 
which indicated the C proton. The methylene proton of the benzyl group was detected at 3.1-
3.2 ppm as a multiplet. In addition the aromatic peak of the benzyl group was observed in the 
region from 7.0-7.3 ppm. In 13C NMR the α-carbon peak was observed at 55.0 ppm while the 
methyl carbon peak of benzyl group was detected at 31.0 ppm. The aromatic peaks of the 
benzyl group were found in the region from 126.0-131.0 ppm which collapsed with the tosyl 
peaks. The mass obtained from the high resolution mass spectroscopy (HRMS) of compound 
53 was 515.1437 [M+H]+ which is in accord with the calculated value. 
Treatment of 51 with methyl iodide afforded (48/52) mixtures of diasteriomeric product 
54 with the yields of 31%. In addition, two other byproducts were also observed. These 
byproducts were characterized as N3 methylated byproduct and both N3 and α-carbon 
methylated byproduct. Like benzylation reaction, dimethylated product at α-carbon was not 
observed. In this α-methylated analogue 54 two proton peaks of H6 at 8.71 and 8.73 were 
observed with the integral ratio 96: 104 which meant that the diasteriomeric ratio was 48/52. 
The α-CH proton peak was observed at 5.96 ppm as a quartet while the methyl peak was 
observed at 1.34 ppm. In 13C NMR α-C peak was observed at 66.0 ppm and the methyl carbon 
peak was found at 10.0 ppm. 
Analogous treatment of 51 with allyl bromide gave 55/45 mixtures of diastereomeric 
product 55 afforded 31% yield. In addition, two byproducts were also produced in similar way 
as discussed before. The 104: 96 integral ratio of H6 proton of the α-substituted analogue 55 
at 8.70 ppm and 8.75 ppm indicated the diastereomeric ratio is 52:48. The α-CH peak was 
detected as a doublet at 6.15 ppm. The allyl sp3 hybridized CH2 proton peak was obtained at 
2.8 ppm and sp2 hybridized CH proton peak was detected at 5.6 ppm. The sp2 hybridized CH2 
proton peak of allyl group was observed at 5.0 ppm. In 13C NMR α-carbon peak was observed 
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at 68.0 ppm. The three carbon peaks of allyl group were found at 30.0, 118.0 and 133.0 ppm 
respectively. 
Treatment of 52 with allyl bromide afforded allyl substituted product 56 with the as a 
diastereomeric mixtures of 52/48 with the yields of 32%. Two byproducts were obtained in 
the similar way as discussed before. No disubstitution observed at the α-carbon. In 56 the 
integral ratio of H6 proton indicated the diastereomeric product was a 52/48 mixtures. The 
multiplet at 6.14-6.20 ppm confirmed the presence of α-CH peak. The three vinyl peaks was 
observed at 2.8, 4.9 and 5.6 ppm respectively. In 13C NMR α-carbon peak was observed at 
69.0 ppm. The allyl peaks were observed at 30.0, 127.0 and 133.0 ppm respectively.  
The 5-(α-iodo-β-keto)sulfone of 2'-deoxyuridine 56 was synthesized as an alternative 
probe to incorporate nucleophile at the α-carbon of the corresponding sulfones via substitution 
reaction. Thus, treatment of β-keto sulfone analogue 51 with iodine monochloride afforded 5-
(α-iodo-β-keto) sulfone of 2'-deoxyuridine 56 as 50/50 mixtures of diastereomeric mixtures 
with the yields of 44% yield (Scheme 56). Alternatively 56 was also synthesized using 
molecular iodine in the presence of hydrogen peroxide and acetic acid and the yield was 55%. 
 
Scheme 55. Synthesis of 5-(α-iodo β-keto sulfone) of 2'-deoxyuridine 
 
 The structuce of the novel probe 56 was established by using different NMR techniques. 
In 1H NMR α-proton of CH group was observed at 7.30 ppm. The higher chemical shift value 
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of this proton can be explained as the incorporation of the relatively electronegative iodine 
atom at the α-carbon. In 13C NMR the α-carbon peak was observed at 128.0 ppm 
3.2.1.2. Nucleophile trapping at the α-carbon of the β-keto sulfones 
 
Treatment of 5-(α-iodo-β-keto) sulfone 56 with propane thiol in the presence of 
triethylamine gave propane thio nucleophile incorporated product 60 as a 50/50 mixture of 
diasteromers and yield was 20% (Scheme 57). Relatively low yield of this reaction could be 
explained due to the formation of methyl ester as by product which was the major product in 
this reaction.  
 
Scheme 56. Synthesis of 5- (α-propanethio β-keto sulfone) of 2'-deoxyuridine  
The structure of the compound 57 was established by NMR techniques. Thus, in 1H NMR 
three signals of the propanethio group were observed at 2.80-2.85 (multiplet), 1.40-1.60 
(multiplet), and 0.85 (triplet) respectively. This ractions implied the feasibility of the 
incorporation the thiol residue of the important amino acid cysteine at the α-position of the 
corresponding β-keto sulfone analogue 56. 
3.2.2. Synthesis and reactivity of 5-(2-tosylacetyl)cytosine nucleosides 
Acetyl protected β-chlorovinyl sulfone analogues (19-20) of cytosine nucleosides have 
been efficiently converted into corresponding β-keto sulfones (58-59). Thus treatment of the 
(β-chloro)vinyl sulfones (19-20) with methanolic ammonia gave β-amino vinyl sulfones in 
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excellent yield. Subsequent acid hydrolysis of these β-amino vinyl sulfones in acetonitrile 
gave β-keto sulfones (61-62) in good yield (Scheme 58) 
 
Scheme 57. Synthesis of 5-(β-keto)sulfone of cytidine and 2'-deoxycytidine 
When β-chlorovinyl sulfones were treated with methanolic ammonia, it converted into the 
corresponding β-aminovinyl sulfones with the deprotection of the acetyl group 
simultaneously. When β-chlorovinyl sulfones 19 and 20 were converted into corresponding β-
keto sulfone the yields were 68% (58) and 57% (59) respectively.  
The structures of these β-keto sulfone analogues (58-59) were determined by applying 
different NMR techniques and actual mass was obtained from high resolution mass 
spectrometry. In β-keto sulfone analogues 58 and 59, chemical shift value of H6 proton was 
observed at 9.0 and 9.05 ppm respectively which was higher compare to chemical shift value 
of H6 proton of the corresponding β-chlorovinyl sulfone analogues 19 and 20. The higher 
chemical shift value of the keto analogues can be explained by the incorporation of electron 
withdrawing keto group at C5 position. In 58 methylene peak was appeared at 4.80-5.0 ppm 
as doublet of doublet. In 59, the same peak was observed at 4.75-4.98 ppm as doublet of 
doublet. In 58 and 59, characteristics peaks of β-keto carbonyl carbon were observed at 185.0 
and 186.0 ppm respectively. In addition characteristic peaks of methylene carbon of  these 
compounds were also observed at 62.4 and 63.0 ppm respectively. In complete accord with 
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the proton NMR, the higher chemical shift value of C6 carbon was observed at 152.0 and 
152.5 ppm respectively. The mass obtained from the high resolution mass spectroscopy 
(HRMS) of compound 58 was 446.1002 [M+Na]+. The theoretical mass of the compound was 
also 446.1002 [M+Na]+ means the theoretical mass was in complete accord with the 
experimental value of the corresponding compound 
The β-keto sulfone analogues of cytosine nucleosides (58-59) were treated with different 
electrophiles and these electrophiles were efficiently trapped at the α-carbon of the 
corresponding keto sulfone analogues with high yield. Thus treatment of β-keto sulfone 
analogue 58 with benzyl bromide in the presence of dil. NaOH, the α-benzylated product 60 
was obtained as a 52/48 mixture of diastereomers with 68% yield. Interestingly, no 
dibenzylation at the α-carbon was observed (Scheme 59).  
 
Scheme 58. Synthesis of 5-(α-subsitituted β-keto sulfone) of cytidine and 2-deoxycytidine  
The structure of the benzylated product 60 was established by applying different NMR 
techniques. In 1H NMR two multiplets of α-proton was observed at 5.45-5.52 and 5.55-5.62 
ppm. In addition methylene proton of benzyl group was found at 3.30-3.40 ppm as a multiplet. 
Aromatic proton of benzyl group was observed at 7.05-7.25 ppm. In 13C NMR α-carbon peak 
was obtained at 69.0 ppm. The methylene carbon peak of benzyl group was observed at 32.0 
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ppm and the aromatic peaks were collapsed with the tosyl peaks in the region between 127.0 
ppm to 130.0 ppm. 
Analogues treatment of 59 with benzyl bromide in the presence of dil. NaOH afforded α-
benzylated product 61 with 67% yield (Scheme 59). Benzyl disubtitution at α-carbon was not 
observed. In 1H NMR of 61, α-proton peak was appeared at 5.60-5.70 ppm as a multiplet. The 
methylene peak of benzyl group was observed at 3.18-3.30 ppm as a multiplet. The aromatic 
peaks were appeared at7.10-7.25 ppm. In 13C NMR the α-carbon peak was appeared at 70.0 
ppm. The methlene carbon peak of benzyl group was found at 31.0 ppm. Aromatic peak of the 
benzyl group was observed at the region from 126.0 to 129.0 ppm which collapsed with the 
tosyl peaks. 
Treatment of compound 58 with methyl iodine in basic medium gave 52/48 mixture of 
diastereomers 62 with 68% yield (Scheme 59). As usual no dimethylation observed at the α-
carbon. Analogue 62 was characterized by applying different NMR techniques. In 1H NMR α-
proton peak was observed at 5.20-5.30 ppm. The methyl proton was appeared at 1.32-1.38 
ppm. In 13C NMR peaks of α-carbon and methyl group were found at 64.0 ppm and 12.0 ppm 
respectively. 
3.3. Incorporation of (β-halo)vinyl sulfone probes at 8-position of 2'-deoxyadenosine 
The β-halo sulfonylation reaction was also extended into the purine nucleosides by the 
reaction of terminal alkyne group via halosulfonylation reactions. Thus the acetylene group 
was incorporated at the 8 position of the 2'-deoxyadenosine analogue following the literature 
procedure117,118 which involved TBDS protection at the sugar moiety, bromination at 8 
position, Sonogashira coupling, and silyl deprotection as depicted in Scheme 60. 
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Scheme 59. Synthesis of protected 8-acetylene 2'-deoxyadenosine 
 
 
Scheme 60. Attempted halosulfonylation of 8-ethynyl -2'-deoxyadenine 23 with tosyl 
hydrazide. Synthesis of 8-(1-chloro-2-tosylvinyl)adenine 
Treatment of 2'-deoxy-3',5'-bis(O-tert-butyldimethylsilyl)-8-ethynyl adenosine 66 with 
tosyl hydrazide gave 8-(1-chloro-2-tosylvinyl)adenine (67) with the yields of 44% (Scheme 
61). In this halosulfonylation reaction the cleavage of β-glycosidic took place which was 
confirmed from the proton NMR as there was no peak of the sugar moiety observed. In aditio 
there was a peak of the NH proton observed at 13.5 ppm. The vinyl peak was observed at 7.90 
ppm. The three tosyl peaks were appeared at 2.40, 7.45, and 7.80 ppm. In the carbon NMR of 
67, vinyl peak was detected at 136.4 ppm while the C-Cl peaks appeared at 143.0 ppm. The 
five tosyl peaks were found at 21.0, 128.0, 130.0, 135.0, and 145.0 ppm. 
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Scheme 61. Synthesis of 8-(β-iodovinyl)sulfone analogue of 2'-deoxyadenosine 
 
Interestingly when silyl protected 8-ethynyl adenosine analogue 66 is reacted with sodium 
salt of p-toluenesulfinic acid and iodine, no glycosidic bond cleavage was observed. Thus, 
treatment of 66 with sodium tosylate and iodine in the presence of sodium acetate afforded 8-
(β-iodovinyl)sulfone of silyl protected 2'-deoxyadenosine analogue 68 with 48% yield 
(Scheme 62). In the proton NMR of 68 the vinyl peak was observed at 7.60 ppm. The three 
tosyl peaks were appeared at 2.40, 7.25, and 7.70 ppm. In the carbon NMR of the vinyl peak 
was detected at 136.0 ppm while the C-I peaks appeared at 129.0 ppm. The C_H peaks from 
tosyl group were converged at 130.0 ppm. The successful conversion of 8-ethylnyl-2'-
deoxyadenosine 66 to 8-(β-iodovinyl)sulfone of 2'-deoxyadenosine 68 showed that 
halovinylsulfonylation can be extended to the purine nucleoside analogues.  
3.4. Incorporation of (E)-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine nucleotide at DNA  
3.4.1. Synthesis of 5'-phosphates 
Phosphorylation is an important technique to study important biological properties of the 
nucleotides in living cell. Phosphorylation at 5' position of the 2'-deoxynecloside analogues 
are widely useful technique to DNA polymerase mediated incorporation in DNA. Here novel 
5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine analogues have been triphosphorylated at 5'-
position in order to polymerase mediated incorporation in DNA and to study the DNA-protein 
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interaction by reacting with protein molecules. Phosphorylation was accomplished by 
applying modified Yoshikawa method.119 
 
Scheme 62. Synthesis of 5'-monophosphate of 5-(β-chlorovinyl sulfone) of 2'-
deoxyuridine by modified Yoshikawa method 
Treatment of β-chlorovinyl sulfone analogue 9 with 1.8 equiv. of phosphoryl chloride in 
the presence of 2.0 equiv. of proton sponge in trimethyl phosphate solvent at 0 oC gave 5-
dichlorophosphate intermediate 70 in very good yield (~70%; TLC). Subsequent treatment of 
intermediate 70 with 4.2 equiv. of tributylammonium pyrophosphate (TBAPP) and 2.7 equiv. 
of tributylamine (TBA) at rt afforded 5'-triphosphorylated analogue 71 in moderate yield 
(32%) as depicted in Scheme 64. Alternatively, the intermediate 70 have been efficiently 
converted into 5'-monophosphate 69 by quenching the reaction with TEAB buffer. 
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Scheme 63. Synthesis of 5'-triphosphate of 5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine 
 
The 5'-triphosphosphate 71 was characterized by applying different NMR techniques such 
as 31P, 1H, COSY, HMQC, DEPT-135, 13C; and FT-ICR mass spectrometry. In phosphorous 
NMR three peaks were observed at δ -23 (β-P), -11.5 (α-P), -10.5 (γ-P). The peaks at -23.0 
ppm confirmed that triphophorylation had been taken place as β-phosphorous atom of 
triphosphorylated compound gave peak at around -23.0 ppm. The chlorine atom of β-
chlorovnyl sulfone analogue was readily substituted by nucleophile through addition-
elimination type reaction. So, it was a concern whether the chlrorine survived at that basic 
condition after triphosphorylation reaction. However, the mass spectrum showed the presence 
of chloride as it has a classic isotopic pattern at the molecular ion peak and the peak intensity 
is 3:1. The observed molecular mass was 680.95172 [M-H]-  which was in very good 
agreement with the theoretical mass of the compound 680.95186 ppm and the mass error was 
64 
 
only 0.2 ppm. All the proton and carbon peaks were assigned by analyzing different NMR 
spectrum and all the values were in accordance with the expected values. 
3.4.2. DNA polymerase catalyzed incorporation into DNA 
To study the bioconjugation of the novel (β-chloro)vinyl sulfone analogue with proteins in 
vivo, it is indispensable to incorporate this novel probe into DNA. The phosphorylated (β-
chloro)vinyl sulfone analogue 71 was incorporated into double strand DNA by using DNA 
polymerase where the extent of incorporation was tested both in DNA leading and lagging 
strand by using bacterial replication DNA polymerase, the Klenow fragment of DNA 
polymerase I  (pol I) and human repair DNA polymerase, DNA polymerase  (pol ). The 
concentration of the DNA pol I (pol I) was 5 U in each time, however different concentrations 
of  DNA polymerase  (pol ) such as 0.5 nM, 1 nM, 5 nM, 10 nM, 25 nM, and 50 nM were 
used. The concentration of the (β-chloro)vinyl sulfone analogue 71 was 50 μM. The 
polymerase mediated DNA incorporation was monitored by applying polyacrylamide gel 
electrophoresis (PAGE) technique. The details of nucleotide sequence and number, primer, 
and template are tabulated below: 
Table 3. Detailed information of nucleotides used during polymerase mediated 
incorporation 
Nucleotide nt Sequence (5'-3') 
Upstream primer 
 
31 
GCA GTC CTC TAG TCG TAG TAG CAG 
ATC ATC A 
# Downstream primer 
 
39 
CAA CCG GCA TTA GGT GTA GTA GCT 
AGA CTT ACT CAT TGC 
Template 71 
GCA ATG AGT AAG TCT AGC TAC TAC 
ACC TAA TGC CGG TTG ATG ATG ATC 
TGC TAC TAC GAC TAG AGG ACT GC 
 
      # Downstream primer was used only in one nucleotide gap DNA template 
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Figure 15. Incorporation of (β-chloro)vinyl sulfone analogue into DNA open template by 
DNA polymerase 
 
    During the polymerase mediated incorporation approach of the substrate 71 in DNA open 
template which leads to DNA synthesis, human repair DNA polymerase (pol ) was unable to 
incorporate the substrate into DNA at any of the concentration mention above (Fig.15, Lane 
8-12). However, bacterial polymerase pol I can efficiently incorporated the substate (Figure 
15, Lane 13) at 5 U concentrations like the natural substrate deoxythymidine triphosphate 
(dTTP). However due to the excessive activities of the pol I on the substrate one more unit of 
the substrate 71 incorporated and thus mismatch happened which was obvious in PAGE 
analysis (Figure 15, Lane13). 
66 
 
 
Figure 16. Incorporation of (β-chloro)vinyl sulfone analogue into DNA one gap 
nucleotide template by DNA polymerase 
 
During the polymerase mediated incorporation of the substrate into the one gap nucleotide 
template of DNA which causes lagging during the DNA synthesis, both human repair DNA 
polymerase (pol ) and bacterial polymerase (pol I) efficiently incorporated the chlorovinyl 
substrate 71 (Figure 16, Lane 13-15). However, human repair DNA polymerase (pol ) 
mediated incorporation of the substrate is dependent on the concentration of the polymerase. 
From the PAGE analysis it was obvious that 0.1 and 0.5 nM concentration of pol  couldn’t 
incorporate the substrate 58 (Figure 16, Lane 8-9). However, at 1.0 nm concentration of pol  
the incorporation was observed (Figure 16, Lane 10), though the extent of incorporation was 
low at that concentration. With the increase of the concentration of the pol  the extent of 
incorporation enhanced significantly. When 25.0 nM pol  was used the polymerase 
incorporated the substrate 71 (Lane 13) as like the natural substrate dTTP (Lane 6). Similar to 
the open template, 5 U concentration of pol I efficiently incorporated the substrated at the 
template with the mismatched (one more unit incorporated) (Figure 16, Lane 15). 
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3.4.3. Conjugation of phosphorylated chlorovinyl sulfone analogue with L-glutathione  
Treatment of monophosphorylated (β-chloro)vinyl sulfone 69 with L-glutathione in the 
presence of triethyl amine in methanol-water mixed solvent system gave the bioconjugated 
product 72  with 55% yield (Scheme 65).  
 
Scheme 64. Conjugation of 5-(β-chlorovinyl sulfone) of 2'-deoxyuridine-5'-
monophosphate with L-glutathione 
The structure of the bioconjugated analogue 72 was determined by applying different 
NMR techniques and experimental mass value was obtained from FT-ICR mass spectrometry 
where the ionization was carried out in the negative mood. 
In the proton NMR distinct peaks of glutathione were observed in the region from 2.0 to 
5.0 ppm. The three amino acids peak of glutathione which are cysteine, glutamic acid and 
glycine were appeared in that region. It was difficult to figure out the multiplicity of some of 
the proton peaks due to the peak overlapping with the sugar moieties of the nucleosides. In 
carbon NMR the four carbonyl carbon peaks of the amide and carboxylic acid groups were 
observed at 171.0, 175.0, 177.0, and 177.0 ppm. The other six carbon peaks were appeared 
from 25.0 to 65.0 ppm. Finally the experimental mass value which was similar with the 
theoretical value confirmed the presence of 72. 
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3.5. Incorporation of 5-(2-tosylacetyl)-2'-deoxyuridine nucleotide at DNA  
3.5.1. 5'- Phosphorylation 
Novel 5-(2-tosylacetyl)-2'-deoxyuridine analogues have been triphosphorylated at 5'-
position in order to polymerase mediated incorporation in DNA and to study the DNA-protein 
interaction by reacting with protein molecules. Phosphorylation was accomplished by 
applying modified Yoshikawa method. Treatment of β-keto analogue 51 with 1.7 equiv. of 
phosphoryl chloride in the presence of 2.0 equiv. of proton sponge in trimethyl phosphate 
solvent gave 5'-dichlorophosphate intermediate compound 73 in very good yield (~70%; 
TLC). Subsequent treatment of 5'-monophosphorylated intermediate 73 with 4.1 equiv. of 
tributylammonium pyrophosphate (TBAPP) and 2.5 equiv. of tributyl amine (TBA) gave 5'-
triphosphorylated analogue 74 in moderate yield (38%) as depicted in Scheme 66. 
 
Scheme 65. 5'-Phosphorylation of 5-(2-tosylacetyl)-2'-deoxyurindine 
The 5'-triphosphate 74 was characterized by applying different NMR techniques such as 
31P, 1H, COSY, HMQC, DEPT-135, 13C; and FT-ICR mass spectrometry. In phosphorous 
69 
 
NMR three peaks were observed at -23.5, -11.7, -11.0 ppm. The peaks at -23.5 ppm 
confirmed that triphophorylation had been taken place as β-phosphorous atom of 
triphosphorylated compound gave peak at around -23.0 ppm. It was a concerned whether the 
acidic α-methylene proton survived at that basic condition. However, the presence of proton 
peak at 4.20 ppm and integration value indicated the survival of the α-methylene proton. In 
addition in DEPT-135 NMR α-CH2 peak was observed at 67.0 ppm which also ensured the 
presence of unaffected α-methylene group. Finally the mass of the compound was determined 
by ultra high resolution mass spectroscopy in negative mood. The experimental value of the 
compound 72 was 662.98595 [M-H]- compared to the theoretical value 662.98575 [M-H]- 
with a mass error of only 0.3 ppm. 
3.5.2. Incorporation into DNA by DNA polymerase 
Both human DNA repair polymerase (pol ) and bacterial polymerase (pol I) efficiently 
incorporated β-keto sulfone analogue 74  into DNA open template. At 5 U concentration pol I 
efficiently incorporated the substrate 74 like the natural substrate dTTP. However, the human 
DNA repair polymerase  mediated incorporation was dependent on the concentration of the 
polymerase (Figure 17) 
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Figure 17. Incorporation of 5 (β-keto)sulfone analogue into DNA open template by DNA 
polymerase 
 
Incorporation started to take place at 1.0 nM polymerase concentration and at 25.0 nM pol 
 the incorporation was about 50% (Figure 17, Lane 13) which increased to about 70% at 50.0 
nM concentration of the polymerase . 
Polymerase mediated incorporation of the (β-keto)sulfone analogue 74 into one nucleotide 
gap template was observed when either of the polymerase was used. 5 U concentration of the 
bacterial polymerase (pol I) efficaciously incorporated the (β-keto)sulfone analogue 74 
(Figure 18, Lane 15). In this nucleotide template enhance activities of the human repair DNA 
polymerase (pol ) was observed. Even at 0.1 nM of this polymerase incorporated about 50% 
of the (β-keto)sulfone analogue 72 (Figure 18, Lane 9) and only 1.0 nM pol  incorporated the 
substrate 74 (Figure 18, Lane 11) like the natural substrate dTTP (Figure 18, Lane 4). 
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Figure 18. Incorporation of (β-keto)sulfone analogue into DNA one nucleotide gap 
template by DNA polymerase 
 
3.6. Prodrugs of C5 modified uracil nucleosides 
       A number of C5-modified uracil nucleoside analogues has been synthesized in our lab90 
and their anticancer and antiviral activities were tested at Rega Institute for Medical Iesearch 
in Belgium. Interestingly, it has been observed that the half maximal inhibitory concentration 
(IC50) of the acetyl protected chlorovinyl sulofne analogue 9a against the proliferation of 
murine leukemia cells (L1210) were much lower as compared to its unprotected chlorovinyl 
sulfone counterpart 9 (5.6 ± 4.7 µM vs. >200 µM). Therefore, based on these findings 
liphophilic long alkyl chain was incorporated at the 5' and/or 3' position of at 5-modified 
analogue 9 and a number of 5-arylated analogues via esterification reaction. 
.  
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Figure 19. Lipophobic (9) and lipophilic (9a) 5-modified-2' deoxynucleoside analogues 
 
3.6.1. Synthesis of prodrug of (E)-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine 
To incorporate more liphophilic long alkyl chain at the sugar moiety of the nucleoside 
analogues more reactive undecanoic anhydride was prepared from undecanoic acid. Thus 
treatment of undecanoic acid with thionyl chloride at ambient temperature for 5 h gave 
undecanoyl chloride with quantitative yield. 
Treatment of undecanoyl chloride with undecanoic acid in the presence of triethylamine 
gave undecanoic anhydride with quantitative yield. 
 
Scheme 66. Preparation of undecanoic anhydride from undecanoic acid 
Further treatment of undecanoyl chloride with undecanoic acid for overnight and 
evaporation of volatiles under reduced pressure gave undecanoic anhydride as white solid 
with quantitative yield (Scheme 67). 
Treatment of β-chloro vinyl sulfone analogue 9 with undecanoic anhydride gave mono 
and diprotected products from moderate to good yield. When β-chloro vinyl sulfone analogue 
9 was treated with 1.2 equiv. of undecanoic anhydride for two hours, the major product was 
(E)-5'-O-undecanoyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (75) with 45% yield. 
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However, treatment of β-chloro vinyl sulfone analogue 9 with 3 equiv.of undecanoic 
anhydride for 6 h gave (E)-3',5'-Di-O-undecanoyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine 
(76) as major product with 75% yield (Scheme 68). Also small quantities of 3'-O-undecanoyl 
product was isolated (see Experimental Part). 
 
Scheme 67. Synthesis of undecanoate protected 5-(1-chloro-2-tosyl)vinyl-2'-deoxyuridine 
Both mono and di-protected compounds 75 and 76 were characterized by applying NMR 
techniques i.e 1H, COSY, HMQC, DEPT-135, 13C and mass of the products were determined 
by high resolution mass spectrometry. The proton NMR peak at 0.88, 1.24-1.39, 1.62, and 
2.34 ppm and integration value of number of proton confirmed the presence of one 
undecanoyl group in the sugar moiety. The higher chemical shift value of H5' proton at 4.40 
ppm while almost unchanged chemical shift value of H3' proton which is at 4.17 ppm 
indicated that esterification took place at 5'-OH group. In addition, the presence of 3'-OH at 
3.00 ppm further justified the regioselective esterification of 9. Eleven carbon peaks at 14.2, 
22.0, 25.0 29.2, 29.4, 29.5, 29.7, 29.8, 32.2, 34.4, and 174.0 ppm in compound 75 indicated 
the presence of one undecanoyl group. Finally, experimental mass value of 633.2013 
[M+Na]+ confirmed the presence of mono protected analogue 75. 
The integration values of different proton peaks at the region from 0.84 to 2.34 ppm and 
higher chemical shift values of H3' and H5' at 4.42 ppm and 5.27 ppm indicated the presence 
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of diprotected compound. In addition the different carbon peaks and experimental mass value 
801.3505 [M+Na]+ confirmed the diprotected compound 76. 
3.6.2. Synthesis of prodrug of 5-(fur-2-yl/5-heptylfur-2-yl)-2'-deoxyuridine 
The 5-(fur-2-yl)-2'-deoxyuridines 78 and 80 have been synthesized from 5-iodo substrates 
2 and 77 following the literature procedure.91 Analogously, tetrabutylammonium fluoride 
(TBAF)-mediated direct C-H arylation of 5-iodouracil nucleosides 2 and 77 with 2-
heptylfuran provided 5-(heptylfur-2-yl)-2'-deoxyuridine 79 and 81.120 Treatment of 
unprotected derivatives 80 or 81 with undecanoic anhydride gave mono and diacylated 
products from moderate to good yield. Thus, treatment of 5-(fur-2-yl) 80 or 5-(5-heptylfur-2-
yl) 81 analogues with 1.2 equiv. of undecanoic anhydride for two hours afforded 5'-O-
undecanoyl-5-(fur-2-yl)-2'-deoxyuridine (82) or 5'-O-undecanoyl-5-(5-heptylfur-2-yl)-2'-
deoxyuridine (84) with the yield of 52% and 48% respectively. Analogues treatment of 80 or 
81 with 3 equiv. of undecanoic anhydride for 6 h afforded 3',5'-di-O-undecanoyl-5-(fur-2-yl)-
2'-deoxyuridine (83) or 3',5'-di-O-undecanoyl-5-(5-heptylfur-2-yl)-2'-deoxyuridine (85) as 
major products with the yield of 77% and 80% respectively (Scheme 69). Also small 
quantities of 3'-O-undecanoyl products were isolated (see Experimental Part) 
 
Scheme 68. Synthesis of 5-(fur-2-yl)/5-(heptafur-2-yl)-2'-deoxyuridine by direct arylation 
and their undecanoate protected analogues 
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Both mono and diprotected compounds were characterized by applying NMR techniques 
and mass values were determined by HRMS. Accumulating the number of proton present in 
the compound 82 or 84, it was confirmed that these are monoprotected compounds. The regio-
selectivity of the monoesterified products were confirmed by comparing the chemical shift 
value of H3' and H5' proton of the products (82 and 84) with the starting compound (63 and 
64) respectively. In the mono protected analogues 82 and 84 the proton peak of H5' is at 4.25 
ppm and 4.28 ppm which are significantly higher than the corresponding proton of the 
unprotected compounds 80 or 81. Additionally, the H3' proton peaks were almost unchanged 
(4.36 ppm and 4.33 ppm respectively) in the monoprotected products (82 and 84) compared to 
the unprotected ananogues (80 and 81). This could be only possible when acyl protection 
takes place at 5'OH group while 3'OH group would be unprotected. In addition each of the 
compound 82 and 84 has one carbon peak at 174.0 ppm which also indicated the presence of 
mono-esterified products. Finally, the experimental mass value of the products 82 and 84 
which are 485.2264 [M+Na]+ and 583.3359 [M+Na]+ respectively confirmed the presence of 
monoprotected products. 
The higher chemical shift values of H3' and H5' proton at 5.27 ppm and 4.36 ppm 
respectively suggested the presence of diprotected analogue 83. The integration value of 
different proton peaks at the region from 0.82 to 2.40 ppm also agreed this claim. Similar 
finding was observed in diprotected 5-(heptylfur-2-yl) analogue 85. Two different carbonyl 
carbon peaks and experimental mass value of 653.3778 [M+Na]+ and 751.4873 [M+Na]+ 
confirmed the synthesis of diprotected 5-arylated analogues 83 and 85 respectively. 
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3.6.3. Selected antiviral and anticancer activities  
All of the uracil nucleoside analogues (Scheme 68 and 69) were sent to our collaborators 
at Raga Institute for Medical Research in Belgium to test their antiviral and anticancer 
activities. The antiproliferative activity of all of the compounds (9, 9a, and 75-76) was tested 
in murine leukemia (L1210), human leukemia (CEM), and human cervical carcinoma (HeLa) 
cells. Only acetyl protected (β-halo)vinyl sulfone 9a inhibited the growth of those cells in 
lower μM range (Table 4). Interestingly, (β-halo)vinyl sulfone derivatives with a larger acyl 
protected group 75 and 76 didn’t show improved activity. The 5-(fur-2-yl) analogues (78-85) 
were also tested against those carcinogenic cells and the acetylprotected 5-heptylfur-2-yl)-2'-
deoxyuridine 79 inhibited the T-lympocyte cells (CEM) in the μM range. Interestingly 
unprotected 5-(5-heptylfur-2-yl) analogue 81 exhibited improved activity against the same 
cells. Both acetyl protected analogue 79 and unprotected analogue 81 showed moderate 
activities against the proliferation of murine leukemia cells (L1210) (Table 4). Unprotected 5-
(fur-2-yl) analogue 80 is moderately active against human cervix carcinoma cells (HeLa) 
proliferation (Table 4). 
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Table 4. Inhibitory effects on the proliferation of murine leukemia cells (L1210), human T-
lymphocyte cells (CEM), and human cervix carcinoma cells (HeLa).120 
Compound 
IC50 (μM) 
L1210 CEM HeLa 
9a 
79 
80 
81 
84 
85 
5.6 ± 4.7 
65 ± 10 
>100 
48± 6 
> 100 
> 100 
11± 10 
36 ± 3 
> 100 
16 ± 4 
93 ± 4 
78 ± 16 
23 ± 8 
> 100 
32 ± 1 
> 100 
> 100 
> 100 
      IC50 is 50% inhibitory concentration 
 
The 5-(β-chlorovinyl)sulfone analogues (9, 9a and 76-77) and 5-(fur-2-yl) analogues (78-
85) were tested against a broad range of DNA and RNA viruses and the human 
immunodeficiency virus (HIV). The (β-chloro)vinyl sulfone 9a showed an EC50 of 4 μM for 
the Oka strain (VZV TK+) and marginal activity against human cytomegalovirus (HCMV) 
(Table 5). The 3',5'-di-O-acetyl -5-(5-heptylfur-2-yl) (79) and 5-(5-heptylfur-2-yl) (81) 
derivatives inhibited the replication of HCMV and varicella zoster virus (VZV) bearing a 
wild-type thymidine kinase (TK+) with 50% effective concentrations (EC50) in the range of 
10-20 μM (Table 5). 5-(Heptylfur-2-yl)-2-deoxyuridine 81 was equally active against TK+ and 
TK- deficient VZV mutant virus. However, neither of the arylated analogues 79 and 81 were 
able to decrease herpes simplex virus 1 (HSV-1) and 2 (HSV-2) induced cytopathic effect 
(Table 5). 
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Table 5. Anti-herpesvirus activity of the tested compounds in HEP (human embryonic 
lung) fibroblasts 
Compd 
Cytotoxicity 
(μM) 
EC50 (μM) 
MCC 
HSV-1 
(KOS) 
HSV-2 
(G) 
HSV-1 
TK-(KOS 
ACV) 
HCMV 
(AD-
169) 
HCMV 
(Davis) 
VZV 
TK+ 
(Oka) 
VZV 
TK- 
(07-1) 
9a 
79 
80 
81 
> 100 
100 
> 100 
100 
> 100 
> 100 
4.0  ±  0 
> 100 
> 100 
> 100 
47 ±  37 
> 100 
> 100 
> 100 
> 100 
> 100 
> 20 
10  ±  2 
45 
10 
20 
12 ±4  
20 
20 
4 
20 
32 
13 ±2 
>20 
>20 
>100 
12 ±5 
EC50 concentration required to reduce virus-induced cytopathogenicity by 50% 
MCC is the Minimum Cytoxic Concentration required to cause a microscopically detectable alteration 
of normal cell morphology 
 
In contrast, the 5-(fur-2-yl)uracil nucleoside 80 emerged among the compounds 
synthesized as the most potent inhibitor the HSV-1 TK+ strain Kos with an EC50 of 4 μM. 
However, this analogue (80) was less active against HCMV, HSV-2, and VZV TK+ Oka strain 
strain than against HSV-1 while it lacke activity against TK- HSV-1 and VZV (Table 5). The 
5-(5-heptylfur-2-yl)-2'-deoxyuridine (81) displayed antiviral activities against parainfluenza 
virus (Table 6) while all others compounds were inactive. 
Table 6. Activity of 5-(5-heptylfur-2-yl)-2'-deoxyuridine against parainfluenza virus 
 
Compound 
Cytotoxicity (μM) EC50 (μM) 
MCC Parainfluenza-3 virus 
81 > 100 14.8 ±8 
EC50 concentration required to reduce virus-induced cytopathogenicity by 50% 
MCC is the Minimum Cytoxic Concentration required to cause a microscopically detectable alteration 
of normal cell morphology 
 
 
79 
 
4. EXPERIMENTAL 
 4.1. General synthetic procedures 
1H NMR spectra at 400 MHz and 13C NMR at 100.6 MHz were recorded in CDCl3 unless 
otherwise noted. All chemical shift values are reported in parts per million (ppm) and 
referenced to the residual solvent peaks [CDCl3 (7.26 ppm) or DMSO-d6 (2.54 ppm)] for 
1H 
NMR and the CDCl3 (77.16 ppm) or DMSO-d6 (39.52 ppm) for 
13C NMR spectra, with 
coupling constant (J) values reported in Hz. HRMS were obtained in TOF (ESI) mode unless 
otherwise specified. TLC was performed on Merck kieselgel 60-F254, and products were 
detected with 254 nm light. Merck kieselgel 60 (230-400 mesh) was used for column 
chromatography. Purity, yields and ratio of the products (crude and/or purified) were 
established via NMR with calibrated standards. All reagents and solvents were purchased 
from commercial suppliers and used without further purification. The 5-ethynylpyrimidine 
nucleosides112,113 or 8-ethynyl-2'-deoxyadenosine117 were synthesized following the literature 
procedure. 
4.2. Synthesis 
5-(1-Chloro/bromo-2-tosylvinyl)uracl/cytosine nucleosides (9a, 8-11, and 19-20). 
Procedure A. 5-Ethynyluracil/cytosine and tosyl hydrazide were dissolved in the acetonitrile 
and treated with iron(III) halide in the presence of tertiary butyl hydrogen peroxide at 80 oC. 
The volatiles were evaporated and the residue was column chromatographed to afford (9a, 8-
11, and 19-20). 
(E)-3',5'-Di-O-acetyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (9a). Treatment of 3',5'-
di-O-acetyl-2'-deoxy-5-ethynyluridine 4 (336 mg, 1 mmol) with p-toluenesulfonyl hydrazide 
(372 mg, 2 mmol) and FeCl3·6H2O (540 mg, 2 mmol) by procedure A (column 
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chromatography; hexane/EtOAc, 1:1 → 4:6) gave 9a (400 mg, 76%): 1H NMR δ 2.12 (s, 3H), 
2.16 (s, 3H), 2.27-2.37 (m, 1H), 2.42 (s, 3H), 2.58 (ddd, J = 1.7, 5.5, 14.3 Hz, 1H), 4.30-4.35 
(m, 2H), 4.46 (td, J = 2.3, 5.0 Hz, 1H), 5.27 (d, J = 6.4 Hz, 1H), 6.35 (dd, J = 5.5, 8.5 Hz, 
1H), 6.89 (s, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.3 Hz, 1H), 7.88 (s, 1H), 8.83 (s, 1H); 
13C NMR δ 21.02, 21.04, 21.8, 28.8, 38.2, 64.0, 74.4, 83.1, 85.7, 109.2, 127.9, 130.2, 134.7, 
136.7, 139.9, 141.5, 145.6, 149.3, 158.9, 170.5, 170.6; HRMS calcd for C22H23
35ClN2NaO9S 
[M+Na]+ 549.0705, found 549.0708.  
(E)-2',3',5'-Tri-O-acetyl-5-(1-chloro-2-tosylvinyl)uridine (8). Treatment of 2,3,5-tri-O-
acetyl-5-ethynyluridine 5 (79 mg, 0.2 mmol) with p-toluenesulfonyl hydrazide  (52.2 mg, 0.28 
mmol) in the presence of FeCl3·6H2O (108 mg, 0.4 mmol) by procedure A gave 8 (80 mg, 
68%): 1H NMR δ 2.12 (s, 3H), 2.14 (s, 3H), 2.18 (s, 3H), 2.42 (s, 3H), 4.37-4.47 (m, 3H), 
5.36-5.41 (m, 1H), 5.44 (t, J = 5.5 Hz, 1H), 6.10 (d, J = 5.3 Hz, 1H), 6.94 (s, 1H), 7.32 (d, J = 
8.1 Hz, 2H), 7.71 (d, J = 8.2 Hz, 2H), 7.82 (s, 1H), 8.63 (s, 1H); 13C NMR δ 20.6, 20.7, 21.0, 
21.8, 63.2, 70.4, 73.4, 80.7, 88.0, 109.4, 128.1, 130.2, 135.3, 136.7, 139.6, 141.6, 145.5, 
149.2, 159.6, 169.6, 169.7, 170.5; HRMS calcd for C24H25
35ClN2NaO11S [M+Na]
+ 607.0760, 
found 607.0755. 
(E)-5-(1-Chloro-2-tosylvinyl)-2'-deoxyuridine (9). Treatment of 5-ethynyl-2'-
deoxyuridine 6 (50.5 mg, 0.2 mmol) with p-toluenesulfonyl hydrazide (52.2 mg, 0.28 mmol) 
in the presence of FeCl3·6H2O (108 mg, 0.4 mmol) by procedure A (column chromatography; 
CHCl3/MeOH; 9:1→85:15) gave 9 (82 mg, 90%) as white solid. 1H NMR (MeOD-d4) δ 2.25-
2.34 (m, 1H), 2.38 (ddd, J = 13.4, 6.0, 4.1 Hz, 1H), 2.45 (s, 3H), 3.78 (dd, J = 12.0, 3.5 Hz, 
1H), 3.84 (dd, J = 12.0, 2.9 Hz, 1H), 3.99 (dd, J = 6.3, 3.0 Hz, 1H), 4.37-4.53(m, 1H), 6.31 (t, 
J = 6.4 Hz, 1H), 7.23 (s, 1H), 7.39 (d, J = 7.8 Hz, 2H), 7.69 (d, J = 7.8 Hz, 2H), 8.31 (s, 1H); 
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13C NMR (MeOD-d4) δ 21.6, 41.8, 62.7, 72.0, 87.0, 89.3, 109.7, 129.1, 131.0, 136.0, 138.3, 
142.0, 143.9, 146.8, 151.3, 161.6; HRMS calcd for C18H19
35ClN2NaO7S [M+Na]
+ 465.0494, 
found 465.0493 
(E)-5-(1-Chloro-2-tosylvinyl)uridine (10). Treatment of 5-ethynyluridine 7 (54 mg, 0.2 
mmol) with p-toluenesulfonyl hydrazide  (80 mg, 0.4 mmol) in the presence of FeCl3·6H2O 
(108 mg, 0.4 mmol) by procedure A (column chromatography; CHCl3/MeOH; 95:5 → 90:10) 
gave 10 (54 mg, 59%): UV (MeOH) λmax 242, 276 nm (ε 14 100, 10 800), λmin 230, 261 nm 
(ε 13 200, 10 200); 1H NMR (DMSO-d6) δ 2.41 (s, 3H), 3.58 (ddd, J = 12.0, 5.0, 3.1 Hz, 1H), 
3.67 (ddd, J = 11.9, 4.9, 3.1 Hz, 1H), 3.90 (q, J = 3.2 Hz, 1H), 4.01 (q, J = 4.9 Hz, 1H), 4.07 
(q, J = 5.0 Hz, 1H), 5.14 (d, J = 5.0 Hz, 1H), 5.47 (d, J = 5.6 Hz, 1H), 5.80 (d, J = 4.8 Hz, 
1H), 7.42 (d, J = 8.1 Hz, 2H), 7.53 (s, 1H), 7.57-7.79 (m, 2H), 8.25 (s, 1H), 11.67 (s, 1H); 13C 
NMR (DMSO-d6) δ 21.1, 60.5, 69.5, 74.1, 79.1, 85.0, 88.5, 108.8, 127.6, 129.8, 134.0, 136.9, 
139.6, 141.5, 144.8, 149.8, 159.4; HRMS calcd for: C18H19
35ClN2O8S [M+H]+ for 459.0623, 
found 459.0620.  
(E)-5-(1-Bromo-2-tosylvinyl)uridine (11). Treatment of 7 (54 mg, 0.2 mmol) with p-
toluenesulfonyl hydrazide (80 mg, 0.4 mmol) in the presence of FeBr3 (36 mg, 0.2 mmol) and 
column chromatography; CHCl3/MeOH, 95:5 → 90:10) gave 11 (41.3 mg, 41%): UV 
(MeOH) λmax 239, 277 nm (ε 13 500, 10 200), λmin 232, 264 nm (ε 12 800, 9600); 1H NMR 
(DMSO-d6) δ 2.4 (s, 3H), 3.54-3.72 (m, 2H), 3.88-3.93 (m,1H), 3.96-4.1 (m, 2H), 5.1-5.2 (m, 
2H), 5.48 (d, J = 5.6 Hz, 1H), 5.8 (d, J = 4.6 Hz, 1H), 7.43 (d, J = 7.9 Hz, 2H), 7.65 (S, 1H), 
7.68 (d, J = 7.5 Hz, 2H), 8.22 (s, 1H), 11.68 (s, 1H); 13C NMR (DMSO-d6) δ 21.1, 60.5, 69.6, 
74.2, 85.0, 88.5, 110.4, 127.7, 129.3, 129.8, 136.7, 136.9, 140.7, 144.8, 149.7, 159.3; HRMS 
calcd for C18H19 
81BrN2NaO8S [M+Na]+ 526.9917, found 526.9916. 
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(E)-3',5'-Di-O-acetyl-5-(1-chloro-2-tosylvinyl)-2'-deoxycytidine (19). Treatment of 
3',5'-di-O-acetyl-5-ethynylcytidine 17 (156 mg, 0.465 mmol) with p-toluenesulfonyl 
hydrazide  (261 mg, 1.39 mmol) in the presence of FeCl3·6H2O (252 mg, 0.93 mmol) by 
procedure A (column chromatography; CHCl3/MeOH; 100:0 → 90:5) gave 19 (168 mg, 
68%): 1H NMR (DMSO-d6) δ 1.97 (s, 3H), 2.08 (s, 3H), 2.28-2.35 (m, 2H), 2.40 (s, 3H), 
4.15-4.26 (m, 3H), 5.18 (br, 1H), 6.12 (br, 1H), 7.40 (d, J = 6.8 Hz, 2H), 7.65 (d, J = 7.1 Hz, 
2H), 7.70 (s, 1H), 7.80 (s, 1H); 13C NMR (DMSO-d6) δ 20.3, 20.7, 21.0, 38.5, 63.0, 74.0, 
75.0, 81.5, 86.0, 101.0, 127.5, 130.0, 136.0, 136.3, 141.2, 145.0, 147.0, 159.5, 169.5, 170.0. 
HRMS calcd for C22H25
35ClN3O8S [M+H]
+ for 526.1051, found 526.1046 
(E)-2',3',5'-Tri-O-acetyl-5-(1-chloro-2-tosylvinyl)cytidine (20). Treatment of 3',5'-di-O-
acetyl-5-ethynylcytidine  18 (66 mg, 0.167 mmol) with p-toluenesulfonyl hydrazide  (90 mg, 
0.5 mmol) in the presence of FeCl3·6H2O (91 mg, 0.33 mmol) by procedure A (column 
chromatography; CHCl3/MeOH; 100:0 → 90:5) gave 20 (48 mg, 60%): 1H NMR (CDCl3) δ 
2.10 (s, 3H), 2.14 (s, 3H), 2.16 (s, 3H), 2.40 (s, 3H), 4.38-4.48 (m, 3H), 5.38 (dd, J = 10.1, 5.5 
Hz, 1H), 5.49 (t, J = 5.2 Hz, 1H), 6.06 (d, J = 5.3 Hz, 1H), 7.10 (s, 1H), 7.32 (d, J = 8.2 Hz, 
2H), 7.68 (d, J = 8.3 Hz, 1H), 7.88 (s, 1H); 13C NMR (CDCl3) δ 20.4, 20.5, 20.8, 21.8, 63.0, 
70.0, 74.0, 80.0, 89.5, 101.0, 128.0, 131.0, 136.0, 137.5, 139.5, 144.0, 146.0, 153.0, 160.5, 
169.5, 169.7, 170.5 
(E)-5-(1-Iodo-2-tosylvinyl)uridine (12).  5-Ethynyluridine 7 (26.8 mg, 0.1 mmol) was 
dissolved in 5 mL THF.Then sodium p-toluenesulfinate (35.6 mg, 0.2 mmol) and NIS (23 mg, 
0.1 mmol) were sequentially added into the solution and the resulting mixtures were stirred at 
64 oC for 4 h. Volatiles were evaporated and column chromatography; CHCl3/MeOH; 95:5 → 
90:10) gave 12 (21.5 mg, 42%): UV (MeOH) λmax 235, 262, 291 (sh) nm (ε 14 150, 12 650), 
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λmin 220, 252 nm (ε 13 100, 12 400); 1H NMR (DMSO d6) δ 2.4 (s, 3H), 3.54-3.70 (m, 2H), 
3.87-3.92 (m, 1H), 3.97-4.09 (m, 2H), 5.8 (d, J = 4.9 Hz, 1H), 7.4 (d, J = 8.1 Hz, 2H), 7.65 (d, 
J = 8.3 Hz, 2H), 7.72 (s, 1H), 8.07 (s, 1H), 11.6 (s, 1H); 13C NMR (DMSO-d6) δ 21.1, 60.7, 
69.7, 74.1, 85.1, 88.4, 99.5, 111.4, 127.6, 129.8, 136.7, 138.3, 142.6, 144.6, 149.8, 159.2; 
HRMS calculated for C18H19IN2NaO8S [M+Na]+ 572.9799, found 572.9798.  
β-Substituted analogues after displacement of halogen via addition-elimination 
reaction (26-29, 32-33). Procedure B. Chlorovinyl sulfone analogues were dissolved in 
methanol. Then methanolic ammonia, or thiol nucleophilic sources with triethyl amine was 
added into the solution and the resulting mixtures were stirred at ambient temperature. The 
volatiles were evaporated and the residue was column chromatographed to afford (26-29, 32-
33). 
(E)-5-(1-(propylthio)-2-tosylvinyl)-2'-deoxyuridine (26). Treatment of 9 (30 mg, 0.07 
mmol) with n-Propanethiol (7.4 µL, 6.2 mg, 0.08 mmol) in the presence of Et3N (11.3 µL, 8.2 
mg, 0.08 mmol) for 2 h following the procedure B (column chromatography; CHCl3: MeOH = 
95:5 → 90:10) gave E-26 (22 mg, 68%). UV (MeOH) λmax = 275 nm; 1H NMR (400 MHz, 
DMSO-d6) δ 0.93 (t, J = 7.3 Hz, 3H) 1.47-1.64 (m, 2H), 2.00-2.11 (m, 1H), 2.14-2.19 (m, 
1H), 2.39 (s, 3H), 2.80 (t, J = 7.2 Hz, 2H), 3.55 (dd, J = 3.5, 7.9 Hz, 2H), 3.82 (dd, J = 3.04, 
6.04 Hz, 1H), 4.22-4.26 (m, 1H), 5.00 (t, J = 4.9 Hz, 1H), 5.27 (d, J = 4.2 Hz, 1H), 6.17 (t, J = 
6.7 Hz, 1H), 6.46 (s, 1H), 7.38 (d, J = 8.1 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H), 7.89 (s, 1H), 
11.51 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 13.2, 20.6, 21.1, 33.6, 61.2, 70.4, 84.6, 87.7, 
122.3, 127.0, 129.5, 138.8, 143.7, 149.8, 160.1; HRMS calcd for C21H26N2NaO7S2 [M + Na]
+ 
505.1074, found 505.1077. 
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(E)-5-(1-Propylthio-2-tosylvinyl)uridine (27). Treatment of 10 (48 mg, 0.1 mmol) with 
n-propanethiol (11 μL, 9 mg, 0.12 mmol) in the presence of Et3N (17 μL, 12 mg, 0.12 mmol)  
for 2 h following the procedure B and column chromatography (CHCl3/MeOH, 95:5 → 9:1) 
gave 27 (38 mg, 75%) as white solid: 1H NMR (DMSO-d6) δ 0.95 (t, J = 7.8 Hz, 3H), 1.55 
(m, 2H), 2.40 (s, 3H), 2.80 (t, J = 7.8 Hz, 2H), 3.52-3.68 (m, 2H), 3.90 (m, 1H), 3.95-4.07 (m, 
2H), 5.04 (brs, 1H) 5.15 (brs, 1H), 5.45 (d, J = 5.8 Hz, 1H), 5.80 (d, J = 5.1 Hz, 1H), 7.38 (d, 
J = 8.1 Hz, 2H), 7.68 (d, J = 8.2 Hz, 2H), 7.96 (s, 1H), 8.32 (s, 1H), 11.45 (s, 1H); 13C NMR 
(DMSO-d6) δ 13.2, 20.6, 21.1, 33.6, 60.7, 69.8, 74.0, 85.0, 88.2, 109.2, 122.1, 127.1, 128.4, 
129.5, 138.2, 138.8, 143.6, 150.1, 160.1; HRMS calculated for C21H26N2NaO8S2 [M+Na]+ 
521.1023, found 521.1019. 
S-[(E)-1-(2'-Deoxyuridin-5-yl)-2-tosylvinyl]-L-cysteine ethyl ester (28). Treatment of 9 
(30 mg, 0.07 mmol) with L-cysteine ethyl ester hydrogen chloride (36 mg, 0.02 mmol, 3 eq.) 
in the presence of Et3N (11.3 µL, 8.2 mg, 0.08 mmol, 1.2 eq.) for 2 h following the procedure 
B (column chromatography; CHCl3: MeOH = 95:5 → 90 : 10) gave 28 (27 mg, 70 %, E/Z, 
80:20) as a mixture of region isomers and further purification gave 28 (19 mg, 50 %) as single 
isomer. 1H NMR (400 MHz, MeOD-d4) δ 1.32 (t, J = 7.2 Hz, 3H), 2.14 (ddd, J = 5.9, 7.3, 13.5 
Hz, 1H), 2.30 (ddd, J = 3.1, 6.2, 13.6 Hz, 1H), 2.43 (s, 3H), 3.02 (dd, J = 7.8, 10.5 Hz, 1H), 
3.12 (dd, J = 5.6, 10.5 Hz, 1H), 3.76 (dd, J = 3.7, 11.9 Hz, 1H), 3.83 (dd, J = 3.6, 11.9 Hz, 
1H), 3.99 (d, J = 14.9 Hz, 1H), 4.03 (q, J = 3.4 Hz, 1H), 4.08 (dd, J = 5.6, 7.8 Hz, 1H), 4.27 
(q, J = 7.1 Hz, 2H), 4.38 (dt, J = 3.0, 6.0 Hz, 1H), 4.75 (d, J = 14.9 Hz, 1H), 6.24 (t, J = 6.7 
Hz, 1H), 7.33 (d, J = 8.1 Hz, 2H), 7.57 (d, J = 8.3 Hz, 2H), 7.99 (s, 1H); 13C NMR (100 MHz, 
MeOD-d4) δ 14.5, 21.7, 37.1, 41.7, 62.8, 63.3, 63.6, 67.1, 72.7, 74.5, 87.0, 89.4, 116.4, 130.0, 
130.9, 137.1, 138.1, 146.5, 151.6, 163.6, 172.8; 13C NMR (101 MHz, MeOD) δ 172.77, 
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163.62, 151.64, 146.47, 138.11, 137.10, 130.89, 129.98, 116.37, 89.40, 87.01, 74.51, 72.73, 
67.13, 63.64, 63.30, 62.79, 41.73, 37.08, 21.66, 14.47; HRMS calcd for C23H29N3NaO9S2 
[M+Na]+ for 578.1237, found 578.1239 
S-[(E)-1-(Uridin-5-yl)-2-tosylvinyl]-L-cysteine ethyl ester (29). Treatment of 10 (19 
mg, 0.04 mmol) with L-cysteine ethyl ester hydrogen chloride (22.8 mg, 0.12 mmol) in the 
presence of Et3N (45.7 μL, 33.2 mg, 0.32 mmol) for 2 h following the procedure B and 
column chromatography; CHCl3/MeOH, 95:5 → 9:1) gave 29 (E/Z, 85:15; 13 mg, 56%) as 
white solid. The E-isomer had: 1H NMR (DMSO-d6) δ1.20 (t, J = 7.2 Hz, 3H), 2.40 (s, 3H), 
2.95 (dd, J = 10.5, 7.8 Hz, 1H), 3.09 (dd, J = 10.5, 5.6 Hz, 1H), 3.53-3.58 (m, 2H), 3.61-3.63 
(m, 1H), 3.87-3.90 (m, 1H), 3.95–4.00 (m, 2H), 4.04–4.12 (m, 4H), 5.00-5.20 (m, 2H), 5.45 
(d, J = 5.7 Hz, 1H), 5.80 (d, J = 5.1 Hz, 1H), 6.58 (s, 1H), 7.48 (d, J = 8.1 Hz, 2H), 7.68 (d, J 
= 8.3 Hz, 2H), 7.96 (s, 1H), 11.50 (s, 1H); 13C NMR (DMSO-d6) δ 14.0, 21.0, 37.0, 53.5, 
61.5, 61.6, 69.5, 74.0, 85.0, 88.5, 96.0, 116.0, 122.5, 127.5, 128.5, 129.5, 138.5, 143.5, 150.5, 
160.0, 173.0; HRMS calculated for C23H29N3NaO10S2 [M+Na]+ 594.1187, found 594.1173. 
        S-[(E)-1-(2'-Deoxyuridin-5-yl)-2-tosylvinyl]-L-glutathione (30). The 5-(β-
chloro)vinyl sulfone analogue 9 (25 mg, 0.056 mmol) was dissolved  in 1 mL methanol-water 
(80:20) cosolvent system. Then, L-glutathione (25.8 mg, 0.084 mmol) and Et3N (59.0 μL, 
42.5 mg, 0.42 mmol) were sequentially added and the resulting mixtures were stirred at 
ambient temperature for 4 h. The volatile were evaporated and reverse phase HPLC separation 
gave 30 (22 mg, 55%) as white solid. 1H NMR (D2O) δ 2.15 (q, J = 7.2 Hz,  2H), 2.27-2.39 
(m, 2H)  2.45 (s, 3H), 2.50 (t, J = 7.5 Hz, 2H), 3.24-3.45 (m, 2H), 3.70-3.80 (m, 3H), 3.85-
4.02 (m, 2H), 4.08 (br, 1H), 4.50 (br, 1H), 4.60-4.70 (m, 2H), 6.25 (t, J = 6.7 Hz, 1H), 6.85 (s, 
1H), 7.42 (d, J = 8.1 Hz, 2H), 7.61 (d, J = 8.0 Hz, 2H), 7.70 (s, 1H); 13C NMR (D2O) δ 21.0, 
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26.4, 31.0, 33.0, 39.5, 43.8, 52.0, 54.0, 61.0, 70.0, 85.5, 94.0, 108.0, 126.0, 130.0, 135.0, 
136.0, 142.0, 145.8, 151.0, 159.8, 170.7, 174.0, 175.0, 176.2; HRMS calculated for 
C28H35N5O16PS2 [M-H]
- 792.12633, found 792.121640 
 
(Z)-5-(1-Amino-2-tosylvinyl)uridine (32). Treatment (2 h) of 10 (25 mg, 0.054 mmol) 
with NH3/MeOH (3 mL) by the procedure B and column chromatography; CHCl3/MeOH, 
9:1) gave 32 (20 mg, 84%): 1H NMR (DMSO-d6) δ 2.37 (s, 3H), 3.59 (ddd, J = 2.8, 5.3, 12.3 
Hz, 1H), 3.68 (ddd, J = 3.0, 5.0, 12.3 Hz, 1H), 3.86-3.8 (m, 1H), 4.00 (q, J = 5.19 Hz, 1H), 
4.10-4.14 (m, 2H), 5.11 (d, J = 5.6 Hz, 1H), 5.21 (s, 1H) ,5.29 (t, J = 5.1 Hz, 1H), 5.44 (d, J = 
5.4 Hz, 1H), 5.72 (d, J = 4.2 Hz, 1H), 6.99 (s, 2H), 7.35 (d, J = 8.1 Hz, 2H), 7.76 (d, J = 8.2 
Hz, 2H), 8.33 (s, 1H), 11.66 (s, 1H); 13C NMR (DMSO-d6) δ 20.9, 60.2, 69.1, 73.9, 84.8, 
88.2, 89.1, 107.2, 125.5, 129.4, 141.5, 142.2, 142.3, 149.4, 150.7, 161.6; HRMS calculated for 
C18H22N3O8S [M+H]+ 440.1122, found 440.1100. 
5-[1-(n-Aminobutyl)-2-tosylvinyl]uridine (33). Treatment of β-chlorovinyl analogue 10 
(25 mg, 0.054 mmol) with n-butyl amine 27 μL, 20 mg, 0.27mmol) for 5 h following the 
procedure B and column chromatography; CHCl3/MeOH, 95:5 → 90:10) gave 33 (19 mg, 
71%) as E/Z mixtures (85:15). The major isomer had: 1H NMR (MeOH-d4) δ 0.85 (t, J = 7.5 
Hz, 3H), 1.40 (sex, J = 7.2 Hz, 2H), 1.58 (quin, J = 7.5 Hz, 2H), 2.40 (s, 3H), 3.00 (t, J = 7.0 
Hz, 2H), 3.75 (dd, J = 10.3, 6.0 Hz, 1H), 3.82 (dd, J = 10.2, 5.8 Hz, 1H), 4.0-4.05 (m, 1H), 
4.20 (ddd, J = 9.4, 6.4, 2.3 Hz, 1H),  4.25 (dd, J = 9.7, 4.6 Hz, 1H), 5.00 (s, 1H), 5.9 (d, J = 
4.5 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.3 Hz, 2H), 7.95(s, 1H). 
(E)-5-(2-Tosylvinyl)uridine (36). Step a. p-Toluenesulfonic acid (62 mg, 0.4 mmol) was 
added to a solution of 2',3',5'-tri-O-acetyl-5-ethynyluridine 5 (68 mg, 0.17 mmol) in dry THF 
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(3 mL) containing Cu(OAc)2•2H2O (3 mg, 0.015 mmol) under nitrogen at ambient 
temperature. The resulting solution was stirred at 60 oC (oil bath) for 7 h. After cooling to 
ambient temperature, the volatiles were evaporated under the reduced pressure and the residue 
was column chromatographed (hexane/EtOAc, 1:1→4:6) to give (E)-2',3',5'-tri-O-acetyl-5-(2-
tosylvinyl)uridine (31.5 mg, 35%): 1H NMR δ 2.10 (s, 3H), 2.12 (s, 2H), 2.21 (s, 3H), 2.42 (s, 
3H), 4.30 – 4.51 (m, 3H), 5.31 (t, J = 5.3 Hz, 1H), 5.36 (t, J = 5.2 Hz, 1H), 6.00 (d, J = 4.8 
Hz, 1H), 7.19 (d, J = 15.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H), 7.62 (d, J = 15.0 Hz, 1H), 7.76 
(d, J = 8.2 Hz, 2H), 7.79 (s, 1H), 8.70 (s, 1H). Step b. Methanolic ammonia (1.5 mL) was 
added to the solution of the material (25.5 mg, 0.045 mmol) in MeOH (1.5 mL) at 0 oC and 
the resulting solution was stirred for overnight. Volatiles were evaporated and the residue was 
column chromatographed (CHCl3/MeOH, 9:1) to give 36 (12 mg, 63%): 1H NMR (MeOD-
d4) δ 2.42 (s, 3H), 3.77 (dd, J = 12.4, 2.6 Hz, 1H), 3.93 (dd, J = 12.4, 2.6 Hz, 1H), 4.02 (dt, J 
= 5.2, 2.6 Hz, 1H), 4.12 – 4.21 (m, 2H), 5.87 (d, J = 3.1 Hz, 1H), 7.30 (d, J = 15.0 Hz, 1H), 
7.39 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 15.0 Hz, 1H), 7.74 (d, J = 8.4 Hz, 2H), 8.61 (s, 1H); 13C 
NMR (MeOD-d4) δ 21.5, 61.5, 70.4, 76.2, 86.2, 91.3, 108.7, 128.2, 128.5, 131.1, 136.2, 
139.6, 145.8, 146.6, 151.1, 163.3. HRMS calculated for C18H20N2NaO8S [M+Na]+ 447.0833, 
found 447.0802. 
Synthesis of protected 5-(β-keto sulfone) of uracil nucleoside (49, 50a and 50b). 
General Procedure C. Protected 5-ethylnyluracil nucleosides were taken in a round bottom 
flask and dissolved in 1, 2 dichloroethane. Then freshly prepared p-toluenesulfinic acid and 
pyridine were sequentially added into the solution. A balloon filled with oxygen was 
connected with the flask and the resulting mixtures were placed in an oil bath and stirred at 45 
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oC for 4 h. The reaction mixtures were washed with dil. HCl followed by NaHCO3 solution. 
The organic layer was column chromatographed to afford (35, 50a, and 50b). 
1-N-benzyl-5-(2-tosylacetyl)uracil (49). Treatment of 1-N-benzyl-5-ethynyluracil 48 
(45.2 mg, 0.2 mmol)  with p-toluenesulfinic acid  (156 mg, 1.0 mmol) and pyridine (66 μL, 
64.9 mg, 0.82 mmol) in the presence of oxygen (balloon) by procedure C and column 
chromatography (Hexane : EtOAc = 1:1) gave 49  (35 mg, 44%) as white solid. 1H NMR δ 
2.42 (s, 3H), 4.98 (s, 4H), 7.29 (d, J = 8.0 Hz, 2H), 7.34-7.31 (m, 2H), 7.45-7.37 (m, 3H), 7.79 
(d, J = 8.3 Hz, 2H), 8.23 (s, 1H), 8.46 (s, 1H); 13C NMR δ 21.8, 52.9, 65.4, 112.0, 128.58, 
128.61, 129.4, 129.6, 129.9, 133.9, 137.0, 145.3, 149.6, 151.7, 160.5, 183.8; HRMS calcd for 
C20H19N2O5S [M + H]+ 399.1009, found 399.1017. 
3',5'-Di-O-acetyl-5-(2-tosylacetyl)-2'-deoxyuridine (50a) Treatment of protected 5-
ethynyl-2'-deoxyuridne 4 (25 mg, 0.074 mmol) with p-toluenesufinic acid (58 mg, 
0.372mmol) and pyridine (14.5 μL, 14.2 mg, 0.372 mmol) in the presence of oxygen (balloon)  
by procedure C and column chromatography (Hexane/EA ; 60:40 → 40:60) gave 50a (6 mg, 
16%) as white solid: 1H NMR (CDCl3) δ 2.13(s, 3H), 2.16 (s, 3H), 2.45 (s, 3H), 2.58-2.66 (m, 
1H), 2.74-2.78 ( m, 1H), 4.35 (dd, J = 6.9, 3.8 Hz, 1H), 4.36-4.40 (m, 2H), 4.93 (d, J = 13.0 
Hz, 1H), 5.04 (d, J = 13.1 Hz, 1H), 5.24-5.30 (m, 1H), 6.35 (dd, J = 11.9, 6.4 Hz, 1H), 7.35 
(d, J = 7.8 Hz, 2H), 7.70 (d, J = 8.1 Hz, 2H), 8.40 (s, 1H), 8.60 (s, 1H). 
2',3',5'-Tri-O-acetyl-5-(2-tosylacetyl)uridine (50b) Treatment of protected 5-
ethynyluridine 5 (36 mg, 0.09 mmol) with p-toluenesufinic acid (78 mg, 0.5 mmol) and 
pyridine (40 μL, 39.2 mg, 0.5 mmol) in the presence of air (balloon) and column 
chromatography (Hexane/EA ; 60:40 → 40:60) gave 50b (9 mg, 20%) as white solid: 1H 
NMR (CDCl3) δ 2.11(s, 3H), 2.14 (s, 3H), 2.19 (s, 3H), 2.45 (s, 3H), 4.35 (ddd, J = 12.1, 6.9, 
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3.8 Hz, 2H), 4.40-4.44 (m, 1H), 4.93 (d, J = 13.3 Hz, 1H), 5.06 (d, J = 13.3 Hz, 1H), 5.33-
5.38 (m, 1H), 6.35 (d, J = 4.5 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 7.80 (d, J = 8.3 Hz, 2H), 8.50 
(s, 1H), 8.65 (s, 1H) 
      5-(2-Tosylacetyl)uracil/cytosine nucleosides (51-52 and 58-59). Procedure D. 
Acetyl protected (8 and 19-20) or unprotected (9-10) 5-(1-chloro-2-tosylvinyl)pyrimidine 
nucleosides were dissolved in methanolic ammonia and the resulting mixtures were stirred at 
0 oC → r.t; The volatiles were evaporated and the residue was dissolved in 4 mL CH3CN. The 
solution was acidified (pH ~ 4) by adding dil. HCl (aq) and stirred for 2h. After neutralizing 
the solution with dil. NaOH(aq), the volatiles were evaporated and the residue was column 
chromatographed to give the  products (51-52 and 58-59). 
5-(2-Tosylacetyl)-2'-deoxyuridine (51). Treatment of 9 (96 mg, 0.21 mmol) with 
methanolic ammonia (3 mL) for 2 h and subsequent acid hydrolysis as described in procedure 
D followed by  column chromatography (CHCl3/MeOH ; 100:0 → 95:5) gave 51 (68 mg, 
72%) as white solid: 1H NMR (DMSO-d6) δ 2.10-2.27 (m, 2H, H2',2"), 2.40 (s, 3, Me), 3.51-
3.63 (m, 2H, H5',5"), 3.87 (q, J = 3.1 Hz, 1H, H4'), 4.23 (q, J = 3.4 Hz, 1H, H3'), 5.10 (t, J = 
4.5 Hz, 1H, 5'OH), 5.15 (s, 2H, α-CH2), 5.30 (d, J = 4.1 Hz, 1H, 3'OH), 6.06 (t, J = 6.3 Hz, 
1H, H1'), 7.42 (d, J = 8.2 Hz, 2H, Ar), 7.74 (d, J = 8.1 Hz, 2H, Ar), 8.68 (s, 1H, H6), 11.80 (s, 
1H, NH); 13C NMR (DMSO-d6) δ 21.0, 41.0, 60.5, 64.0, 70.0, 86.0, 88.0, 110.5, 128.0, 130.0, 
137.0, 144.0, 148.0, 149.0, 161.0, 184.0; HRMS calcd for C18H20N2NaO8S [M+Na]
+ for 
447.0833, found 447.0874 
5-(2-Tosylacetyl)uridine (52). Treatment of 10 (96 mg, 0.21 mmol) with methanolic  
ammonia (3 mL) for 2 h and subsequent acid hydrolysis as described in procedure D followed 
by column chromatography (CHCl3/MeOH ; 100:0 → 95:5) gave 52 (65 mg, 70%) as white 
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solid: 1H NMR (DMSO-d6) δ 2.40 (s, 3H, Me), 3.55-3.75 (m, , 1H, H5'5"), 3.93 (q, J = 3.2 
Hz, 1H, H4'), 3.95 (t, J = 4.9 Hz, 1H, H3'), 4.08 (t, J = 5.0 Hz, 1H, H2'), 5.12 (t, J = 4.5 Hz, 
1H, 5'OH), 5.14 (s, 2H, α-CH2), 5.21 (d, J = 4.1 Hz, 1H, 3'OH), 5.51 (d, J = 4.9 Hz, 1H, 
2'OH), 5.75 (d, J = 2.2 Hz, 1H, H1'), 7.42 (d, J = 7.8 Hz, 2H, Ar), 7.74 ( d, J = 7.8 Hz, 2H, 
Ar), 8.80 (s, 1H, H6), 11.85 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.0, 60.0, 64.2, 69.5, 75.0, 
85.0, 89.5, 111.0, 128.0, 130.0, 137.0, 144.5, 148.0, 149.5, 161.0, 185.0 
 5-(2-Tosylacetyl)-2'-deoxycytidine (58). Treatment of acetyl protected (β-chloro) vinyl 
sulfone 19 (150 mg, 0.28 mmol) with methanolic ammonia (5 mL) for 12 h and subsequent 
acid hydrolysis as described in procedure D followed by column chromatography 
(CHCl3/MeOH ; 100:0 → 95:10) gave 58 (70 mg, 59%) as white solid: 1H NMR (DMSO-d6) 
δ 2.05-2.10 (m, 1H, H2'), 2.30 (ddd, J = 13.2,  8.2, 2.1 Hz, 1H, H2"), 2.40 (s, 3H, Me), 3.62-
3.68 (m, 1H, H5'), 3.70-3.76 (m, 1H, H5"),  3.92 (q, J = 3.4 Hz, 1H, H4'), 4.30 (quint, J = 4.6 
Hz, 1H, H3'), 4.86 (d, J = 14.1 Hz, 1H, α-CH), 4.95 (d, J = 14.1 Hz, 1H, α-CH), 5.29 (d, J = 
4.4 Hz, 1H, 3'OH), 5.34 (t, J = 5.3 Hz, 1H, 5'OH), 6.09 (t, J = 5.9 Hz, 1H, H1'), 7.45 (d, J = 
8.3 Hz, 2H, Ar), 7.75 ( d, J = 7.8 Hz, 2H, Ar), 8.10 (d, J = 5.4 Hz, 2H, NH2), 9.02 (s, 1H, H6); 
13C NMR (DMSO-d6) δ 21.0, 41.5, 61.0, 62.5, 69.5, 86.0, 88.0, 103.0, 128.0, 130.0, 136.0, 
144.5, 152.0, 152.5, 163.0, 185.5; HRMS calcd for C18H22N3O7S [M+H]
+ 424.1178, found 
424.1176 
5-(2-Tosylacetyl)cytidine (59). Treatment of acetyl protected (β-chloro) vinyl sulfone 20 
(35 mg, 0.06 mmol) with methanolic ammonia (4 mL) for 12 h and subsequent acid 
hydrolysis as described in procedure D followed by column chromatography (CHCl3/MeOH ; 
100:0 → 95:10) gave 59 (17 mg, 64%) as white solid: 1H NMR (DMSO-d6) δ 2.40 (s, 3H, 
Me), 3.68 (ddd, J = 12.5, 5.2, 3.0 Hz, 1H, H5'), 3.85 (ddd, J = 12.1, 4.5, 2.3 Hz, 1H, H5"),  
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3.95 (q, J = 3.4 Hz, 1H, H4'), 3.98-4.02 (m, 1H, H3') 4.03-4.09 (m, 1H, H2'), 4.80 (d, J = 14.1 
Hz, 1H, α-CH), 4.95 (d, J = 14.1 Hz, 1H, α-CH), 5.05 (d, J = 6.5 Hz, 1H, 3'OH), 5.45 (t, J = 
5.0 Hz, 1H, 5'OH), 5.58 (d, J = 4.8 Hz, 1H, 2'OH), 5.71 (d, J = 1.9 Hz, 1H, H1'), 7.43 (d, J = 
8.3 Hz, 2H, Ar), 7.74 ( d, J = 8.2 Hz, 2H, Ar), 8.06 (d, J = 3.2 Hz, 1H, NH), 8.13 (d, J = 3.2 
Hz, 1H, NH), 9.05 (s, 1H, H6); 13C NMR (DMSO-d6) δ 21.0, 60.0, 62.5, 68.3, 74.0, 84.0, 
91.0, 103.5, 128.0, 130.0, 136.0, 145.0, 152.0, 152.5, 162.5, 185.5 
Incorporation of electrophiles at the α-carbon of β-keto sulfone moiety of 
pyridmidine nucleoside analogues (53-56 and 60-62). Procedure E. 5-(β-keto)sulfones of 
uracil/cytosine nucleoside were dissolved in 1 mL MeOH. Then 5M NaOH/H2O solution (2 
equiv.) were added and the solution was stirred for 20 min. Finally, 1.2 equiv. of the 
electrophile source (R-X) was added and the resulting solution was stirred at ambient 
temperature. The solution was neutralized by adding dil. HCl and volatiles were evaporated. 
The residue was column chromatographed to give the desired products (53-56 and 60-62). 
5-(2-Benzyl-2-tosylacetyl)-2'-deoxyuridine (53). Treatment of 51 (18 mg, 0.042 mmol) 
with NaOH(aq) (16 µL, 3.36 mg, 0.084 mmol), and benzyl bromide (10 µL, 14.4 mg, 0.05 
mmol) for 3 h as described in procedure E followed by column chromatography 
(CHCl3/MeOH; 100:0 → 95:5) gave 53 as a (50/50) mixture of diastereomers (6 mg, 28%) 
along with byproducts. 1H NMR (DMSO-d6) δ 2.05-2.20 (m, 1.0, H2'), 2.22-2.32 (m, 1.0, 
H2"), 2.40 (s, 1.5, Me), 2.41 (s, 1.5, Me), 3.25-3.30 (m, 1, Bn), 3.10-3.20 (m, 1.0, Bn), 3.54-
3.68 (m, 2.0, H5',5"), 3.88 (q, J = 3.2 Hz, 1.0, H4'), 4.20 (dd, J = 9.2, 4.2 Hz, 0.5, H3'),  4.25 
(dd, J = 9.2, 4.2 Hz, 0.5, H3'), 5.12-5.18 (m, 1.0, 5'OH), 5.28 (d, J = 4.3 Hz, 0.5, 3'OH), 5.33 
(d, J = 4.3 Hz, 0.5, 3'OH), 5.97 (t, J = 6.2 Hz, 0.5, H1'),  6.06 (t, J = 6.3 Hz, 0.5, H1'), 6.52 (t, 
J = 3.4 Hz, 0.5, α-CH ),  6.56 (t, J = 3.4 Hz, 0.5, α-CH), 7.05 (d, J = 7.1 Hz, 2.0, Ar) 7.13 (t, J 
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= 6.5 Hz, 1.0, Ar), 7.18 (t, J = 6.9 Hz, 2.0, Bn) 7.42 (d, J = 7.9 Hz, 1.0, Ar), 7.44 (d, J = 7.9 
Hz, 1.0, Ar), 7.67 (d, J = 8.1 Hz, 1.0, Ar), 7.69 (d, J = 8.1 Hz, 1.0, Ar),  8.63 (s, 0.5, H6), 8.70 
(s, 0.5, H6), 11.50 (s, 1.0, NH); 13C NMR (DMSO-d6) δ 21.0, 31.3, 31.6, 40.5, 40.9, 54.8, 
60.7, 60.8, 69.9, 86.0, 86.5, 88.0, 88.2, 111.0, 111.4, 126.6, 128.4, 128.5, 128.6, 128.8, 128.9, 
129.6, 129.8, 134.5, 136.1, 136.2, 145.0, 145.1, 148.0, 148.1, 149.1, 149.2, 161.4, 161.5, 
186.1, 186.2; HRMS calcd for C25H27N2O8S [M+H]
+ 515.1488, found 515.1437 
  5-(2-Methyl-2-tosylacetyl)-2'-deoxyuridine (54). Treatment of 51 (16 mg, 0.037 mmol) 
with NaOH(aq) (16 µL, 2.96 mg, 0.074 mmol), and methyl iodide (4.60 µL, 10.50 mg, 0.074 
mmol) for 4 h as described in procedure E followed by column chromatography 
(CHCl3/MeOH; 100:0 → 95:5) gave 54 as a (50/50) mixture of diastereomers (5 mg, 31%) 
and two byproducts. 1H NMR (DMSO-d6) δ 1.32 (t, J = 7.4 Hz, 3.0), 2.10-2.18 (m, 1.0, H2'), 
2.20-2.30 (m, 1.0, H2"), 2.39 (s, 1.5, Me), 2.40 (s, 1.5, Me), 3.53-3.64 (m, 2.0, H5',5"), 3.87-
3.92 (m, 1H, H4'), 4.21-4.29 (m, 1.0, H3'), 5.11-5.16 (m, 1.0, 5'OH), 5.30 (d, J = 4.3 Hz, 0.5, 
3'OH), 5.33 (d, J = 4.3 Hz, 0.5, 3'OH), 5.97 (q, J = 6.5 Hz, 1.0, α-CH), 6.05 (t, J = 6.3 Hz, 0.5, 
H1' ),  6.11 (t, J = 6.4 Hz, 0.5, H1'), 7.42 (t, J = 7.6 Hz, 2.0, Ar), 7.65 (d, J = 8.1 Hz, 1.0, Ar), 
7.68 (d, J = 8.1 Hz, 1.0, Ar), 8.71 (s, 0.5, H6), 8.73 (s, 0.5, H6), 11.80 (s, 1.0, NH); 13C NMR 
(DMSO-d6) δ 11.0, 11.2, 21.1, 40.8, 41.0, 60.8, 60.9, 65.5, 70.0, 86.0, 86.5, 88.0, 88.1, 111.0, 
111.2, 128.8, 128.9, 129.6, 129.8, 145.0, 145.1, 148.0, 148.1, 149.1, 149.2, 161.3, 161.4, 
186.1, 187.8 
5-(2-Allyl-2-tosylacetyl)-2'-deoxyuridine (55). Treatment of 51 (18 mg, 0.042 mmol) 
with NaOH(aq) (16 µL, 3.36 mg, 0.084 mmol), and Allyl bromide (6 µL, 8.38 mg, 0.069 
mmol) for 4 h as described in procedure E followed by column chromatography (CHCl3/ 
MeOH; 100:0 → 95:5) gave 55 as a (52/48) mixture of diastereomers (6 mg, 31%) and two 
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byproducts: 1H NMR (DMSO-d6) δ 2.05-2.20 (m, 1.10, H2'), 2.22-2.35 (m, 0.90, H2"), 2.39 
(s, 1.65, Me), 2.40 (s, 1.35, Me), 2.66-2.78 (m, 2.00, CH2), 3.56-3.53-3.68 (m, 2.00, H5',5"), 
3.89 (q, J = 3.3 Hz, 1.00, H4'), 4.21-4.29 (m, 1.00, H3'), 4.93-5.01 (m, 1.65, allyl), 5.11-5.17 
(m, 1.00, 5'OH), 5.30 (d, J = 4.3 Hz, 0.55, 3'OH), 5.35 (d, J = 4.3 Hz, 0.45, 3'OH), 5.55-5.66 
(m, 1.00, allyl), 6.05 (t, J = 6.2 Hz, 0.45, H1'), 6.10 (t, J = 6.2 Hz, 0.55, H1'), 6.18 (d, J = 2.6 
Hz, 0.55, α-CH), 6.21 (d, J = 2.6 Hz, 0.45, α-CH),  7.40 (d, J = 8.2 Hz, 1.10, Ar), 7.44 (d, J = 
8.2 Hz, 0.90, Ar), 7.65 (d, J = 7.5 Hz, 2.00, Ar), 8.71 (s, 0.45, H6), 8.73 (s, 0.55, H6), 11.80 
(s, 1.00, NH); 13C NMR (DMSO-d6) δ 21.1, 30.0, 30.3, 40.5, 41.0, 60.8, 60.9, 68.9, 70.0, 70.1, 
86.0, 86.5, 88.0, 88.1, 110.8, 111.2, 118.0, 129.0, 129.6, 129.9, 133.0, 134.5, 134.6, 148.0, 
148.1, 149.0, 149.2, 161.5, 161.6, 186.5, 186.7 
5-(2-Allyl-2-tosylacetyl)uridine (56). Treatment of 51 (18 mg, 0.04 mmol) with 
NaOH(aq) (16 µL, 3.36 mg, 0.084 mmol), and allyl bromide (6 µL, 8.38 mg, 0.069 mmol) for 
4 h as described in procedure E followed by column chromatography (CHCl3/ MeOH; 100:0 
→ 95:5) gave 56 as a (52/48) mixture of diastereomers (6 mg, 32%) and two byproducts: 1H 
NMR (DMSO-d6) δ 2.39 (s, 0.48, Me), 2.40 (s, 0.52, Me), 2.66-2.78 (m, 2.00, allyl), 3.57-
3.63 (m, 0.96, H5'), 3.69-3.77 (m, 1.04, H5"), 3.4 (q, J = 3.3 Hz, 1.00, H4'), 3.95-4.02 (m, 
1.00, H3'), 4.03-4.09 (m, 1.00, H2'), 4.93-5.01 (m, 1.04, allyl), 4.93-5.10 (m, 0.96, allyl), 5.13 
(d, J = 5.3 Hz, 1.04, 3'OH), 5.20 (d, J = 5.4 Hz, 0.96, 3'OH), 5.23-5.28 (m, 1.00, 5'OH), 5.48 
(d, J = 5.3 Hz, 0.48, 3'OH), 5.58 (d, J = 5.2 Hz, 0.52, 3'OH), 5.59-5.67 (m, 1.00, allyl), 5.71 
(d, J = 3.7 Hz, 0.48, H1'),  5.78 (d, J = 4.0 Hz, 0.52, H1'), 6.13-6.21 (m, 1.00, α-CH), 7.42 (d, 
J = 8.2 Hz, 0.96, Ar), 7.46 (d, J = 8.2 Hz, 1.04, Ar), 7.65 (d, J = 7.1 Hz, 2.00, Ar), 8.81 (s, 
0.48, H6), 8.90 (s, 0.52, H6), 11.80 (s, 1.00, NH); 13C NMR (DMSO-d6) δ 21.1, 30.0, 30.1, 
60.0, 60.2, 68.8, 69.0, 69.2, 69.6, 74.4, 74.6,  85.0, 85.3, 89.2, 89.6, 111.2, 111.4, 117.6, 
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128.8, 129.0, 129.8, 130.0, 133.0, 135.4, 145.0, 148.5, 148.8, 149.4, 149.6, 161.4, 161.5, 
186.7, 186.8 
5-(2-Benzyl-2-tosylacetyl)-2'-deoxycytidine (60). Treatment of 58 (18 mg, 0.043 mmol) 
with NaOH(aq) (11 µL, 2.2 mg, 0.055 mmol), and benzyl bromide (6.5 µL, 9.4 mg, 0.05 
mmol) for 8 h as described in procedure E followed by column chromatography (CHCl3/ 
MeOH; 100: 0 → 95:5) gave 60 as a (52/48) mixture of diastereomers (15 mg, 68%). 1H 
NMR (DMSO-d6) δ 1.93-2.03 (m, 1.04, H2'), 2.22-2.30 (m, 0.96, H2"), 2.38 (s, 1.42, Me), 
2.41 (s, 1.58, Me), 3.20-3.30 (m, 2.00, Bn), 3.54-3.68 (m, 2.00, H5',5"), 3.89 (q, J = 3.5 Hz, 
0.52, H4'), 4.00 (q, J = 3.5 Hz, 0.48, H4'), 4.20 (quint, J = 4.9 Hz, 0.52, H3'), 4.38 (quint, J = 
4.7 Hz, 0.48, H3'), 5.28 (d, 0.52, J = 4.6 Hz, 3'OH), 5.35 (d, J = 4.3 Hz, 0.48, 3'OH), 5.48 (dd, 
J = 11.3, 3.6 Hz, 0.48, α-CH), 5.58 (dd, J = 10.7, 4.4 Hz, 0.48, α-CH),  ,5.68 (t, J = 4.6 Hz, 
0.48, 5'OH), 5.75 (t, J = 4.9 Hz, 0.52, 5'OH), 5.94-6.20 (m, 1.00, H1' ),  7.08-7.23 (m, 5.00, 
Bn), 7.42 (d, J = 8.2 Hz, 1.04, Ar), 7.46 (d, J = 8.2 Hz, 0.96, Ar), 7.67 (d, J = 9.7 Hz, 0.52, 
Ar) 7.71 (d, J = 8.8 Hz, 0.48, Ar), 8.03 (d, J = 3.6 Hz, 0.52, NH2), 8.14 (d, J = 3.5 Hz, 0.48, 
NH2), 8.92 (s, 0.48, H6), 9.06 (s, 0.52, H6); 
13C NMR (DMSO-d6) δ 21.0, 31.8, 32.2, 41.4, 
41.6, 60.5, 60.8, 68.5, 69.0, 69.4, 69.6, 69.8, 86.0, 86.8, 87.6, 88.0, 104.0,104.8, 126.7, 126.9, 
128.4, 128.5, 128.6, 128.7, 128.8, 128.9, 129.8, 129.9, 133.7, 133.8, 135.6, 135.8,  145.1, 
145.3, 151.0, 151.2, 152.0, 162.0, 162.4, 187.4, 188.0 
 5-(2-Methyl-2-tosylacetyl)-2'-deoxycytidine (61). Treatment of 58 (18 mg, 0.043 mmol) 
with NaOH(aq) (20 µL, 4.0 mg, 0.1 mmol), and benzyl bromide (7.5 µL, 9.4 mg, 0.086 mmol) 
for 24 h as described in procedure E followed by column chromatography (CHCl3/ MeOH; 
100: 0 → 95:5) gave 61 as a (52/48) mixture of diastereomers (15 mg, 68%).1H NMR 
(DMSO-d6) δ 1.33 (d, J = 6.5 Hz, 1.44, CH3), 1.37 (d, J = 6.5 Hz, 1.56, CH3), 2.03-2.18 (m, 
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0.96, H2'), 2.28-2.35 (m, 1.04, H2"), 2.40 (s, 3.00, Me), 3.60-3.95 (m, 2.00, H4' & H5'5"), 
4.20 (quint, 0.52, H3'), 4.39 (q, J = 3.5 Hz, 0.52, H4'), 4.00 (q, J = 3.5 Hz, 0.48, H4'), 4.20 
(quint, J = 4.8 Hz, 0.52, H3'), 4.39 (quint, J = 4.8 Hz, 0.48, H3'), 5.16-5.28 (m, 1.00, α-CH), 
5.30-5.45 (m, 2.00, 3' & 5'OH), 6.00 (t, J = 4.8 Hz, 0.52, H1'), 6.15 (t, J = 5.5 Hz, 0.48, H1'), 
7.42 (d, J = 7.8 Hz, 1.04, Ar), 7.46 (d, J = 7.8 Hz, 0.96, Ar),  7.62 (d, J = 8.2 Hz, 1.04, Ar), 
7.66 (d, J = 8.2 Hz, 0.96, Ar), 8.05-8.12 (m, 0.52, NH2), 8.22 (d, J = 3.5 Hz, 0.48, NH2), 9.08 
(s, 0.48, H6), 9.16 (s, 0.52, H6); 13C NMR (DMSO-d6) δ 12.0, 21.0, 41.2, 41.4, 60.2, 60.5, 
63.3, 64.1, 68.8, 69.0, , 86.0, 86.8, 87.6, 88.1, 104.0,104.5, 129.0, 129.2, 130.0, 130.5, 133.4, 
133.7, 145.1, 145.3, 151.8, 152.0, 152.4, 162.8, 163.0, 189.0, 189.2 
5-(2-Benzyl-2-tosylacetyl)cytidine (62). Treatment of 59 (15 mg, 0.034 mmol) with 
NaOH(aq) (13.6 µL, 2.7 mg, 0.068 mmol), and benzyl bromide (8.5 µL, 11.6 mg, 0.068 
mmol) for 8h as described in procedure E followed by column chromatography (CHCl3/ 
MeOH; 100: 0 → 95:5) gave 62 as a (54/46) mixture of diastereomers (12 mg, 67%). 1H 
NMR (DMSO-d6) δ 2.38 (s, 1.62, Me), 2.40 (s, 1.38, Me), 3.15-3.30 (m, 2.00, Bn), 3.72-3.90 
(m, 2.00, H5',5"), 3.91-3.97 (m, , 1.00, H4'), 3.98-4.03 (m, 1.00, H3'), 4.04-4.20 (m, 1.00, 
H2'), 5.28 (d, J = 4.6 Hz,  0.54, 3'OH), 5.05 (d, J = 6.3 Hz, 0.46, 3'OH), 5.20 (d, J = 3.6 Hz, 
0.54, 3'OH), 5.45-5.52 (m, 1.00, 2'OH ),  5.53-5.58 (m, 1.00, 1'), 5.59-5.63 (m, 1.00, α-CH), 
5.72-5.88 (m, 1.00, 5'OH ), 7.09-7.23 (m, 5.00, Bn), 7.42 (d, J = 8.3 Hz, 1.08, Ar), 7.46 (d, J = 
8.2 Hz, 0.92, Ar), 7.66 (d, J = 8.2 Hz, 1.08, Ar), 7.69 (d, J = 8.2 Hz, 0.92, Ar), 7.98-8.08 (m, 
1.08, NH2), 8.15 (d, J = 3.6 Hz, 0.92, NH2), 8.90 (s, 0.54, H6), 9.06 (s, 0.46, H6); 
13C NMR 
(DMSO-d6) δ 21.0, 31.8, 32.0, 59.4, 60.0, 67.5, 68.2, 68.3, 68.5, 69.2, 74.8, 75.0, 79.2, 83.8, 
84.2, 90.6, 91.4, 104.1,104.7, 126.6, 126.9, 128.4, 128.5, 128.6, 128.7, 128.8, 128.9, 129.8, 
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130.1, 133.7, 134.1, 135.6, 135.7,  145.1, 145.2, 151.0, 151.5, 152.0, 162.4, 162.6, 187.4, 
188.0 
5-(2-Iodo-2-tosylacetyl)-2'-deoxyuridine (56). Method A. (β-Keto)sulfone analogue 51 
(18 mg, 0.042 mmol) was dissolved in 1 mL MeOH. Then, NaOH(aq) (8.4 µL, 1.68 mg, 
0.042 mmol) was added into the solution and was stirred for 30 min. Later, iodine 
monochloride (42 µL, 6.18 mg, 0.042 mmol) was added into solution and the resulting 
mixtures were stirred for 3 h . The solution was neutralized by adding dil. HCl and volatiles 
were evaporated. The residue was column chromatographed (CHCl3/ MeOH; 100:0 → 95:5) 
to afford 56 as a (50/50) mixture of diastereomers (8 mg, 35%). 1H NMR (DMSO-d6) δ 2.08-
2.30 (m, 2H, H2'2"), 2.40 (s, 3H, Me), 3.55-3.75 (m, 2H, H5',5"), 3.85 (q, J = 3.4 Hz, 1H, 
H4'), 4.22 (m, 1H, H3'), 5.13 (t, J = 4.6 Hz, 0.5H, 5'OH), 5.17 (t, J = 4.5 Hz, 0.5H, 5'OH),  
5.28 (d, J = 4.4 Hz, 0.5H, 3'OH), 5.31 (d, J = 4.6 Hz, 0.5H, 3'OH), 5.58-6.10 (m, 1H, H1'), 
7.30 (s, 1H, α-CH), 7.45 (d, J = 8.1 Hz, 2H, Ar), 7.75 (d, J = 8.1 Hz, 2H, Ar), 8.80 (s, 0.5H, 
H6), 8.82 (s, 0.5H, H6), 11.90 (s, 1H, NH); 13C NMR (DMSO-d6) δ 21.1, , 40.5, 41.0, 60.8, 
60.9, 68.9, 69.9, 70.0, 86.3, 86.5, 88.0, 88.1, 107.7, 107.9, 128.5, 129.5, 129.6, 129.7, 129.8, 
133.3, 133.4, 134.5, 134.6, 145.0, 145.2, 150.0, 150.2, 161.0, 161.1, 186.5 
Method B. (β-Keto)sulfone 51 (40 mg, 0.094 mmol) was taken in a round bottom flask 
containing 0.3 mL of acetic acid. Then iodine (15 mg, 0.056 mmol) and 50% H2O2(aq) (60 
μL, 0.94 mmol) were sequentially added into the flask. The resulting mixtures were stirred for 
1 h at ambient temperature. The volatiles were evaporated and column chromatography 
(CHCl3/ MeOH; 100:0 → 95:5) afforded 5-(α-iodo-β-keto)sulfone 56  ( 21 mg, 41%). 
5-(2-Propanethio-2-tosylacetyl)-2'-deoxyuridine (57). The 5-(α-iodo-β-keto)sulfone 56 
(10 mg, 0.018 mmol) was  dissolved in 1 mL of MeOH. Then 1:1 mixture of propanethiol and 
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TEA(8.5 µL, 6.8 mg, 0.076 mmol)  was added into a stirring solution of 56 at ambient 
temperature for 24 h. The volatiles were evaporated and column chromatography (CHCl3/ 
MeOH; 100:0 → 95:5) afforded 57 as a (50/50) mixture of diastereomers (2 mg, 22%). 1H 
NMR (DMSO-d6) δ 2.08-2.30 (m, 2H, H2'2"), 2.40 (s, 3H, Me), 3.55-3.75 (m, 2H, H5',5"), 
3.85 (q, J = 3.4 Hz, 1H, H4'), 4.22 (m, 1H, H3'), 5.13 (t, J = 4.6 Hz, 0.5H, 5'OH), 5.17 (t, J = 
4.5 Hz, 0.5H, 5'OH),  5.28 (d, J = 4.4 Hz, 0.5H, 3'OH), 5.31 (d, J = 4.6 Hz, 0.5H, 3'OH), 5.58-
6.10 (m, 1H, H1'), 7.30 (s, 1H, α-CH), 7.45 (d, J = 8.1 Hz, 2H, Ar), 7.75 (d, J = 8.1 Hz, 2H, 
Ar), 8.80 (s, 0.5H, H6), 8.82 (s, 0.5H, H6), 11.90 (s, 1H, NH) 
8-(1-Chloro-2-tosylvinyl)adenine (67). Treatment of 8-ethynyl adenosine analogue 66 
(100 mg, 0.198 mmol) with p-toluenesulfonyl hydrazide  (110.6 mg, 0.594 mmol) in the 
presence of FeCl3·6H2O (108 mg, 0.396 mmol) by procedure A (column chromatography; 
CHCl3/MeOH; 100:0 → 95:5) gave 67 (30 mg, 44%):) 1H NMR (DMSO-d6) δ 2.40 (s, 3H), 
7.45 (d, J = 7.9 Hz, 2H), 7.49 (bs, 2H), 7.81(d, J = 8.2 Hz, 2H), 7.88 (s, 1H), 8.18 (s, 1H), 
13.6 (s, 1H); 13C NMR (DMSO-d6) δ 21.2, 119.4, 128.1, 129.8, 135.2, 136.4, 139.6, 145.0, 
149.0, 150.7, 153.0, 156.2. 
3',5'-Bis-(O-tert-butyldimetylsilyl)-8-(1-iodo-2-tosylvinyl)-2'-deoxyadenosine (68). 
TBDMS protected 8 ethynyl 2'-deoxyadenosine 66 (200 mg, 0.4 mmol) was dissolved in 
CH3CN. Then, sodium salt of p-toluenesulfinic acid (205.6 mg, 1.2 mmol) , iodine (152.0 mg, 
0.60mmol), and sodium acetate (49.2 mg, 0.6 mmol) were sequentially added into the 
solution. The resulting mixtures were stirred at 80oC for 5 h. The volatiles was evaporated and 
column chromatography (Hexane/EA; 70:30 → 50:50) gave 68 (148 mg, 48%) as pale yellow 
solid. 1H NMR (CDCl3) δ 0.10 (s, 6H), 0.15 (s, 6H), 0.80 (s, 9H), 0.90 (s, 9H), 2.30-2.35 (m, 
1H), 2.40 (s, 3H), 3.45-3.55 (m, 1H), 3.80 (bs, 1H), 4.00- 4.10 (m, 2H), 4.85 (bs, 1H), 5.85 (s, 
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2H), 6.20 (dd, J = 13.5, 6.7 Hz, 1H),  7.24 (d, J = 8.1 Hz, 2H), 7.58 (s,1H), 7.68 (bs, 2H), 8.32 
(s, 1H); 13C NMR (CDCl3) δ -0.6, -0.5,-0.4, -0.3, 18.0, 18.5,  22.0, 26.0, 38.0, 63.0, 73.0, 86.0, 
88.0, 120, 128.3, 130.0, 136.0, 146.0, 147.5, 150.0, 153.0, 156.0.  
       S-[(E)-1-(2'-Deoxyuridin-5-yl)-2-tosylvinyl]-L-glutathione monophosphate (72). 
The 5'-monophosphate 69 (12 mg, 0.022 mmol) was added in 1 mL of methanol-water (50:50) 
co-solvent system. Then, L-glutathione (8.9 mg, 0.029 mmol) and triethylamine (25.0 μL, 
17.8 mg, 0.176 mmol) were sequentially added into the solution. The resulting mixtures were 
stirred at ambient temperature for 4 h. The volatiles were evaporated and sephadex column 
separation (TEAB buffer 0.1-0.3M) gave 72 (10 mg, 57%) as white solid. 1H NMR (D2O) δ 
2.15 (q, J = 7.4 Hz,  2H), 2.28-2.41 (m, 2H), 2.44 (s, 3H), 2.52 (dt, J = 15.5, 7.5 Hz, 2H), 
3.32-3.38 (m, 1H), 3.70-3.90 (m, 5H), 4.05 (q, J = 3.9 Hz, 1H), 4.45(br, 1H), 4.65-4.72 (m, 
2H), 6.30 (t, J = 6.4 Hz, 1H), 6.95 (s, 1H), 7.42 (d, J = 8.2 Hz, 2H), 7.62 (d, J = 8.0 Hz, 2H), 
7.95 (s, 1H); 13C NMR (D2O) δ 20.8, 26.2, 31.5, 33.5, 39.5, 42.5, 52.0, 54.0, 59.0, 64.0, 85.0, 
86.0, 108.7, 127.0, 130.0, 133.0, 136.0, 142.0, 146.3, 150.6, 161.8, 170.7, 174.0, 175.0, 176.2; 
31P NMR (D2O) δ 3.75; HRMS calculated for C28H35N5NaO13S2 [M+Na]+ 736.1570, found 
736.1513 
   General procedure for the phosphorylation of 5-(β-chloro)vinyl and 5-(β-
keto)sulfone of 2'-deoxyuridne, synthesis of 5'-triphosphates (71 and 74). Procedure F. 
The 5-(β-Chloro)vinyl sulfone 9 or 5-(β-keto)sulfone 51 and proton sponge were placed in a 
flame dry round bottom flask. 1 mL trimethyl phosphate was added into the flask and the 
mixtures were allowed to cool at 0 oC for 5 min. POCl3 was added and the mixtures were 
stirred for 30 min. at 0 oC. Then TBAPP 0.5M solution in DMF and tributylamine were added 
sequentially and the resulting mixtures were stirred for 10 min at 0 oC. The reactions were 
99 
 
quenched by dropwise adding 2M TEAB buffer. The reaction mixtures were extracted with 
ethylacetate two times and the aqueous layer was collected. The volatiles were evaporated and 
the residue was column chromatographed using Sephadex as adsorbent and TEAB buffer as 
eluting solovent to afford product 71 or 74. 
 (E)-5-(1-Chloro-2-tosylvinyl)-2'-deoxyuridine triphosphate (71). Treatment of  
chlorovinyl sulfone 28 (30 mg, 0.067 mmol) solution in 0.5 mL PO(OMe)3 with POCl3 (16 
μL, 26.2 mg, 0.17 mmol) in the presence of proton sponge (37 mg, 0.172 mmol)  and 
subsequent treatment  of the mixtures with 0.5 M TBAPP solution (700 μL, 192 mg, 0.35 
mmol) and TBA (50 μL, 39 mg, 0.21 mmol) by procedure F and column chromatography 
(TEAB buffer; 0.1M → 0.5M) afforded 5'-triphosphate  71 (15 mg, 32%). 1H NMR (D2O) δ 
2.28-2.40 (m, 2H, H2',2"), 2.45 (s, 3H, CH3), 4.14-4.20 (m, 2H, H5',5"), 4.15-4.28 (m, 1H, 
H4'), 4.62 (dd, J = 5.7, 2.9 Hz, H3'), 6.28 (t, J = 6.7 Hz, 1H, H1'), 7.44 (d, J = 8.0 Hz, 2H, Ar), 
7.45 (s, 1H, vinyl), 7.65 (d, J = 8.2 Hz, 2H, Ar), 8.20 (s, 1H, H6); 13C NMR (D2O) δ 21.0, 
39.0, 66.0, 71.0, 85.0, 86.0, 108.5, 128.0, 130.5, 135.0, 136.0, 141.0, 142.5, 146.0, 150.0, 
161.0; 31P NMR (D2O) δ -23.00 (β-P), -11.50 (α-P), -10.50 (γ-P); HRMS calcd for 
C18H21ClN2O6P3S [M-H]
-680.9513, found 680.9517 
Note: Treatment of the crude product of the reaction between 9 and POCl3 with 2M TEAB 
buffer and column chromatography using Sephadex as adsorbent and TEAB buffer as eluting 
system (0.1M → 0.25 M) gave 5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine phosphate 69. 
 5-(2-Tosylacetyl)-2'-deoxyuridine triphosphate (74). Treatmento of β-keto sulfone 
analogue 51 (20 mg, 0.047 mmol) solution in 0.5 mL PO(OMe)3  with POCl3 (10 μL, 16.4 
mg, 0.107 mmol) in the presence of proton sponge (21 mg, 0.097 mmol) and subsequent 
treatment of the mixtures with 0.M TBAPP solution (400 μL, 110 mg, 0.2 mmol) and TBA 
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(28 μL, 22 mg, 0.118 mmol) by procedure F and column chromatography (TEAB buffer; 
0.1M → 0.5M) afforded desired 5'-triphosphate 74 (12 mg, 38%). 1H NMR (D2O) δ 2.35-2.48 
(m, 2H, H2',2"), 2.45 (s, 3H, CH3), 3.58-3.68 (m, 2H, H5',5"), 4.21 (dd, J = 5.6, 4.0 Hz, 2H, α-
CH2), 4.28 (br, 1H, H4'), 4.62 (dd, J = 6.0, 2.8 Hz, H3'), 6.13 (t, J = 6.4 Hz, 1H, H1'), 7.47 (d, 
J = 8.0 Hz, 2H, Ar), 7.65 (d, J = 8.0 Hz, 2H, Ar), 8.46 (s, 1H, H6); 13C NMR (D2O) δ 21.0, 
39.0, 59.0, 65.0, 71.0, 87.0, 88.0, 112.0, 128.0, 130.5, 134.0, 148.0, 149.0, 150.0, 161.0, 
185.0; 31P NMR (D2O) δ -23.50 (β-P), -11.70 (α-P), -11.00 (γ-P); HRMS calcd for 
C18H22N2O17P3S [M-H]
- 662.9852, found 680.9859 
General procedure for esterification of 5-(β-chloro)vinyl sulfone and 5-
heteroarlyated compounds. Synthesis of liphophilic analogues (75-76 and 82-85). 
Procedure G. 5-(β-Chloro)vinyl sulfone  or 5-arlyated compound was dissolved in 1 mL 
DMF. Undecanoic anhydride and DMAP were sequentially added into the solution and stirred 
at ambient temperature. The volatiles were evaporated and the residue was partitioned 
between CH2Cl2 and 0.1 M HCl/H2O. The organic layer was washed with NaHCO3/H2O and 
brine and was column chromatographed to afford (75-76 and 82-85). 
 (E)-5'-O-Undecanoyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (75). Treatment of 5-
(β-chloro)vinyl sulfone 9 (25 mg, 0.056 mmol) with undecanoic anhydride (24 mg, 0.067 
mmol) and DMAP (6.0 mg, 0.05 mmol) in DMF at ambient temperature for 2 h by Procedure 
G and column chromatography (hexane/EtOAc, 90:10 → 60:40) afforded 75 (15 mg, 45%): 
1H NMR δ 0.88 (t, J = 6.6 Hz, 3H, CH3), 1.24-1.39 (m, 14H, 7 x CH2), 1.62 ("quin", J = 7.4 
Hz, 2H, CH2), 2.10-2.18 (m, 1H, H2'), 2.34 (t, J = 7.7 Hz, 2H, CH2), 2.42 (s, 3H, CH3), 2.49 
(ddd, J =13.8, 6.3, 4.0 Hz, 1H, H2''), 3.00 (br s, 1H, 3'-OH), 4.17-4.40 (m, 4H, H3',4',5',5"), 
6.26 (t, J = 6.5 Hz, 1H, H1'), 6.85 (s, 1H, CH), 7.35 (d, J = 8.1 Hz, 2H, Ar), 7.74 (d, J = 8.1 
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Hz, 2H, Ar), 8.33 (s, 1H, H6), 8.44 (s, 1H, NH); 13C NMR δ 14.2, 21.9 (CH3), 22.0, 25.0, 
29.2, 29.4, 29.5, 29.7, 29.8, 32.2, 34.4 (CH2), 40.8 (C2'), 63.7 (C5'), 71.6 (C3'), 84.7 (C4'), 
85.8 (C1'), 108.2 (C5), 128.0 (Ar), 130.3 (Ar), 134.0 (Ar), 136.0 (=CH), 140.8 (Ar), 143.0 
(=CCl), 146.0 (C6), 149.3 (C2), 159.0 (C4), 174.0 (C=O); HRMS calcd for 
C29H39
35ClN2NaO8S [M+Na]
+ 633.2013, found 633.2018. 
Note: The (E)-3'-O-undecanoyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (7 mg, 20%) 
were also isolated:  1H NMR (CDCl3) δ 0.88 (t, J = 6.6 Hz, 3H, CH3), 1.22 -1.37 (m, 14H, 7 x 
CH2), 1.58 -1.68 (m, 2H, CH2), 2.35 (t, J = 7.6 Hz, 2H, CH2), 2.38 -2.42 (m, 1H, H2'), 2.44 (s, 
3H, CH3-tosyl), 2.5 -2.58 (m, 1H, H2"), 3.89 -3.94 (dd, 1H, H5'), 4.01 -4.06 (dd, 1H, H5"), 
4.15 -4.19  (m, 1H, H4'), 5.38 -5.42 (dd, 1H, H3'), 6.34 -6.38 (dd, 1H, H1'), 6.87 (s, 1H, 
vinyl), 7.34 (d, J = 8.1 Hz, 2H-tosyl), 7.70 (d, J = 8.1 Hz, 2H-tosyl), 8.34 (s, 1H, H6), 8.44 
(s,1H, NH).  
     (E)-3',5'-Di-O-undecanoyl-5-(1-chloro-2-tosylvinyl)-2'-deoxyuridine (76). Treatment of  
(25 mg, 0.056 mmol) with undecanoic anhydride (62 mg, 0.17 mmol) and DMAP (6.0 mg, 
0.05 mmol) in DMF for 6 h by Procedure G and  column chromatography (hexane/EtOAc, 
100:0 → 80:20) gave 76 (32 mg, 75%): 1H NMR δ 0.84-0.90 (m, 6H, 2 x CH3), 1.20-1.37 (m, 
28H, 14 x CH2), 1.60-1.68 (m, 4H, 2 x CH2), 2.35 ("t", J = 8.2 Hz, 4H, 2 x CH2), 2.38-2.42 
(m, 1H, H2'), 2.46 (s, 3H, CH3), 2.57 (ddd, J = 12.8, 5.4, 2.1 Hz, 1H, H2"), 4.29-4.32 (m, 1H, 
H4'), 4.42 (dd, J = 12.1, 2.4 Hz, 1H, H5'), 4.50 (dd, J = 12.1, 2.3 Hz, 1H, H5"), 5.23-5.27 (m, 
1H, H3'), 6.35(dd, J = 8.5, 5.5 Hz, 1H, H1'), 6.88 (s, 1H, vinyl), 7.34 (d, J = 8.1 Hz, 2H, Ar), 
7.70 (d, J = 8.1 Hz, 2H, Ar), 7.90 (s, 1H, H6), 8.34 (s, 1H, NH); 13C NMR δ 14.2, 21.8 (CH3), 
22.8, 24.9, 25.0, 29.3, 29.37, 29.43, 29.5, 29.58, 29.63, 29.69, 29.72, 32.0, 34.2, 34.3 (CH2), 
38.2 (C2'), 63.8 (C5'), 74.2 (C3'), 83.3 (C4'), 85.8 (C1'), 109.1 (C5), 128.0 (Ar), 130.2 (Ar), 
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134.9 (=CH), 136.9 (Ar), 139.9 (Ar), 141.6 (C6), 145.6 (=CCl), 149.1 (C2), 158.6 (C4), 
173.3, 173.4 (C=O); HRMS calcd for C40H59
35ClN2NaO9S [M+Na]
+ 801.3527, found 
801.3505.  
3',5'-Di-O-acetyl-5-(5-heptylfur-2-yl)-2'-deoxyuridine (79). 2121 (150 mg, 0.34 mmol) 
was dissolved in 2 mL of DMF. 2-Heptylfuran (0.6 mL, 565 mg, 3.4 mmol), TBAF (2.3 mL, 
2.38 mmol), and Pd2(dba)3 (12 mg, 0.021 mmol) were sequentially added into the solution. 
The resulting mixtures were stirred at 100 oC for 1 h. The volátiles were evapórated and 
column chromatography; hexane/EtOAc, 80:20 → 60:40 gave 79 (86 mg, 60%): 1H NMR δ 
0.87 (t, J = 7.1 Hz, 3H, CH3), 1.22-1.37 (m, 8H, 4 x CH2), 1.61 (q, J = 7.4 Hz, 2H, CH2), 2.11 
(s, 3H, CH3), 2.12 (s, 3H, CH3), 2.25 ("ddd", J = 16.6, 8.7, 2.2 Hz, 1H, H2'), 2.50-2.57 (m, 
1H, H2"), 2.59 (t, J = 7.5 Hz, 2H, CH2), 4.30-4.34 (m, 1H, H4'), 4.38-4.42 (m, 2H, H5',5"), 
5.28 ("dt", J = 6.4, 1.6 Hz, 1H, H3'), 6.05 (d, J = 3.3 Hz, 1H, furan), 6.40 (dd, J = 8.6, 5.5 Hz, 
1H, H1'), 6.98 (d, J = 3.3 Hz, 1H, furan), 7.85 (s, 1H, H6), 9.30 (s, 1H, NH); 13C NMR δ 14.2 
(CH3), 20.9, 21.1 (Ac), 22.8, 28.1, 28.2, 29.2, 29.3, 31.9 (CH2), 38.1(C2'), 61.2 (C5'), 74.7 
(C3'), 82.7 (C4'), 85.7 (C1'), 107.4 (furan), 108.2 (C5), 111.0 (furan), 131.3 (C6), 143.8, 149.4 
(furan), 156.2 (C2), 159.9 (C4), 170.3, 170.5 (Ac); HRMS calcd for C24H32N2NaO8 [M+Na]
+ 
499.2056, found 499.2078.  
5-(5-Heptylfur-2-yl)-2'-deoxyuridine (81). 5-Iodo-2'-deoxyuridine 77 (53 mg, 0.15 
mmol) was dissolved in 2 mL DMF. Then, 2-heptylfuran (0.29 mL, 249 mg, 1.5 mmol), 
TBAF (1 mL, 1.05 mmol), Pd2(dba)3 (10 mg, 0.017 mmol) were sequentially added into the 
solution. The mixtures were stirred at 100 oC for 1 h. The volatiles were evaporated and 
column chromatography (hexane/EtOAc, 20:80) gave 81 (35 mg, 61%): UV (MeOH) λmax 
256, 326 nm (ε 14 250, 11 300), λmin 287 nm (ε 4000); 1H NMR (DMSO-d6) δ 0.86 (t, J =6.7 
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Hz, 3H, CH3), 1.24-1.31 (m, 8H, 4 x CH2), 1.60 (quin, J = 6.7 Hz, 2H, heptyl), 2.17 ("dd", J = 
6.6, 4.9 Hz, 2H, H2',2''), 2.60 (t, J = 7.4 Hz, 2H, CH2), 3.60-3.62 (m, 2H, H5',5''), 3.83 (q, J = 
3.3 Hz, 1H, H4'), 4.29 (quin, J = 4.2, 1H, H3'), 5.05 (t, J = 5.0 Hz, 1H, 5'-OH), 5.28 (d, J = 4.1 
Hz, 1H, 3'-OH), 6.11 (d, J = 3.1 Hz, 1H, furan), 6.21 (t, J = 6.6 Hz, 1H, H1'), 6.72 (d, J = 3.1 
Hz, 1H, furan), 8.27 (s, 1H, H6), 11.58 (s, 1H, NH); 13C NMR δ 14.2, 22.1, 27.0, 28.6, 31.1, 
39.4, 60.8, 70.3, 84.5, 87.4, 105.7, 106.8, 108.6, 133.6, 144.5, 149.6, 154.8, 160.0; HRMS 
calcd for C20H29N2O6 [M+H]
+ 393.2020, found 393.2023 
5'-O-Undecanoyl-5-(fur-2-yl)-2'-deoxyuridine (82). Treatment of 80122 (25 mg, 0.08 
mmol) with undecanoic anhydride (34 mg, 0.096 mmol) in the presence of DMAP (6.0 mg, 
0.05 mmol) in DMF for 2 h by Procedure G and column chromatography; hexane/EtOAc, 
100:0 → 70:30) gave 82 (18 mg, 52%) and 83 (5 mg, 10%) in addition to unchanged 80 
(~15%; TLC). Compound 82 had: 1H NMR δ 0.88 (t, J = 7.1 Hz, 3H, CH3), 1.22-1.40 (m, 
14H, 7 x CH2), 1.60 ("quin", J = 7.3 Hz, 2H, CH2), 2.10-2.17 (m, 1H, H2'), 2.35 (t, J = 7.6 Hz, 
2H, CH2), 2.50 (ddd, J =13.7, 6.3, 3.9 Hz, 1H, H2''), 3.05 (br s, 1H, 3'-OH), 4.15 (q, J = 3.9, 
1H, H4'), 4.25 (dd, J = 12.1, 3.3 Hz, 1H, H5'), 4.36-4.42 (m, 2H, H3',5"), 6.26 (t, J = 6.3 Hz, 
1H, H1'), 6.60 (dd, J = 3.3, 1.8 Hz, 1H, furan), 7.05 (d, J = 3.5 Hz, 1H, furan), 7.38 (d, J = 1.2 
Hz, 1H, furan), 8.25 (s, 1H, H6), 8.38 (s, 1H, NH); HRMS calcd for C24H34N2NaO7 [M+Na]
+ 
485.2264; found 485.2271. 
Note: 3'-O-Undecanoyl-5-(fur-2-yl)-2'-deoxyuridine (6.0 mg, 15%) was also isolated: 1H 
NMR (CDCl3) δ 0.85-0.93 (m, 6H, 2 x CH3), 1.22 -1.37 (m, 24H, 12 x CH2), 1.58 -1.68 (m, 
4H, 2 x CH2), 2.35 (t, J = 7.6 Hz, 2H, CH2- undecanoyl), 2.45 (dt, 1H, H2'), 2.55 (dt, 1H, 
H2"), 2.64 (t, 2H, J = 7.6 Hz, CH2- heptyl), 3.90 - 4.00 (dd, 1H, H5'5"), 4.13 -4.18 (m, 1H, 
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H4'), 5.38 -5.42 (dd, 1H, H3'), 6.05 (d, , J = 3.2 Hz, 1H-furan), 6.29 -6.35 (dd, 1H, H1'), 6.90 
(d, J = 3.2 Hz, 1H-furan), 8.10 (s, 1H, H6), 8.44 (s,1H, NH). 
3',5'-Di-O-undecanoyl-5-(fur-2-yl)-2'-deoxyuridine (83). Treatment of 80122 (25 mg, 
0.08 mmol) with undecanoic anhydride (84 mg, 0.24 mmol) in the presence of DMAP (6.0 
mg, 0.05 mmol) by Procedure G (6 h) gave 83 (38.5 mg, 77%): 1H NMR δ 0.82-0.91 (m, 6H, 
2 x CH3), 1.20-1.40 (m, 28H, 14 x CH2), 1.60-1.68 (m, 4H, 2 x CH2), 2.24 (ddd, J = 14.6, 8.6, 
6.5 Hz, 1H, H2'), 2.33-2.40 (m, 4H, 2 x CH2), 2.54 (ddd, J = 14.1, 5.6, 1.3 Hz, 1H, H2"), 4.30 
("q", J = 2.7 Hz, 1H, H4'), 4.36 (dd, J  = 12.2, 2.8 Hz, 1H, H5'), 4.45 (dd, J  =11.8, 3.5 Hz, 1H, 
H5"), 5.27 ("dt", J = 6.4, 1.6 Hz, 1H, H3'), 6.40 (dd, J  = 8.8, 6.1 Hz, 1H, H1'), 6.47 (dd, J = 
3.3, 1.8 Hz, 1H, furan), 7.05 (d, J = 3.4 Hz, 1H, furan), 7.33 (d, J = 1.6 Hz, 1H, furan), 8.00 
(s, 1H, H6), 8.95 (s, 1H, NH); 13C NMR δ 14.5, 23.0, 25.1, 25.2, 29.3, 29.4, 29.6, 29.7, 29.9, 
32.3, 34.1, 34.3, 34.5, 39.0 (C2'), 64.0 (C5'), 74.6 (C3'), 83.2 (C4'), 86.0 (C1'), 108.0 (C5), 
110.0 (furan), 112.5 (furan), 133.0 (C6), 142.0 (furan), 146.0 (furan), 149.5 (C2), 160.2 (C4), 
173.2, 173.4 (C=O); HRMS calcd for C35H54N2NaO8 [M+Na]
+ 653.3778, found 653.3778. 
5'-O-Undecanoyl-5-(5-heptylfur-2-yl)-2'-deoxyuridine (84). Treatment of 81 (25 mg, 
0.064 mmol) with undecanoic anhydride (27.2 mg, 0.0768 mmol) in the presence of DMAP 
(6.0 mg, 0.05 mmol) for 2 h and column chromatography (hexane/EtOAc, 100:0 → 80:20) 
gave 84(17 mg, 48%). 1H NMR δ 0.85-0.90 (m, 6H, 2 x CH3), 1.28-1.31 (m, 22H, 11 x CH2), 
1.54-1.64 (m, 4H, 2 x CH2), 2.13-2.16 (m, 1H, H2'), 2.27-2.32 (m, 2H, CH2), 2.46 (ddd, J 
=13.9, 6.4, 4.3 Hz, 1H, H2''), 2.56 (t, J = 7.4 Hz, 2H, CH2), 2.98 (s, 1H, 3'-OH), 4.19 (q, J = 
3.5, 1H, H4'), 4.28 (dd, J = 12.3, 3.4 Hz, 1H, H5'), 4.33-4.41 (m, 2H, H3',5"), 6.05 (d, J = 3.2 
Hz, 1H-furan), 6.28 (t, J = 6.4 Hz, 1H, H1'), 6.90 (d, J = 3.2 Hz, 1H-furan), 8.10 (s, 1H, H6), 
8.44 (s,1H, NH); 13C NMR δ 14.2, 22.9 (CH3), 24.9, 28.1, 28.2, 29.2, 29.2, 29.3, 29.4, 29.5, 
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29.6, 29.7, 31.9, 32.1, 34.2, 34.3, 34.4 (CH2), 40.7 (C2'), 63.6 (C5'), 71.8 (C3'), 84.4 (C4'), 
85.5 (C1'), 108.2 (C5), 110.6 (furan), 113.0 (furan), 129.0 (furan), 133.0 (C6), 149 (C2), 156.0 
(furan), 159.6 (C4), 174.0 (C=O); HRMS calcd for C31H48N2NaO7 [M+Na]
+ 583.3359, found 
583.3375. 
Note: 3'-O-undecanoyl-5-(heptylfur-2-yl)-2'-deoxyuridine (6.1 mg, 17%) was also 
isolated: 1H NMR (CDCl3) δ 0.88 (t, J = 7.1 Hz, 3H, CH3), 1.22 -1.40 (m, 14H, 7 x CH2), 1.60 
-1.65 (m, 2H, CH2), 2.35 (t, J = 7.6 Hz, 2H, CH2), 2.44 -2.58 (m, 2H, H2'), 4.0 (dd, 2H, H5'), 
4.15(m, 1H, H4'), 5.40 (dd, 1H, H3'), 6.35 (dd, 1H, H1'), 6.6 (dd, 1H, furan), 7.05 (d, J = 3.5 
Hz, 1H, furan), 7.38 (d, J = 1.2 Hz, 1H, furan), 7.34 (d, J = 8.1 Hz, 2H-tosyl), 8.25 (s, 1H, 
H6), 8.38 (s, 1H, NH). 
3',5'-Di-O-undecanoyl-5-(5-heptylfur-2-yl)-2'-deoxyuridine (85). Treatment of 81 (25 
mg, 0.064 mmol) with undecanoic anhydride (65 mg, 0.19 mmol) in the presence of DMAP 
(6.0 mg, 0.05 mmol) for 6 h and column chromatography (hexane/EtOAc, 100:0 → 80:20) 
gave 85 (36 mg, 80%). 1H NMR δ 0.83-0.92 (m, 9H, 3 x CH3), 1.22-1.38 (m, 36H, 18 x CH2), 
1.55-1.70 (m, 6H, 3 x CH2), 2.25 (ddd, J  = 14.7, 8.5, 6.6 Hz, 1H, H2'), 2.30-2.40 (m, 4H, 2 x 
CH2), 2.53-2.57 (m, 1H, H2"), 2.60 (t, J = 7.6 Hz, 2H, CH2), 4.31 (q, J = 3.0 1H, H4'), 4.38 
(dd, J  = 12.2, 2.8 Hz, 1H, H5'), 4.42 (dd, J  =11.3, 3.8 Hz, 1H, H5"), 5.26 ("dt", J  = 6.8, 1.6 
Hz, 1H, H3'), 6.05 (d, J = 3.2 Hz, 1H, furan), 6.37 (dd, J  = 8.8, 6.1 Hz, 1H, H1'), 6.95 (d, J = 
3.3 Hz, 1H, furan), 7.88 (s, 1H, H6), 9.00 (s, 1H, NH); HRMS calcd for C42H68N2NaO8 
[M+Na]+ 751.4873, found 751.4851. 
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 4.3. Incorporation of 5-modified nucleotides into DNA 
Materials of enzymatic reactions  
  All DNA oligonucleotides were synthesized following the Integrated DNA Technologies 
(Coralville, IA). The radionucleotides -32P] ATP (6000 mCi/mmol) was purchased from MP 
biomedicals Inc. (Santa Ana, CA) while T4 polynucleotide kinase and deoxynucleoside 5’-
triphosphates (dNTPs) were purchased from Thermo Scientific (Pittsburgh, PA). Micro Bio-
Spin TM 6 Columns were purchased from Bio-Rad (Hercules, CA). All other chemicals were 
purchased from Thermo Scientific (Pittsburgh, PA) and Sigma-Aldrich (St. Louis, MO). 
Purified DNA polymerase β (pol β) were purified following the procedures described 
previously.123,124 Klenow fragment was bought from New England Biolabs (Ipswitch, MA).  
Oligonucleotide substrates 
 Substrates with an upstream primer annealed to the template strand were designated as 
open template substrates. The substrates were made by annealing upstream primer (31nt) with 
the template strand (71 nt) at a molar ratio of 1:3. The substrate containing one-nucleotide gap 
were made by annealing an upstream primer and downstream primer with the template strand 
at the molar ratio of 1:3:3. The open template and one-nucleotide gap substrates were 
employed to mimic the intermediates formed during DNA replication.  
Enzymatic activity assay  
Nucleotides incorporation by DNA polymerases were performed by incubating different 
concentrations of pol β or Klenow fragment with 25 nM 32P labeled substrates at 37°C for 15 
min. The enzymatic reactions were assembled in the presence of 5-(β-chlorovinyl)sulfone of 
dU (50 μM) or 5-(β-keto)sulfone of dU (50 μM) alone or in the presence of 50 μM 5-(β-
chlorovinyl)sulfone of dU or 50 μM 5-(β-keto)sulfone of dU along with 50 μM dATP, 50 μM 
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dCTP and 50 μM dGTP. This allows to examine if 5-(β-chlorovinyl)sulfone of dU or 5-(β-
keto)sulfone of dU residue can be directly incorporated into a double-strand DNA during 
DNA leading and lagging strand maturation. DNA synthesis was separated in a 15% urea 
denaturing polyacrylamide gel were detected by Pharos FX Plus PhosphorImager (Bio-Rad 
Laboratory, CA). 
4.4. Cytotoxic evaluation 
Proliferation Assays 
Human cervical carcinoma (HeLa) cells were seeded in 96-well plates at 15,000 cells/well 
in the presence of 5-fold dilutions of the compounds. After 4 days of incubation, the cells 
were trypsinized and counted by means of a Coulter counter (Analis, Belgium). Suspension 
cells (Mouse leukemia L1210 and human lymphoid CEM cells) were seeded in 96-well plates 
at 60,000 cells/well in the presence of the compounds. L1210 and CEM cells were allowed to 
proliferate for 48 h or 96 h, respectively and then counted. The 50% inhibitory concentration 
(IC50) was defined as the compound concentration required to reduce cell proliferation by 
50%.  
Antiviral Assays 
The compounds were evaluated against the following viruses: herpes simplex virus type 1 
(HSV-1) strain KOS, thymidine kinase-deficient (TK-) HSV-1 KOS strain resistant to ACV 
(ACVr), herpes simplex virus type 2 (HSV-2) strain G, varicella-zoster virus (VZV) strain 
Oka, TK- VZV strain 07-1, human cytomegalovirus (HCMV) strains AD-169 and Davis, 
vaccinia virus Lederle strain, respiratory syncytial virus (RSV) strain Long, vesicular 
stomatitis virus (VSV), Coxsackie B4, parainfluenza 3, influenza virus A (subtypes H1N1, 
H3N2), influenza virus B, Sindbis, reovirus-1, Punta Toro, human immunodeficiency virus 
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type 1 strain IIIB and human immunodeficiency virus type 2 strain ROD. The antiviral, other 
than anti-HIV, assays were based on inhibition of virus-induced cytopathicity or plaque 
formation in human embryonic lung (HEL) fibroblasts, African green monkey cells (Vero), 
human epithelial cells (HeLa) or Madin-Darby canine kidney cells (MDCK). Confluent cell 
cultures in microtiter 96-well plates were inoculated with 100 CCID50 of virus (1 CCID50 
being the virus dose to infect 50% of the cell cultures) or with 20 or 100 plaque forming units 
(PFU) (VZV or HCMV) in the presence of varying concentrations of the test compounds. 
Viral cytopathicity or plaque formation was recorded as soon as it reached completion in the 
control virus-infected cell cultures that were not treated with the test compounds. Antiviral 
activity was expressed as the EC50 or compound concentration required to reduce virus-
induced cytopathogenicity or viral plaque formation by 50%. Cytotoxicity of the test 
compounds was expressed as the minimum cytotoxic concentration (MCC) or the compound 
concentration that caused a microscopically detectable alteration of cell morphology 
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5. CONCLUSION 
I have successfully synthesized 5-(1-chloro/bromo-2-tosylvinyl)pyrimidine nucleosides 
from their corresponding 5-ethynyl analogues via transition metal catalyzed halosulfonylation 
reaction with moderate to excellent yield (45-90%). The 5-(1-iodo-2-tosylvinyl)pyrimidine 
nucleosides analogues were obtained via halosulfonylation reaction by reaction of 5-ethynyl 
pyrimidine nucleoside analogue with sodium salt of p-toluenesulfinic acid and N-
iodosuccinamide in moderate yield (42-50%). The physical, chemical, and biological 
properties of these novel 5-(1-halo-2-tosylvinyl)pyrimidine nucleosides analogues were also 
explored. It was discovered that unlike the unsubsituted vinyl sulfone, the (β-halo)vinyl 
sulfones underwent addition-elimination reaction efficiently with varieties of nucleophiles 
such as amines, thiols etc. Although the (β-halo)vinyl sulfones substrates possesses 
exclusively E stereochemistry at the vinylic position, their addition-elimination products 
possess either E or Z stereochemistry which was found to be dependent on the type of 
nucleophiles substitute the halogen atom at the β-position. If the halogen atom is substituted 
by the thiolate nucleophile, the addition-elimination reaction occurs with retention of 
configuration to give exclusively E stereochemistry. If the same halogen atom of the vinyl 
sulfone analogue is replaced by amino nucleophile in the analogous reaction the 
stereochemistry of resulting aminovinylsulfones is Z which means that reaction occurs with 
the inversion of configuration. From the kinetics data it was determined that the rate of 
reaction follows the descending order as I ≥ Br > Cl. That means the rate of addition-
elimination reaction of novel (β-halo)vinyl sulfone analogues is dependent on the halogen 
110 
 
atoms attached at the β-position. The vinylic proton exchange with deuterium during the 
addition-elimination reaction was investigated by carrying the reaction in different deuterated 
solvents such as DMSO-d6, D2O, or MeOH-d4. The cysteine and tripeptide L-glutathione were 
incorporated at the β-position of the uracil nucleoside analogues via conjugated addition-
elimination reaction. Antiproliferative and antivirul properties of the (β-halo)vinyl sulfone 
analogues were examined and it was found that acetyl protected (β-chloro)vinyl sulfone 
analogue inhibited the growth of the L1210, CEM, and HeLa cancer cells in the lower μM 
range. The lipophilic undecanoyl groups were incorporated at the sugar moiety via 
esterification reaction to enhance the cell permeability of these analogues but unfortunately 
they did not show improved cytostatic activity. 
Novel (β-keto)sulfone analogues of 5-modified pyrimidine nucleoside have been 
synthesized and their reactivity at the acidic α-carbon were explored. So, 5-(β-
chloro)vinylsulfones were efficiently converted into the corresponding 5-(β-keto)sulfone 
analogues via a  one pot synthetic procedure. Thus, (E)-(β-chloro)vinylsulfone analogues were 
converted into (Z)-(β-amino)vinylsulfone by treatment with methanolic ammonia. Subsequent 
acid hydrolysis efficiently converted the intermediary amino sulfone into β-keto sulfone 
analogues with good yield (60-70%). Since the proton at α-carbon of β-keto sulfone is acidic, 
novel chemistry at the α-carbon of β-keto sulfones were investigated. The reactivity at the α-
carbon of β-keto sulfone analogues with different electrophiles and nucleophiles were 
elaborately explored to find a suitable way to incorporate amino acid residues at the α-carbon 
which would verify the feasibility of the bioconjugation of the 5-(β-keto)sulfone-modified 
DNA with proteins. Different electrophiles derived from benzyl, methyl, or allyl halides were 
efficiently incorporated at the α-carbon of β-keto sulfone analogues. In addition, it was 
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demonstrated that in two step protocols the α-carbon of β-keto sulfones can be also substituted 
by nucleophile. Thus, treatment of 5-(β-keto)sulfone-modified 2'-deoxyuridine with 
iodinemonochloride afforded the product with the α-carbon substituted by iodo group. 
Subsequently, this iodo group served as a good leaving group and was displaced by the 
thiolate in the presence of triethyl amine. Such approach might be extended to incorporate 
amino acid possessing active nucleophilic groups at the α-carbon of the β-keto sulfones. 
The silyl protected 8-(1-iodo-2-tosylvinyl)-2'-deoxyadenosine was also efficiently 
synthesized by the iodine mediated halosulfonylation of the corresponding 8-alkynyl 
substrates with the yield of 48%. The success of this reaction was encouraging to extend this 
halosulfonylation reaction in future into other purine nucleoside systems. 
        The 5-(β-chloro)vinylsulfone- or 5-(β-keto)sulfone modified 2'-deoxyuridine were 
efficiently converted to the 5'-triphosphates by applying Yoshikawa method followed by 
treatment with ammonium pyrophosphate in the presence of tributylamine. These nucleotides 
were successfully inserted into the DNA by polymerase-catalyzed reactions with either human 
DNA repaired polymerase (pol β) or bacterial polymerase (pol I). The (β-chloro)vinyl sulone 
analogue was efficiently incorporated both into the open template that leads the DNA 
synthesis and one nucleotide gap template that lags the DNA synthesis via bacterial 
polymerase (Pol I) catalyzed reaction. However, the human DNA polymerase (pol β) 
catalyzed process was successful to incorporate the chlorovinyl analogue into the one 
nucleotide gap template only. The (β-keto) sulfone analogue was efficiently inserted into 
DNA open template and one nucleotide gap template either by human DNA repaired 
polymerase (pol β) or bacterial polymerase (pol I). 
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The 5-(β-chloro)vinyl and/or 5-(β-keto) sulfones might be bioconjugated with the 
proteins which are involved in DNA replication process. Specifically it would be interested to 
examine whether the (β-chloro)vinyl sulfone modified DNA might bioconjugate with thiol 
residues of transcription factors such as c-Myc protein and thus uncover the mystery of 
critical biological functions related to DNA-c-Myc protein interactions.  
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